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PREFACE 
The experimental work presented in this thesis was performed at the Pharmacology 
Division at the Department of Medicine at the Faculty of Health Sciences, of the University 
of Cape Town, South Africa.  Plant material from X. villosa and X. retinervis were collected 
and dried.  Plant products were extracted from the leave bases using different organic 
solvents.  These extracts were tested for antiplasmodial activity and the most promising 
ones were further purified to obtain single compounds.  These compounds were tested for 
antiplasmodial activity and cytotoxicity and structural information was obtained to 
determine their structures.   The bioavailability, metabolism and in vivo efficacy of the most 
active antiplasmodial compound were investigated in a mouse model.  
 
This thesis has been divided into twelve chapters.  Chapter 1 presents an introduction to 
malaria, traditional medicine and traditional healing, medicinal plants, natural products and 
malaria medicine, drug discovery and development, antiplasmodial development of plant 
derived products, as well as the scope of the study.  Chapters 2 to 6 present in vitro work 
and Chapter’s 7 to 10 present in vivo animal testing.  The research summary, final 
thoughts and research prospects, as well as presentations and manuscripts (in 
preparation) are presented in Chapter 11.  Methodology details of all experimental work 
are presented in Chapter 12.  A comprehensive and descriptive section about the method 
development process of the novel methodologies, which have been developed for the 
bioavailability and metabolism studies, is also presented in Chapter 12.  Plant collection 
and extract preparation are presented in Chapter 2.  Antiplasmodial activity and 
cytotoxicity screening of X. villosa and X. retinervis extracts are presented in Chapter 3.  
Isolation of pure compounds is presented in Chapter 4.  Antiplasmodial activity and 
cytotoxicity screening of isolated compounds are presented in Chapter 5.  Structural 
elucidation of antiplasmodial compounds that were isolated from Xerophyta species is 
presented in Chapter 6.  Antimalarial assessment of the most active antiplasmodial 
compound (9-O-acetylhydnocarpin) in a mouse model (using a polar formulation) is 
presented in Chapter 7.  Bioavailability investigation of 9-O-acetylhydnocarpin in mice is 
presented in Chapter 8.  A metabolite study of 9-O-acetylhydnocarpin in mice is presented 
in Chapter 9.  Chapter 10 provides an optimised assessment of the antimalarial activity of 
9-O-acetylhydnocarpin in mice, using an improved dosing strategy.  HPLC, UV, MS and 
NMR spectra are presented in Appendix 1.  Body weight and %parasitaemia data of 
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antimalarial experiments are presented in Appendix 2.  Bioavailability data is presented in 
Appendix 3.  Metabolite spectral data is presented in Appendix 4. 
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ABSTRACT 
 
Malaria is one of the most serious infectious diseases of the tropics, and has a significant 
impact on health and economic systems worldwide.  The malaria situation is deteriorating 
faster at present than at any time in the past, due to drug and insecticide resistance and 
environmental and social changes.  Malaria control relies strongly on drug treatment, but 
many of the first-line treatments are failing due to the parasites ability to develop 
resistance against drug action over time.  There is an urgent need to discover new classes 
of antimalarial compounds, which use different mechanisms of action against the 
Plasmodium parasites, and to develop some of these compounds into antimalarial drugs.  
Most of the existing antimalarial drugs originated from higher plants as novel compounds 
or chemically modified derivatives.  South Africa is rich in plant diversity with about 3 000 
species that are used as medicines, yet very little is known about their antimalarial activity.  
One of these species as well as a related species from the same genus were targeted as a 
potential source for novel antimalarial compounds.   
 
X. villosa and X. retinervis were targeted as a potential source of new antiplasmodial 
compounds.  The compounds were grouped according to their polarity using sequential 
solvent extraction.   Ethyl acetate sub-fractions of the methanol extracts of both species 
were screened against chloroquine sensitive (D10) and resistant (K1) P. falciparum strains 
and showed excellent antiplasmodial activity.   
 
Six pure compounds were successfully isolated from X. villosa and two from X. retinervis 
using two reverse phase HPLC gradient systems.  These isolated compounds were 
screened against a chloroquine sensitive (D10) P. falciparum strain.  Two of these 
compounds showed good antiplasmodial activity, three showed mild activity, and one 
showed no activity.  The two most active compounds were also screened against a 
chloroquine resistant (K1) P. falciparum strain and showed similar antiplasmodial activity 
(compared to the D10 strain), which indicates that these compounds probably use a 
different mechanism of action against the parasites (compared to chloroquine).  
Cytotoxicity testing of the extracts and isolated compounds was done to determine their 
toxic properties against living cells, and all tested extracts and compounds showed little 
toxicity.  The two most active compounds showed good selective antiplasmodial activity. 
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The chemical structures of the three most active antiplasmodial compounds were 
determined using mass spectrometry and nuclear magnetic resonance spectroscopy (1D 
and 2D).  The most active compound was identified as 9-O-acetylhydnocarpin.  This is the 
first study that has shown the presence of 9-O-acetylhydnocarpin in X. villosa.  The 
second best compound was identified as hydnocarpin.  Again this is the first report of the 
presence of hydnocarpin in X. villosa and X. retinervis.  The third best compound was 
identified as the flavonoid luteolin and showed mild antiplasmodial activity.   
 
Bioavailability and metabolite studies of 9-O-acetylhydnocarpin were conducted in a 
mouse model, and the information that was generated during these experiments was used 
to design an improved treatment strategy for in vivo antimalarial testing on P. berghei 
infected mice.  The antiplasmodial compound, 9-O-acetylhydnocarpin showed a 
reasonable level of protection for the mice against the malaria parasites, but could not cure 
the animals under the tested experimental conditions.  
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1   Literature review  
 
1.1   Malaria 
1.1.1   History 
Malaria has troubled humanity since ancient times.  Evidence of malaria was found in 
Chinese and Egyptian documents, which are more than 6000 years old.  The ancient 
Greeks noted that people who were exposed to swamp lands usually develop fevers.  The 
Italians later on called this disease mal’aria, due to the awful smell near swamps.  
Historical documents by the Vedic civilization in India, which date back 1600 B.C., also 
show evidence of malaria.  The first clinical symptoms and complications of malaria were 
described by Hippocrates during the fifth century B.C.  Many years later, during the 1880s, 
the first single-celled Plasmodium parasites were observed in blood by French Scientist 
Alphonse Laveran.  The mosquito vector, which is responsible for transmitting the disease, 
was only discovered approximately twenty years later, by scientists from India and Italy.  
The major features of the parasitic life cycle were described by Sir Ronald Ross in 1902.  
He received the Nobel Prize for this work.  Much progress has been made during the 20th 
century towards the understanding of the disease [WHO, 1986; NIAID, 2007; Johns 
Hopkins Bloomberg School of Public Health]. 
 
1.1.2   International malaria perspective  
Malaria is a major threat to the human race and results in more than a million deaths per 
year.  It is found in the tropical and sub-tropical regions of the world where more than half 
of the world’s population lives.  The environmental conditions in these regions are ideal for 
parasite and vector development.  The global distribution of malaria is presented in 
figure 1. 
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Figure 1  Global distribution of malaria transmission risk [World Malaria Map] 
 
The worldwide malaria situation is deteriorating faster at present than at any time in the 
past.  We are facing a rapidly increasing disease burden because of more people moving 
into malaria regions, deforestation, building of dams and irrigation systems in agriculture, 
climate changes and global warming.  The number of new malaria infections has increased 
dramatically during the last decade.  More than 2 billion people (40% of the human 
population) are at risk of being infected, mostly in the tropics and subtropics, and about 
50% of these live in sub-Saharan Africa.  The disease is currently endemic in 107 
countries.  In 1990, 80% of malaria cases were reported in Africa, and the rest found in 
countries such as India, Brazil, Afghanistan, Sri-Lanka, Thailand, Indonesia, Vietnam, 
Cambodia, China, and others.  About 300 to 500 million malaria infections occur per year, 
and 90% of these are also concentrated in sub-Saharan Africa.  Children are particularly 
susceptible, and according to the WHO, more children die from malaria than any other 
single disease.  Pregnant women are the second highest risk group for malaria infection 
[World Health Report, 1999, 2005; Bremen, 2001; Johns Hopkins Bloomberg School of 
Public Health]. 
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1.1.3   Malaria situation in South Africa  
KwaZulu-Natal, Mpumalanga and Limpopo are malaria endemic areas, and the Northern 
Cape and North West provinces occasionally experience malaria infections.  The malaria 
season is usually experienced between October and May.  A relatively high occurrence 
of malaria cases were experienced between 1996 and 2000, especially in KwaZulu-
Natal.  The treatment strategy was altered in 1998, and chloroquine was replaced with 
sulfadoxine-pyrimethamine as first-line treatment, due to parasite resistance that has 
developed against chloroquine.  Unfortunately, sulfadoxine-pyrimethamine has lost its 
efficacy relatively fast and was replaced with artemisinin-based combinatorial treatment 
during 2001, which resulted in more than a 75% reduction in malaria deaths within one 
year.  The Lubombo Spatial Development Initiative programme was established in 1999, 
which included South Africa, Swaziland and Mozambique.  This project aimed to manage 
and reduce malaria in these regions, which would contribute towards economic 
development.  The first-line treatment was replaced with co-artemether in some areas, 
and DDT was reintroduced as insecticide in spraying programmes.  This project was very 
successful:  a 90% reduction in KwaZulu-Natal, a 75% reduction in Mpumalanga, a 90% 
reduction in Swaziland and an 88% reduction in Mozambique, were observed.  The 
South African Health Department also received an award by the World Health 
Organization for the best malaria control management programme in Africa, due to the 
sharp decrease in malaria morbidity and mortality [Department of Health, South Africa; 
Medical Research Council, South Africa; World Health Organization; Roper et aI., 2003]. 
 
1.1.4   Economic burden 
The current spending on malaria prevention and treatment is less than $100 million per 
year, but the actual needs are more than an order of magnitude greater.  The World Health 
Organisation estimates that $2,5 billion per year is required for effective prevention and 
treatment programmes as from 2007.  The world’s poorest countries and their people 
cannot afford western medicine for malaria treatment and rely on local flora to prevent and 
treat malaria.  People have used plants for many centuries to treat malaria and it seems 
that they will continue to do so for many years to come [Sachs and Malaney, 2002].  
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1.1.5   Malaria the disease 
Malaria is described as an infectious disease which is characterized by extreme 
exhaustion, fever, chills, and anaemia.  The malaria symptoms usually begin 10 days to 4 
weeks after infection.  Symptoms are:  high fever, shaking chills, sweating, headache, 
muscle aches, tiredness, and sometimes nausea, vomiting and diarrhoea.  Malaria is often 
described as a flu-like illness due to its related symptoms.  The malaria parasite modifies 
human red blood cells, causing them to attach to the surface of blood vessels, which lead 
to blockage of capillaries to the brain and other organs.  The clinical response after 
infection with protozoan parasites varies, due to genetic makeup, age, parasite species 
and duration of infection.  The diagnosis of malaria is difficult because symptoms are 
unspecific and mimic other diseases.  A definite diagnosis is only possible if blood is tested 
for parasite presence and should be tested at different time intervals because parasites 
may disappear from peripheral blood during the schizogonic phase of the parasites life 
cycle.  Severe malaria is caused when more than 5% of the red blood cells are infected 
with parasites (hyperparasitaemia).  Severe anaemia is caused by the destruction of red 
blood cells and cerebral malaria is caused by the obstruction of small brain vessels. 
 
Malaria is caused by Plasmodium protozoan parasites and is transmitted to humans by 
female Anopheles mosquitos.  There are four species of the Plasmodium protozoan 
parasite that infect humans; Plasmodium falciparum, Plasmodium vivax, Plasmodium 
ovale and Plasmodium malariae.  P. falciparum is the most common and deadliest 
species, which causes 90% of malaria deaths worldwide.  If the disease is not promptly 
treated, severe infection with P. falciparum may lead to coma, severe anaemia, cerebral 
malaria, hypoglycaemia, renal failure, acidosis, repeated convulsions and finally death.  P. 
vivax accounts for approximately 70-80 million malaria cases annually.  P. vivax is not as 
lethal as P. falciparum, but can have major negative effects on general health, growth and 
development.  Young red blood cells (reticulocytes) are infected by this species.  P. vivax 
is found in Asia, the Western Pacific and the Americas.  P. vivax infections do not occur in 
West Africa, because of the absence of Duffy blood group antigens in West Africans.  
These antigens are required for red blood cell invasion.  This species have dormant liver 
stage parasites, hypnozoites, which can cause relapses if left untreated.  P. malariae has 
a relatively low occurrence, but is still found in Africa.  It causes typical malaria-like 
symptoms, but can also persist in the blood for years without ever producing symptoms.  
P. ovale is the rarest of the four human malaria parasites, and is found in Tropical Africa 
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and some Western Pacific islands.  P. ovale infections rarely cause clinical symptoms, 
because of the low occurrence of parasitaemia [Miller et aI., 1976; Oaks et al., 1991; 
Cogswell, 1992; Faye et aI., 1998; Mendis et aI., 2001; NIAID, 2007]. 
 
1.1.6   Life cycle of P. falciparum 
The life cycle of the malaria parasite (figure 2) is complex and requires two hosts to 
complete its life cycle.  The parasites alternate between female Anopheles mosquitos and 
human hosts.  The human host is infected during blood feeding of infected mosquitos.  
Sporozoites are inoculated during this process, and migrate rapidly through the 
bloodstream to the liver where hepatocytes are invaded.  The parasites undergo a series 
of asexual replications during the liver stage infection.  The liver stage infection is 
asymptomatic, regardless of the many parasites that are generated during this phase.  
After some time the infected hepatocytes rupture and merozoites are released into the 
bloodstream.  These “free” merozoites invade erythrocytes, and undergo a series of 
asexual replication within the host erythrocyte.  After some time the infected erythrocytes 
rupture and merozoites are released, which infect other erythrocytes every 48 hours.  The 
parasites feed on the globin part of haemoglobin, which is the source of amino acids.  
Haem, which is toxic to the parasites, is released during the feeding process.  The 
parasites however, have developed mechanisms to detoxify haem.  This by-product is 
polymerised by the parasites to form haemozoin, which is stored as a non-toxic complex in 
the parasites food vacuole.  Some of the merozoites develop into either male or female 
gametocytes and are ingested by another mosquito vector during a blood meal.  The 
gametocytes fuse inside the mosquito’s mid-gut and form zygotes.  A series of sexual 
replications occur inside the mosquito and sporozoites are formed, which migrate to the 
salivary glands of the mosquito and are released into another human host during the next 
blood meal [Oaks et al., 1991; NIAID, 2007]. 
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Figure 2  Life cycle of P. falciparum parasites [Life cycle of the malaria parasite] 
 
1.1.7   Malaria control 
People have used natural products for many centuries to control malaria, but since the 
development of modern science alternative methodologies and strategies have been 
developed to control the disease.  Many different strategies are used to control the 
disease, including traditional medicines, antiplasmodial drugs, insecticides and bed nets.  
Paraffin has also been used to coat marshes to prevent the development of mosquito 
larvae, and many attempts have been made to drain stagnant water to keep mosquitos 
from breeding.  Insecticides such as the chlorinated hydrocarbons (DDT and dieldrin), 
organophosphate compounds (malathion, fenitrothion), carbamates (propoxure), 
pyrethrins and pyrethroids are used to target the mosquito hosts.  Mosquitos become 
resistant to insecticides over time, therefore insecticides are used alternately in spraying 
programmes.  Insecticides are normally applied to the interior of houses and are very 
effective against some species, but are ineffective against species that stay primarily 
outside buildings.  Outdoor spraying is the option of choice in malaria epidemic areas 
where mosquitos stay outside buildings, but may have an impact on environmental 
conditions and should be monitored closely when this control method is used [Oaks et al., 
1991; NIAID, 2007].  
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1.1.8   Antimalarial drugs 
A number of antimalarial drugs have been developed during modern times, which 
specifically target either the liver or blood stage parasites.  Examples of liver stage drugs 
are doxycycline, proguanil and pyrimethamine.  Examples of blood stage drugs are 
quinine, chloroquine and artemisinin.  Most antimalarial drugs target the intra-erythrocytic 
growth stage of the parasites, thus preventing the development of the parasites [Oaks et 
al., 1991]. 
 
Antimalarial drugs can be classified into three main groups.  The first group consists of the 
quinoline based antimalarials (figure 3), which are also the most frequently used drugs.  
These drugs include:  quinine and its derivatives (chloroquine, amodiaquine and 
mefloquine).  The second group includes the antifolate drugs (figure 4), which are 
dihydrofolate reductase inhibitors.  These drugs are:  pyrimethamine, proguanil, 
sulfonamides and sulfones.  The third group (figure 5) consists of artemisinin and its 
derivatives:  artesunate and artemether. 
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Figure 3  Chemical structures of the quinoline based antimalarials 
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Figure 4  Chemical structures of the antifolate drugs 
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Figure 5  Chemical structures of artemisinin and its derivatives 
 
1.1.8.1   Quinoline based antimalarials 
One of the first effective treatments in modern malaria medicine was quinine, an 
antimalarial compound that was first isolated from the bark of the Cinchona tree.  At 
present, quinine is still used as an option for second-line treatment. Chloroquine was 
synthesised in the 1930s as a less toxic analogue of quinine and has been used 
extensively as the mainstay antimalarial drug for many decades.  Chloroquine is safe, cost 
effective and suitable for oral administration.  Unfortunately, resistance of P. falciparum to 
chloroquine appeared in Thailand in 1957 and in Colombia and Venezuela in 1960.  
artemisinin artesunate artemether 
pyrimethamine sulfadoxine 
dapsone proguanil 
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Chloroquine resistance has now spread to most countries.  It was at first restricted to the 
Indochinese peninsula (Asia), but spread westwards and towards the neighbouring islands 
in the south and east during the 1970s.  Chloroquine resistance in Africa happened much 
later, and it took a decade to spread across the continent.  Chloroquine resistance in Africa 
was not linked to a new mutation, but appeared due to a gradual spread from South-East 
Asia.  Chloroquine resistant P. falciparum malaria has not been observed in countries of 
Central America and the island of Hispaniola.  Chloroquine accumulates in the parasite's 
food vacuole, and interferes with the polymerization of toxic haem that is produced during 
haemoglobin digestion.  This leads to parasite death due to haem poisoning.  The 
chloroquine resistant strains (mutations of the pfct gene) accumulate less drug and are 
therefore better protected against haem poisoning.  These strains become dominant over 
time under constant chloroquine pressure.  The precise mode of action still remains to be 
understood [Mehlotra et al., 2001; Wellems and Plowe, 2001; W rld Health Organization, 
2005]. 
 
Chloroquine resistance has led to the development of the synthetic analogues 
amodiaquine and mefloquine.  Amodiaquine is more effective than chloroquine against 
chloroquine resistant P. falciparum parasites, but could lose its efficacy fast if used 
intensively in choroquine resistance areas.  Amodiaquine was first studied as a single-drug 
therapy at a dose of 25-30 mg/kg, and later on as a combination treatment strategy with 
sulfadoxine-pyrimethamine or artesunate.  Mefloquine was also introduced to many 
countries, but resistance occurred soon thereafter [Boudreau et al., 1982; Lobel et al., 
1998; Ringwald et al., 1998; Rwagacondo et al., 2003; World Health Organization, 2005].  
 
1.1.8.2   Antifolate drugs 
Chloroquine was replaced by a combination formulation of sulfadoxine and pyrimethamine 
in most countries at the beginning of the 1980s.  This combination treatment became 
ineffective in Thailand and bordering countries, because of parasite resistance.  Parasite 
resistance against sulfadoxine-pyrimethamine treatment spread fast in South America.  
Malawi was the first country in East Africa to replace chloroquine with sulfadoxine-
pyrimethamine as first-line treatment during the early 1990s, and other African countries 
followed during the late 1990s.  Parasite resistance against sulfadoxine-pyrimethamine 
also spread relatively fast in East Africa, because of extensive use.  Antifolate resistance 
has emerged rapidly.  It takes about 2 years for the parasites to develop resistance against 
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antifolate drugs when used intensively at national level.  Sulfadoxine-pyrimethamine kills 
the malaria parasite through inhibition of two successive enzymes in the biosynthesis of 
folic acid.  Mutations in the dhfr and dhps genes are responsible for parasite resistance 
against sulfadoxine-pyrimethamine [Doumbo et al., 2000; Nsimba et al., 2004; World 
Health Organization, 2005].   
 
1.1.8.3   Artemisinin and its derivatives 
Artemisinin was first isolated from the Chinese medicinal plant qing hao (Artemisia annua) 
in 1971.  Artemisinin contains an endoperoxide group that may be responsible for the 
antimalarial activity.  It belongs to the sesquiterpene lactone family of compounds (figure 
5).  Artemisinin is poorly water and oil soluble, hence the low bioavailability after oral 
administration.  Structural modifications were made to improve these properties and 
resulted in artesunate (figure 5) which is water soluble and artemether (figure 5) which is 
oil soluble.  Artesunate can be administered intravenously and artemether intramuscularly.  
Artemisinin and its related analogues are effective against multi-drug resistant strains of P. 
falciparum parasites and are used to treat uncomplicated and severe forms of malaria. 
 
The mechanism of action of artemisinin and its derivatives is not fully understood, but it 
seems to involve two steps. The endoperoxide bridge is initially cleaved to produce 
artemisinin-derived free radicals, which are strong alkylating agents.  The second step 
involves covalent bond formation with various parasite proteins.  The initial activation step 
appears to be catalysed by ferrous haem and free iron (Fe II), and is thought to be 
responsible for the selective toxicity to malaria parasites.  Artemisinin and its derivatives 
are very potent antimalarial agents.  Patients on these treatment regimens are normally 
clinically cured within 3 days.  Low levels of resistance have been reported, and some 
decrease of in vitro sensitivity has also been reported [Zhang et aI., 1992; Hien and White, 
1993; Meshnick, 1994; Kamchonwongpaisan and Meshnick, 1996; Krishna et al., 2004; 
World Health Organization, 2005]. 
 
1.1.9   Need for new strategies 
The genetic diversity of the malaria parasite is responsible for its ability to escape adverse 
conditions imposed by drug therapy.  Genotypes that are not affected by the drug therapy 
escape undamaged and pass along their resistance to its progeny.  The drug sensitive 
genotypes die and the more drug resistant genotypes survive, as a result parasites 
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become resistant against drug efficacy over time.  For this reason most antimalarial 
therapies that are used extensively have lost their efficacy over time. 
 
Additional control measures such as vaccines and new anti-malarial compounds are 
urgently needed.  Vaccines have proven to control other infectious diseases most cost-
effectively.  It has also been shown that malaria can be preventable by vaccination, both in 
experimental animals and humans.  A significant progress has been made in the 
understanding of the immune mechanisms involved in malaria protection and in identifying 
vaccine candidate antigens and their genes during the last decade.  Several new vaccines 
have entered Phase I/II clinical trials.  Malaria vaccines are probably the best option for 
gaining control of malaria, but it will probably take many more years to develop 
[Nussenzweig and Nussenzweig, 1989; Engers and Godal, 1998; Stoute et al., 1998; 
Herrera et al., 2002]. 
 
New antimalarial compounds that use different mechanisms of action against the malaria 
parasites (compared to drugs that are currently used) are urgently needed to control the 
disease effectively during the next few decades.  Malaria management programmes are 
still relying greatly on antimalarial drugs, and because of the phenomenon of drug 
resistance, it is essential to develop new antimalarial compounds.  Traditional medicinal 
plants and natural products are believed to be an excellent source for new antimalarial 
compounds.       
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1.2   Traditional medicine and Traditional healing 
Traditional medicine has been used to treat health problems around the world for 
centuries, but has not always been appreciated by modern medicine.  Traditional 
medicines are generally prepared by traditional healers from different ethnic groups and 
are mainly natural medicinal plant products.  A renewed interest in this field, especially 
from the Western world, was observed during the previous few decades, because of more 
people seeking alternative or complementary remedies to treat health problems.  
Examples of traditional remedies are:  herbal medicine from many different cultures, 
Oriental therapies, Ayuverdic medicine, acupuncture, homeopathy and aromatherapy.  
These remedies have become more available, which resulted in an increasing number of 
traditional medicines being used globally.  Western medicine has been introduced to most 
parts of the world for a long time, but most people, especially those from rural areas of 
Africa, Asia and South America still prefer to use traditional medicine for their health 
problems.  The reason for this preference is because traditional medicine is more 
affordable and easily available than modern medicine.  Traditional medicine has also been 
part of people’s tradition and culture. 
 
The preferred use of traditional medicine in developing countries could also be ascribed to 
traditional medicine having less adverse effects than Western medicine.  Another reason 
may be the fact that no resistance to whole-plant extracts has been recorded.  It is 
estimated by the WHO that 80% of the world's population still relies exclusively on 
traditional medicine for their physical and psychological health needs.  It has also been 
observed that people that are living in urban areas in developing countries still consult 
traditional healers.  Some people consult medical doctors first, but if their health condition 
is not resolved, traditional healers are consulted.  Others do just the opposite:  they consult 
traditional healers first, and if their health condition is not resolved, medical doctors are 
consulted.  There are also those people that only consult traditional healers.  Most of the 
traditional medicine knowledge is transferred verbally from one generation to the next 
through traditional healers [Baker et al., 1995; World Health Organization, 1998, 2002; 
Willcox and Bodeker, 2000]. 
 
There are approximately 200 000 practising traditional healers in South Africa, which is 
eight times more than medical doctors.  Traditional healers are still consulted by about 
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80% of the black South African population, because of the high cost of modern medicine, 
as well as the unavailability of medical infrastructure in rural areas.  It also has much to do 
with cultural background and believe.  It is also believed by many South Africans that 
disease is caused by a supernatural phenomenon, which involves ancestral spirits, social 
relations or the environment.  The traditional healers can relate to peoples cultural and 
believe backgrounds and treat them accordingly. They are also highly appreciated in their 
communities and are often seen as leaders.  In the South African context, which is rich in 
cultural diversity, traditional healers are described as people who are practising indigenous 
medicine. 
 
There are three main groups of traditional healers within the Zulu, Xhosa and Sotho 
communities.  The first group refers to the herbalists (90% male) who have an extensive 
knowledge about medicinal herbs and plant derived medicines (Zulu:  inyanga, Xhosa:  
ixwele, Sotho:  nqaka).  The second group refers to diviners (90% female) who integrate 
ancestral spirits and supernatural forces into their healing rituals (Zulu:  isangoma, Xhosa: 
amagquira, Sotho: dingaka).  The third group refers to faith healers in the Zulu community 
of a Christian denomination and heal through religious intervention and prayer.  They are 
known as umthandazi.  There are also traditional healers within the Khoi-San communities 
of the Kalahari and descendants of the Dutch settlers [Edwards, 1986; Kale, 1995; De 
Wet, 1998; Cocks and Moller, 2002].   
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1.3   Medicinal plants 
1.3.1   Global perspective 
Higher plants form the basis of traditional medicine, and were once the major source of 
medicines in the world.  A few examples of medicinal plants that were used during ancient 
times are:  Papaver somniferum (poppy juice), Commiphora species (myrrh), Glycyrrhiza 
glabra (liquorice), Cupressus sempevrens (cypress) and Cedrus species (cedar).  These 
plants are still used today to treat a range of health conditions.  It is estimates that about 
20 000 species of higher plants are currently being used globally to treat health conditions 
[Akerele, 1993; Phillipson, 1994; Baker et al., 1995; Cragg and Newman, 2001].  
 
1.3.2   Local perspective 
Medicinal plants are part of the daily lives of many South Africans and are an important 
part of its indigenous knowledge.  Extracts from these plants have been used to treat 
infectious diseases and other health problems for many centuries.  The medicinal plant 
knowledge is transferred verbally from one generation to the next, which increases the risk 
of losing this knowledge.  Nowadays, much of this knowledge gets lost because of the fast 
tempo of urbanization and acculturation. 
 
South Africa is rich in species diversity with more than 30 000 species of higher plants 
recorded, which is about 10% of the earth's plant diversity.  The Cape Floral Kingdom 
alone has more than 9 000 species.  South Africans use about 3 000 species as 
medicines, and about 350 of these are the most commonly used.  The most frequently 
used medicinal plants of South Africa are described in Medicinal Plants of South Africa 
and Zulu Medicinal Plants, and it is also noted that relatively little scientific work has been 
done on the medicinal plants of South Africa.  The market value of the informal and 
commercial trade in medicinal plants was estimated in 1998 at about 60 million American 
dollars per year, which is significant in the broader South African economic context.  
Conservation measurements had to be implemented due to the unsustainable and 
uncontrolled harvesting activities of many of the popular medicinal plants.  Some of these 
species are being cultivated to reduce the stress on natural populations.  South Africa's 
medicinal plants are extremely important potential sources of new therapeutic agents or 
starting materials for drug synthesis.  South Africa's natural product contribution to world 
medicines are:  buchu (Agathosma betulina), Cape aloes (Aloe ferox) and devil's claw 
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(Harpagophytum procumbens) [Mander et al., 1995; Mander 1998; Coetzee et al., 1999; 
Van Wyk et aI., 2002; Hutchings et al]. 
 
1.3.3   Plant-derived drugs 
Medicinal plant extracts that are used in traditional medicine contain many components 
that are thought to contribute to the overall healing effect.  In modern medicine the illness 
is mostly targeted by a single specific active ingredient.  The foundation for the isolation of 
pharmacologically active compounds from medicinal plants was laid in 1804 when 
morphine was isolated from Papaver somniferum L. (Opium) [Farnsworth, 1984]. 
 
Traditional herbal medicine is thought to be a good source for potential pharmacological 
active compounds, because of extensive screening that took place over many years.  
Scientific evidence also indicated a favourable correlation between biological activity and 
traditional use.  Bioactive natural products and their chemically modified derivatives are 
still presenting more than 50% of all clinically used drugs, worldwide.  The higher plants 
contribution is about 25%.  Some well known examples of plant-derived drugs are:  
Digoxin (atrial fibrillation), isolated from Digitalis purpurea; Morphine (analgesic), isolated 
from Papaver somnifernum; Ephedrine (bronchodilator), isolated from Ephedra sinica; 
Quinine (antimalarial), extracted from the bark of Cinchona species; Vincristine 
(anticancer), obtained from Catharanthus roseus; Atropine (anticholinergic), obtained from 
Atropa belladonna; Reserpine (antihypertensive), isolated from Rauwolfia serpentine; 
Salicylic acid, isolated from the bark of the Salix species; Taxol (anticancer), isolated from 
the Taxus species; and Artemisinin (antimalarial), extracted from Artemisia annua 
[Farnsworth, 1990; Akerele, 1993; De Smet, 1997; Newman et al., 2003; Newman and 
Cragg, 2007]. 
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1.4   Natural products and malaria medicine 
Humanity has used local natural products for the treatment and prevention of malaria 
for many centuries.  More than 1200 plant species are currently used throughout the 
world to treat malaria.  These medications are available where modern drugs are not.  
At present up to 75% of patients choose to use traditional medicines to treat malaria.  
Traditional antimalarial medicines present a good and reliable source for the discovery 
of novel antimalarial compounds that could be developed into new drugs.  Several 
antimalarial drugs have been discovered from natural products, and some of these 
have been chemically modified to improve drug efficacy.   The two most important 
discoveries from plants were quinine from Cinchona species and artemisinin 
(qinghaosu) from Artemisia annua.  The discovery of these two compounds has been a 
milestone in the history of modern medicine for malaria [Willcox and Bodeker, 2004]. 
 
1.4.1   Cinchona 
Cinchona bark has been used to treat malaria for many centuries.  It is safe, effective and 
affordable and will probably be in use for many years to come.  Cinchona belongs to the 
Rubiaceae family and comprises of 23 species.  Cinchona is indigenous to South America, 
but is cultivated in many tropical countries today.   The most important Cinchona species 
are:  Cinchona ledgeriana, Cinchona officinalis and Cinchona succirubra.  Many claims 
were made about the discovery of Cinchona bark for the treatment of malaria but it is not 
clear who made the original discovery.  Alkaloids were discovered in the bark of Cinchona 
plants at the beginning of the 19th century.  French chemists, Pierre Pelletier and Joseph 
Caventou discovered the first two alkaloids and named the first cinchonine and the second 
quinine.  Today, about thirty alkaloids have been isolated from Cinchona species and 
some of these have good antiplasmodial activity [Andersson, 1998; Karle and 
Bhattacharjee, 1999].  Examples of the most well-known Cinchona alkaloids are presented 
in figure 6. 
 
Quinine and quinidine have excellent pharmacokinetic properties with low toxicity and are 
regularly used to treat malaria patients.  Scientific evidence also confirms that extracts 
from Cinchona bark are as effective as quinine for the treatment against P. falciparum and 
P. vivax parasites.  A period of synthetic organic chemistry followed after the discovery of 
quinine and its related antiplasmodial alkaloids.  The molecular scaffold of quinine was 
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cinchonine cinchonidine
used as a template for synthesizing quinine derivatives.  A number of useful 
aminoquinoline-based antimalarials were developed into synthetic antimalarial drugs.  
Examples of these drugs are:  pamaquine, chloroquine, amodiaquine, pentaquine, 
primaquine, and mefloquine [Kofoed et al., 1999; Kofoed et al., 2002; Willcox et al., 2004]. 
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Figure 6  Examples of the most well-known Cinchona alkaloids 
 
1.4.2   Artemisia annua 
Artemisia belongs to the Asteraceae family and comprises over 400 species.  Artemisinin 
was originally isolated from Artemisia annua in China (1971), and was also found in two 
other species: Artemisia lancea and Artemisia apiacea.  It is not clear where the genus 
name Artemisia originated from.  Ferreira believes the genus is named after the Greek 
goddess Artemis which means “she who heals sickness”.  Bruce-Chwatt believes that the 
genus Artemisia was named after Queen Artemisia of Caria (Turkey).  A. annua is the only 
member of the Artemisia genus with an annual cycle, therefore the species name annua.  
A. annua has been used as a medicinal plant for many years, the earliest record dating 
back to 168 BC.  Li Shizhen has described the use of A. annua for malarial fever treatment 
in 1596 [Bruce-Chwatt, 1982; Ferreira et al., 1997; Tan et al., 1998; Willcox et al., 2004]. 
   
quinine quinidine
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1.5   Drug discovery and development 
1.5.1   Introduction 
Many of the drugs used today have been isolated from natural products, and some have 
been chemically modified.  Natural products have been used by many cultures around the 
world to treat disease for a very long time, even before written history was recorded.   
Early scientists found that the bioactivity from crude plant extracts could be reproduced by 
isolating constituents from the same extract.  This discovery laid the foundation of the 
modern scientific presentation of orthodox pharmaceuticals.  During most of the twentieth 
century the pharmaceutical industry shifted their focus to synthetic molecules, and has not 
taken plant extracts and the potential of the natural world to provide new biological active 
compounds seriously.  There was an unexpected shift back to traditional medicine during 
the last 20 to 25 years, because of worldwide interest in herbal medicine.  Plant derived 
extracts are now recognised by modern science as a potential source for new active 
chemical entities [Houghton and Raman, 1998].   
 
1.5.2   General approach in drug discovery and development 
A general methodology approach in drug discovery and development is presented in figure 
7, which contains four major research areas namely in vitro studies, animal testing, clinical 
testing and marketing.  Drug discovery and development is a complex and expensive 
process.    The cost to develop a new drug ranges between 150 - 800 million US dollars 
and takes on average twenty years to reach the market.  The initial step is the discovery of 
new compounds, either from biological products or from organic synthesis, and to screen 
these compounds against in vitro models.  The active compounds are then taken further in 
animal testing (toxicity, safety, efficacy, selectivity, mechanism, metabolism and 
pharmacokinetics).  The pre-clinical compounds then enter clinical testing in phase I, II and 
III studies.  The final step is marketing of the new product where post marketing 
surveillance takes place.   Generic products become available twenty years after the 
original filing of application occurred [Katzung, 2004].      
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Figure 7  Flow-diagram of the general drug discovery and development process 
 
1.5.3   Stages in drug discovery 
Drug discovery and development requires different stages (figure 8).  This process begins 
with screening compounds against biological targets or whole organisms.  Compounds 
that show in vitro bioactivity are defined as hits.  These hits can be considered for further 
testing in animal models of the disease.  During this early development stage the 
compound’s pharmacokinetic properties are also investigated in the same animal model.   
Compounds that are active in the animal model with good quality pharmacokinetic 
properties are defined as leads.  The lead compounds then undergo a series of 
optimization and efficacy studies to prove good pharmaceutical properties.  Once the lead 
reaches a stage where it can be considered for testing in humans it is defined as a drug 
candidate.  The drug candidate then enters preclinical testing and finally clinical testing in 
proper drug development platforms [Nwaka and Ridley, 2003].  
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Figure 8  Flow-diagram of the different stages in drug discovery 
 
 
1.5.4   Approaches in drug discovery 
Fundamental approaches in drug discovery can be classified as short to medium term and 
long term processes.  The short to medium term approach is the exploitation of known 
compounds or compound classes.  For example: combinations of existing drugs, which 
offer possibilities of reduced toxicity; shorter treatment regimens; slower development of 
resistance and synergy; and new indications for existing drugs, which offer major savings.  
This approach has been shown to be very successful in the antiparasitic drug development 
platform and has delivered many drugs that are currently in use.  The long term approach 
requires the discovery of new compounds or compound classes.  For example: 
improvement to known drugs and compound classes, by making use of chemical 
modification and organic synthesis, and focused sample collection, where large libraries of 
Hit 
disease animal model and pharmacokinetics 
Drug candidate 
Drug  
whole parasite screen biological target screen 
compound 
active in vitro 
or 
active in vivo, low general toxicity and 
good PK properties 
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compounds are screened against whole organisms to discover new active compounds that 
are unrelated to known compounds.  The search for novel active compounds in natural 
products, especially medicinal plants, is considered attractive because of their structural 
diversity [Mpia and Pepin, 2002; Rosenthal, 2003; TDR, 2003; Kremsner and Krishna 
2004].  
 
1.5.5   Challenges in antiparasitic drug discovery 
Many of the drugs that are used to treat antiparasitic diseases have been introduced 
decades ago and are far from ideal.   The markets have been unsuccessful in facilitating 
the discovery and development of new antiparasitic drugs during recent years.  During 
1975 and 1999, 1300 new drugs were introduced for all indications, but only 13 were for 
antiparasitic diseases.  The discovery and development of antiparasitic drugs is not more 
expensive or technically difficult than for other diseases.  The estimated cost of bringing a 
new antimalarial to the market is estimated at 300 million US dollars.  The average cost of 
each new drug for other diseases is about 500 million US dollars.  The discovery and 
development of antiparasitic drugs is not commercially driven.  Many of the drugs used to 
treat these tropical infectious diseases have previously been used for other indications.  
Today the picture is more optimistic, as many new partnerships have been established 
between the public and private sectors.  New funds were introduced for antiparasitic drug 
discovery by generous organisations, like the Bill and Melinda Gates foundation.   
Examples of public-private partnerships are:  Medicines for Malaria Venture, Drugs for 
Neglected Diseases and the Institute for One World Health [Trouiller, 2002; Medicines for 
malaria venture; Nwaka and Ridley, 2003; Kettler and Marjanovic, 2004; Ridley 2004].  
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1.6   Antiplasmodial evaluation of plant derived products  
1.6.1   Introduction 
The clinical efficacy of herbal antimalarials is often questioned and debated by the 
scientific community.  There are probably two complementary approaches that can be 
followed to validate the clinical effectiveness of herbal antimalarials: firstly, by conducting 
clinical trials and secondly, by performing biological in vitro and in vivo testing.  
Unfortunately, inconsistencies are often experienced when laboratory findings are 
compared with field studies.  The complexity of the Plasmodium life cycle makes it difficult 
to select appropriate laboratory models; however four stages of the parasites life cycle 
could be targeted and are described in 1.6.3.1.   
 
1.6.2   Traditional medicine as sources of antiplasmodial compounds 
Plant derived traditional medicine has developed over many years and is in general 
accepted as a good source for potential pharmacological active compounds.  More than 
1200 plant species are used to treat malaria and can be categorized in three groups:  
Firstly, plants which directly inhibit parasite development at either the erythrocytic stage or 
the hepatic stage.  The second group consists of plants that affect host-parasite 
relationships for example immunostimulants and antipyretics.  The third group has no clear 
effect on malaria, but may probably have a psychosomatic effect (ethnomedical beliefs).  
Much progress have been made during the last few years in our understanding of the 
biology and biochemistry of the malaria parasite and it has also been shown that the 
erythrocytic stage of the Plasmodium parasite is the most important target in malaria 
chemotherapy.  It is therefore suggested that traditional medicine be evaluated for its 
ability to inhibit parasites in the blood stage, as well as in the hepatic stage of parasite 
development [Olliaro and Goldberg, 1995; Rasoanaivo, 2002].   
   
1.6.2.1   Plant material 
The biological identity of the plant material must be verified by a professional taxonomist 
and voucher specimens of the plants must also be kept at the organization where the work 
is performed or should be kept at an officially recognized herbarium.   The details of the 
plant harvesting conditions must be recorded, such as the time of collection, season, and 
stage of the plant development.  The plant parts that are collected must be the same as 
the material that is used in the traditional preparations.   The plant material is generally air-
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dried at room temperature and is also protected from direct sunlight.  The dried material is 
then macerated to a fine powder using a blender and kept at -20 °C in the laboratory until 
extraction.  In some cases the material is processed fresh to prevent enzymatic 
degradation or hydrolysis.  It is also important to make sure that the plant material is not 
contaminated with other plant material that grows nearby.  The plant material should also 
be inspected for viral, bacterial or fungal infections.  Such infections may alter the 
metabolism of the plant and unexpected products could be formed [Houghton and Raman, 
1998]. 
 
1.6.2.2   Ethnopreparation-based extraction 
Leaman and co-workers showed that the degree of local consensus about a given remedy 
is a good indicator of its potential biological efficacy.  They conducted a study on malaria 
remedies derived from natural sources of the Kenyah civilization, which live in the highland 
forests of Kalimantan (Indonesian Borneo) and Sarawak (Malaysian Borneo).   These 
people have developed 17 local plant-derived remedies to treat malaria.  The results from 
Leaman’s study confirmed the rational selection and use of traditional remedies for malaria 
by the Kenyah people [Leaman et al., 1995]. 
 
It is observed in the scientific literature that the traditional healer’s recipes, for preparing 
these tradition medicines, are often ignored in medicinal plant evaluation programmes.  
The ethno-based extraction methodology approach is strongly recommended for the 
evaluation of traditional medicines in antimalarial drug discovery and development 
programmes.  The plant extracts should be prepared in exactly the same way as described 
by the healers, and it is therefore important to consult the healers before extraction is 
performed. 
 
1.6.2.3   Solvent extraction 
The recipes for preparing traditional antimalarial remedies are not always available, or 
described in the medicinal plant literature.  Therefore, scientists have to rely on other 
extraction methods to evaluate such plant products for their efficacy and safety.  There are 
many different solvent extraction approaches described in the literature.  The conventional 
approach is to separate compounds according to their polarity into groups.  Non-polar 
solvents, such as petroleum ether, cyclohexane, heptane or hexane are firstly used to 
“defat” the plant material.  The non-polar plant constituents are extracted with these non-
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polar solvents.  Hexane is usually avoided because of its toxicity and flammability.  The 
remaining plant material is then extracted with organic solvents of increasing polarities, 
such as dichloromethane and ethyl acetate.  Thereafter, the residue is extracted with 
methanol or ethanol and finally with water.  This approach is based on the Roman principle 
of solubility:  similia similibus solvuntur (the similar dissolves the similar) [Gessler et al., 
1994; Houghton and Raman, 1998].   
 
Another approach is to use mixtures of ethanol and water to selectively target the more 
polar compounds [Munoz et al., 2000].  Simonsen and co-workers also showed that 
ethanol can be used to successfully extract more polar compounds from plant material 
[Simonsen et al., 2001].  Alcohol extraction with a Soxhlet apparatus has been used for 
various parts of antimalarial plants.  [Sharma and Sharma, 1999]  This methodology 
approach is avoided by many groups because of the risk of alternating labile constituents. 
 
Alternative extraction methods are:  percolation, infusions with hot solvents, reflux 
extraction, steam distillation, supercritical fluid extraction and many more industrial 
processes.  The extraction process is usually followed by clean-up techniques to separate 
compounds of interest from unwanted substances.  Examples of these techniques are:  
filtration, precipitation, size exclusion chromatography, solvent partitioning, normal phase 
chromatography and reverse phase chromatography [Houghton and Raman, 1998].  
 
1.6.2.4   Bioassay-Guided fractionation 
The number of plants with confirmed antiplasmodial activity could be significantly 
increased if the plants are subjected to fractionation before screening.  It has also been 
suggested that plants with moderate antiplasmodial activity should be allocated for 
bioassay-guided fractionation.  There are a few fractionation methods described in the 
literature, i.e. solvent partitioning, countercurrent distribution, solid-liquid column 
chromatography and preparative HPLC.  Continuous screening for antimalarial activity is 
performed with all the fractions, and the active fractions are taken further in the 
fractionation and purification process.  [Statz and Coon, 1976; Samuelson et al., 1985;  
Samuelson 1987; Galeffi et al., 1997; Houghton and Raman, 1998; Rasoanaivo, 2002; 
Willcox et al., 2004]. 
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1.6.3   Antimalarial bioassays 
The worldwide antimalarial drug discovery and development community have developed a 
number of in vitro and in vivo screening models for the evaluation of plant extracts and 
compounds for their antimalarial efficacy and safety, during the last few decades.  The 
focus of these programmes has been on the erythrocytic stage of the parasites 
development; however, three more targets have been added to these in vitro screens.  
 
1.6.3.1   In vitro antiplasmodial assays 
The first target is the asexual erythrocytic stage, which is mostly targeted by scientists 
because of the availability of this screening model in many laboratories.  The asexual 
stage P. falciparum parasites is maintained in continuous culture and a parasite lactate 
dehydrogenase assay is used to determine parasite viability [Trager and Jensen, 1976; 
Makler et al., 1993]. 
 
Numerous in vitro antiplasmodial activity studies, which target the asexual erythrocytic 
stage, have been carried out on plant extracts and compounds.  These screening systems 
have been used very successfully in evaluating plant extracts and compounds for 
bioactivity against the erythrocytic stage of the parasites.  Two examples of such studies 
are presented below.  
 
Fischer and co-workers have studied the in vitro antiplasmodial activity of nine Brazilian 
plant species.  Six species were selected from the Annonaceae family, two from 
Menispermaceae and one from Siparunaceae.  Ethanol and “alkaloid” extracts were 
prepared and screened against chloroquine-sensitive and chloroquine-resistant strains of 
P. falciparum.  Most of the “alkaloid” extracts were more active than the ethanol extracts.  
The IC50 values, for both strains were between 0.3 - 8.2 µg/ml.  The alkaloid extract of 
Guatteria australis was the most active against K1, with an IC50 value of 0.3 µg/ml.  The 
screening of these nine plants resulted in 6 potential lead extracts that should be 
considered for further antiplasmodial bioassay-guided fractionation [Fischer et al., 2004] 
 
Chukwujekwu and co-workers have isolated an active antiplasmodial compound from a 
petroleum ether extract of the leaves of Hyptis suaveolens, with an IC50 value of 0.1 µg/ml 
(tested against a chloroquine sensitive D10 strain).  Bioassay-guided fractionation resulted 
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in the isolation of the active, abietane-type diterpenoid endoperoxide, 13α-epi-dioxiabiet-
8(14)-en-18-ol [Chukwujekwu et al., 2005] 
 
The second target is the hepatic stage of the Plasmodium parasites.  The hepatic stage 
Plasmodium parasites can also be maintained in culture.  This, relatively new methodology 
has opened up many new strategies in antimalarial research programs.  Presently, only 
tafenoquine and primaquine are used as antirelapse and prophylactic agents.  These 
drugs have shown haematological toxicity and are therefore not ideal drugs.  Atovaquone 
is also used as a hepatic stage inhibitor, but is not an effective antirelapse agent.  It is 
essential to develop new, more effective anti-hepatic stage drugs, because of the following 
reasons:  Firstly, prophylactic drugs prevent parasites from reaching the blood.  Secondly, 
it is commonly accepted that only a few sporozoites are injected into human hosts by 
Anopheles mosquitos during infection.  The probability for mutant hepatic phase parasites 
emerging under drug pressure is much less compared to the blood stage parasites.  It is 
therefore unlikely that resistance will develop against hepatic stage drugs.  This stage of 
the Plasmodium parasites development is an important and attractive target and will play a 
major role in future antimalarial drug development programmes. Thirdly, more effective 
antirelapse compounds could prevent recrudescence of P. vivax, which causes about 80 
million clinical cases annually [Mazier et al., 1984, 1985; Marussig et aI., 1993; Shanks et 
al., 1998; Basco et al., 1999; Mendis et al., 2001]. 
 
The third target is an antidisease screening approach for cerebral malaria.  P. falciparum 
infected red blood cells that stick to the endothelium of micro vessels are responsible for 
cerebral malaria.  The adhesion of infected erythrocytes to the endothelium leads to an 
overexpression of different mediators such as cytokines, which add to the pathology.  
Compounds that would interfere with adhesion of infected erythrocytes to endothelial cells 
might be of interest.   Two enzyme linked immunosorbent assays (ELISA) have been 
developed to screen compounds for potential anti-cerebral malaria activity [Muanza et al., 
1996; Salgame et al., 1997; Pino et al., 2003]. 
 
The fourth target is the sexual erythrocytic stage, which is asymptomatic (similar to the 
hepatic stage).  However, prevention of gametocyte formation would prevent parasite 
transmission to mosquitos.  This target is especially important in parasite genomes which 
carry drug resistant alleles.  Rodent models and in vitro P. falciparum screening models 
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have been established to target this stage of parasite development [Ramakaran and 
Peters, 1970; Hogh et al., 1998].  
 
1.6.3.2   Cytotoxicity assays 
The next phase is to investigate the general cytotoxicity of extracts or compounds that 
have shown good antiplasmodial activity.  These tests are performed to determine the 
potential of an extract or compound to selectively inhibit parasite growth without damaging 
host cells. 
 
The selectivity index was introduced to evaluate an extract or a compound’s specificity to 
parasite cells, and is defined as the ratio of the IC50 cytotoxicity to the IC50 antiplasmodial 
activity.  These selectivity index values are used as a guide in selecting plant extracts or 
compound for further examination (the higher the value, the better the selectivity to the 
malaria parasites).  There are several methods available for performing cytotoxicity tests 
and are described by Husoy and co-authors [Husoy et al., 1993].   
 
A few examples of studies that incorporate cytotoxicity testing for extract or compound 
evaluation are presented below.  
 
Kanokmedhakul and co-workers have isolated a novel, 1,3-dihydroxy-2-methyl-5,6-
dimethoxyanthraquinone and six other known anthraquinones, a β-sitosterol, and two 
known triterpenoids from the roots and stems of Prismatomeris fragrans.  These 
compounds have been evaluated for their antiplasmodial, antituberculosis, antifungal and 
anticancer cell properties.  The antiplasmodial assay showed that only β-acetylolean-12-
en-28-oIic acid exhibited moderate antimalarial activity (IC50 value of 5.9 µg/ml against K1, 
which is a multidrug resistant Plasmodium falciparum strain).  This compound also showed 
moderate cytotoxicity to a NCI-H187 cell line (IC50 value of 9.4 µg/ml) [Kanokmedhakul et 
al., 2005].  
 
Otshudi and co-authors studied the antimicrobial, antiplasmodial and cytotoxic properties 
of four bisbenzylisoquinoline alkaloids, i.e., cycleanine, cycleanine-N-oxide, 
isochondodendrine and cocsoline.  These alkaloids were isolated from roots of Epinetrum 
villosum (Exell) Troupin, which belongs to the Menispermaceae family.  
Isochondodendrine was the most active compound against FcB1, a chloroquine resistant, 
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P. falciparum strain, with an IC50 value of 0.2 µM (which correlated well with quinine’s IC50 
value, which was 0.21 µM).  This compound also showed a favourable selectivity index 
value of 175.    Cocsoline was the second most active compound, with an IC50 value of 
0.54 µM.  The selectivity index value of this compound was 9.3, which indicates some 
degree of toxicity [Otshudi et al., 2005]. 
 
Zirihi and co-workers have studied the antiplasmodial activity and cytotoxic affect of four 
steroidal alkaloids (holarrhetine, conessine, holarrhesine and isoconessimine) that were 
isolated from an ethanol extract of the stem bark of Funtumia elastica.  Bioassay-guided 
fractionation of the ethanol extract was performed to obtain the antiplasmodial compounds.  
The compounds were screened against an FcB1, which is a chloroquine-resistant, P. 
falciparum strain, and showed IC50 values ranging from 0.97 to 3.39 µM.  These 
compounds were also screened against a rat L-6 cell line to determine their general 
toxicity, and showed weak cytotoxicity, ranging from 5.13 to 36.55 µM [Zirihi et al., 2005].   
 
De Mesquita and co-workers have studied the antiplasmodial activity of 27 species of 
native Brazilian Cerrado plants, which are commonly used by traditional healers to treat 
malaria and other diseases.  Hexane and ethanol extracts from various parts of the plants 
were prepared and screened against an FcB1, a chloroquine resistant, P. falciparum 
strain.  Sixteen of these extracts showed good antiplasmodial activity against FcB1, with 
IC50 values below 10 µg/ml.  Some of these extracts were also tested for general toxicity 
against L-6 cell lines of rats and MRC-5 cell lines of humans.  Four of these extracts 
showed selectivity index values above 10, which could be considered for further 
antiplasmodial evaluation [de Mesquita et al., 2007].    
 
Pillay and co-workers have studied the antiplasmodial activity of Oncosiphon piluliferum, 
which belongs to the Asteraceae family.  They have isolated sesquiterpene lactones of the 
germacranolide and eudesmanolide type through conventional chromatographic 
techniques and bioassay-guided fractionation.  They have also studied the antiplasmodial 
and cytotoxicity activities of these compounds.  Five of these compounds showed good 
antiplasmodial activity against the D10, chloroquine sensitive, Plasmodium falciparum 
strain, with IC50 values between 0.4 and 4.4 µg/ml.  These compounds were also screened 
against Chinese Hamster Ovarian cells and showed to be toxic to these cells at similar 
concentrations.  [Pillay et al., 2007]. 
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These above mentioned studies illustrate the value of performing cytotoxicity testing on 
extracts or compounds with good antiplasmodial properties.  These screens are used to 
select active, as well as selective antiplasmodial extracts or compounds in antimalaria 
drug discovery and development programmes. 
 
1.6.3.3   In vivo antiplasmodial assays 
The most active and selective extracts or compounds are normally selected for in vivo 
antiplasmodial evaluation during the early stages of drug development, however studies 
on this subject are limited, especially for plant derived pure compounds.  The reference 
test for blood schizontocidal activity of plant extracts or compounds is the Peters 4-day 
suppressive test on mice infected with Plasmodium berghei Anka parasites, and a few 
variations on this method have developed during the years.  The plant extract or 
compound is administered to P. berghei infected mice as described by Peters and co-
workers, and is evaluated according to the reduction in parasitaemia [Peters et al., 1975]. 
 
A few examples of studies that have included in vivo antimalarial testing for extract or 
compound evaluation are presented below.  
 
Muthaura and co-workers have studied the antiplasmodial activity and cytotoxicity of 
methanolic and water extracts of five medicinal plant species that are used for malaria 
treatment by the Kwale people in Kenya.  They have also studied the in vivo activity of 
these extracts in a P. berghei mouse model.  Four of the plants showed good, selective 
activity against the D6, chloroquine sensitive, strain, with IC50 values below 10 µg/ml.  The 
water extract of Mayte us undata showed to be the most promising extract, with an IC50 
value of 0.95 µg/ml against D6, and 1.90 µg/ml against W2 (chloroquine resistant strain).  
The selectivity index value of this extract was also favourable, which indicates selective 
inhibition of the malaria parasites.  At least one of the extracts of all the plant species 
showed good in vivo activity in a murine model of P. berghei infected mice.  This study 
shows the value of in vitro (antiplasmodial and cytotoxicity) and in vivo examination of 
plant extracts to evaluate their potential as sources of antimalarial compounds [Muthaura 
et al., 2007]. 
 
Ojo-Amaize and co-workers have isolated hypoestoxide (a diterpene) from Hypoestes 
rosea, which is an indigenous Nigerian plant.  This species belongs to the Acanthaceae 
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family.  They have studied the in vitro and in vivo antiplasmodial activity of this compound.  
The in vitro activity of hypoestoxide against P. falciparum parasites was relatively weak, 
with an IC50 of 10 µM (IC50 of chloroquine was 0.11 µM).  They also showed that the dose 
required to reduce parasitaemia by 90% in P. berghei-infected mice, is much lower than 
standard antimalaria drugs (SD90 = 250 µg/kg versus 5 mg/kg for chloroquine) [Ojo-
Amaize et al., 2007]. 
 
This compound showed relatively poor in vitro activity, and excellent in vivo activity.  These 
rather unexpected in vivo results should be explored further.    
 
Portet and co-workers have isolated four monoterpene or prenyl-substituted 
dihydrochalcones, and the following known compounds:  2',6'-dihydroxy-4'-
methoxydihydrochalcone, linderatone, strobopinin, adunctin E and (-)-methyllinderatin from 
the leaves of Piper hostmannianum var. berbicense.  The compounds were screened 
against F32, which is a chloroquine sensitive P. falciparum strain, and FcB1, which is a 
chloroquine resistant Plasmodium falciparum strain.  (-)-Methyllinderatin was the most 
active antiplasmodial compound against both strains.  These compounds were also tested 
for cytotoxicity against a human cell line, MCF7.  The selectivity index values of (-)-
methyllinderatin, against F32 and FcB1, were 12.2 and 13.0, respectively, which indicate 
relatively good selectivity for the malaria parasites.  The in vivo activity of (-)-
methyllinderatin was also studied in a Plasmodium oinckei petteri mice model, and an 80% 
reduction of parasitaemia at a dose of 20 mg/kg/day was observed [Portet et al., 2007].  
 
These above mentioned studies are the first step in animal testing of good, selective in 
vitro antiplasmodial compounds or extracts, and are used to evaluate the efficacy in vivo.   
 
Milligram quantities of test material are needed for these in vivo efficacy tests, which poses 
a great challenge for phytochemists.  The isolation of antiplasmodial pure compounds from 
plant extracts is a time consuming and expensive task, especially if the compound of 
interest is only present in low amounts.  Many of the antimalarial drug discovery and early 
drug development programmes are carried out at academic and governmental institutions, 
with limited resources, which may be the explanation for the relatively few publications in 
this field.  It is often observed that in vivo efficacy testing is only performed in polar 
chemical environments, which is not always the best method of testing compounds in 
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animal models.  Compounds should be evaluated for efficacy in animal models in an 
optimised chemical environment, which leads to the subject of formulation.  The test 
compound should be available at the target site at high enough levels to have a chance to 
inhibit parasite growth.   
 
The intention of the in vivo phase of this project is to illustrate the importance of conducting 
bioavailability and metabolic testing, in the same animal model that will be used for 
efficacy testing, before in vivo efficacy testing is performed.  This approach should give the 
investigator a better understanding about the chemical properties of the test compound in 
a complex animal model.  This approach will also require less starting material for initial 
bioavailability and metabolic studies.  It should also assist with the decision making 
process regarding which compounds should be taken further in the early drug 
development process, which will require relatively high amounts of the test compound. 
 
Bioavailability and metabolic evaluation of active in vitro compounds is one of the most 
important secondary screening procedures in drug development and should also be 
included on a larger scale in preliminary antimalarial screening programmes.  Literature on 
this subject is limited; however, a few examples of pharmacokinetic studies in mice are 
presented next (other research fields): 
 
Bryant and co-workers have shown that pharmacokinetic screening for the selection of 
new drug discovery candidates could be greatly enhanced through the use of liquid 
chromatography-atmospheric pressure ionization tandem mass spectrometry.  They have 
compared the time required to develop a conventional GC-NPD method with a new LC-
MS/MS method, and have reported that it takes about 3 weeks to develop a GC-NPD 
method, and 1 week to develop an LC-MS/MS method.  LC-MS/MS methods could be 
developed in less time compared to conventional methods, and are also more selective 
and sensitive analytical detection systems [Bryant et al., 1997].   
 
Feng and co-workers have developed and validated a highly sensitive Electrospray LC-
MS/MS assay for the analysis of a bradykinin antagonist polypeptide B201 (NSC 710295) 
in mouse plasma.  They have used a Finnigan LCQ ion trap mass spectrometer as a 
detection system, which was set in the selected reaction monitoring mode.  The transitions 
of the ions were:  m/z 938.93+ to 816.02+ for B201, and m/z 674.32+ to 665.72+ for the 
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internal standard.  A C18 solid phase extraction method was developed to extract B201 and 
the internal standard from plasma, 200 µl of sample was used (plasma from four animals 
per time point was pooled).  Chromatography was performed on a reverse phase C8 
column, using a gradient mobile phase which consisted of TFA in water and acetonitrile.  
They have used the assay method to study the pharmacokinetics of B201 in mice.  A 
preliminary two-compartment model was constructed.  Bioavailability was poor, only 1%.  
This study shows that LC-MS/MS assays can be used to quantify “test compounds”, in the 
low nanogram per ml concentrations, in mouse blood.  This study shows the ability to 
develop very sensitive and selective analytical methods that can be used for 
pharmacokinetic studies of “test compounds” in mice [Feng et al., 2002]. 
 
Jia and co-authors have developed a high-throughput LC-MS/MS system, which was used 
for pharmacokinetic screening of three anti-tubercular ethambutol analogs in human, dog, 
rat and mouse plasma.  They developed a protein precipitation method (using acetonitrile) 
to extract the compounds of interest from the plasma samples (200 µl).  Chromatography 
was performed on a gradient reversed phase C18 column, and the mobile phase consisted 
of methanol, 5 mM ammonium acetate and 0.1% TFA.  They used a PE Sciex API 3000 
triple quadrupole mass spectrometer as a detection system, which was set in the multi 
reaction monitoring mode, and was also set in the positive Electrospray mode.  The 
transitions of the ions were:  m/z 377 to 224 for SQ37, m/z 307 to 154 for SQ59 and m/z 
331 to 178 for SQ109.  The oral bioavailability of SQ59, SQ37 and SQ109, was 5.1%, 
20.1% and 7.8%, respectively.  They also reported that the use of LC-MS/MS has greatly 
enhanced their ability to profile many drug candidates simultaneously in a single sample 
[Jia et al., 2005].   
 
Singh and Vingkar have used a reverse phase HPLC system to study the oral 
bioavailability of primaquine (incorporated into lipid nanoemulsion) in mouse blood. The 
animals were sacrificed at every time point and average animal data was used to construct 
drug-concentration time profiles.  Primaquine is an antirelapsing drug, and is very 
important in P. vivax and P. ovale relapse treatment strategies.  This drug acts specifically 
on the relapse causing pre-erythrocytic schizonts, which are found mainly in the liver.  
Unfortunately, treatment is limited due to severe tissue toxicity caused when primaquine is 
administered at relatively high doses.  Lipid nanoemulsion has been used successfully in 
improving bioavailability for many other drugs.  Singh and Vingkar have studied the 
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bioavailability of primaquine when incorporated into oral lipid nanoemulsion having particle 
size in the range of 10-200 nm.  Effective antimalarial activity has been reported, against 
P. berghei infection in mice, at a 25% lower dose as compared to conventional oral dose.  
The HPLC analytical system was successfully used to analyse the mouse samples, 
however many animals have been used to evaluate the lipid nanoemulsion drug delivery 
system.  Quadrupole mass spectrometers are much more sensitive and selective detection 
systems compared to conventional HPLC detectors, which poses the possibility to develop 
methods that only use very small sample volumes.  Such methods would make it possible 
to collect samples from all the sampling points from one mouse.  These animals could also 
be re-used after a recovery period of about 3 weeks [Singh and Vingkar, 2008]. 
 
From an ethical perspective it is also important to work towards a more focused in vivo 
screening system.  Bioavailability and metabolic studies should reduce the number of 
compounds that are normally tested for in vivo efficacy, which will lessen the animal 
numbers significantly.   
 
The first objective for the more focused in vivo testing was to develop methodology that 
could study a test compounds bioavailability properties in mice.  The intention was to use 
one animal for all the sampling points and to use three animals per experimental group.  
The animals will also be reused after a recovery period of about 2 weeks.  The second 
objective was to develop methodology that could study the metabolics of the test 
compound in mouse blood, urine and faeces.  The intention was to use only one animal for 
this experiment.  The new methodology would also require no killing of animals during the 
bioavailability and metabolic experiments.   
 
An understanding of the absorption, distribution, metabolism and excretion of a test 
compound is essential in order to be able to design effective treatment regimens.  The P. 
berghei mouse model is the most frequently used animal model for efficacy testing, but is 
rather a challenging model for pharmacokinetic and metabolic studies, because of the 
animal’s small blood volume.  However, triple quadrupole mass spectrometry has been 
successfully applied to detect trace amounts of compounds from biological matrixes in 
similar applications. 
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1.7   Scope of Study 
It is the intention of this study to identify and characterise antiplasmodial compounds within 
the Xerophyta genus, and to evaluate the most promising compound in a mouse model. 
 
The first objective of this project was to isolate and characterise new antiplasmodial 
compounds from the Xerophyta genus.  This objective was subdivided into the following 
categories: 
 
 in vitro antiplasmodial screening and cytotoxicity testing of X. villosa and X. retinervis  
extracts 
 isolation of potential antiplasmodial compounds 
 in vitro antiplasmodial screening and cytotoxicity testing of potential antiplasmodial 
compounds 
 structural elucidation of the most promising compounds 
 
A second objective was to study the bioavailability and metabolism of the most promising 
compound in a mouse model and to use this information to design a treatment strategy to 
investigate the antimalarial activity of this compound in a mouse model.  This objective 
was subdivided into the following categories: 
 
 bioavailability study of the most promising compound in a mouse model 
 metabolism investigation   
 in vivo antimalarial study of the most promising compound in a mouse model 
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CHAPTER 2 
 
X. villosa and X. retinervis   
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2   X. VILLOSA AND X. RETINERVIS  
 
2.1   Introduction 
The Medicinal Plants of South Africa and a M. Sc thesis by Dianne Chen were used to 
select plants for this project [Van Wyk et al., 2002; Chen, 1997].  The following two species 
of the Xerophyta genus (figure 9) were selected as a potential source of antimalarial 
compounds:  Xerophyta villosa (Bak.) and Xerophyta retinervis Bak. FP. [Arnold and De 
Wet, 1993]. 
 
X. retinervis has antimicrobial, anti-ulcer, central nervous system and anti-inflammatory 
activity.  Extracts from X. retinervis are also used as traditional remedies for health 
problems like nose bleeding, asthma and general aches.  Xerophyta species belong to the 
family Velloziaceae and is usually found in rocky areas in the northern grassland areas of 
South Africa.  These plants have thick erect stems which are covered with leaf bases.  The 
secondary metabolites from these plants are poorly known, but some biflavonoids have 
been isolated from X. retinervis with the main compound amentoflavone.  Differences in 
flavonoid patterns between genera within the Velloziaceae have also been reported 
previously.  [Williams et al., 1994; Chen, 1997; Van Wyk et al., 2002].   
 
X. villosa was collected at the Blyde River Canyon Nature Reserve (Mpumalanga, South 
Africa) and X. retinervis was collected on a farm at Hoedspruit (Mpumalanga, South 
Africa). 
 
Plant collection information is presented in Chapter 12 (12.1).  
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X. villosa                X. retinervis 
 
 
   
X. villosa                X. retinervis 
 
   
Dried plant material of X. villosa      Leave bases of X. villosa 
 
Figure 9  Photograph gallery of X. villosa and X. retinervis  
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The ethno-based extraction methodology approached (as suggested in 1.6.2.2) could not 
be followed for this project, because of the non specific use of Xerophyta as traditional 
medicine by traditional healers.  It was decided to follow the “similia similibus solvuntur” 
extraction approach, as discussed in 1.6.2.3, to group the plant constituents according to 
its polarity in different groups.  Different extraction procedures were used for the two 
Xerophyta species and are described in Chapter 12 (12.2).  
 
A flow-diagram, which summarises the extraction procedure, is presented in figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10  Flow-diagram of the X. villosa and X. retinervis extraction model  
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2.2   Results 
The recovery yields of the X. villosa and X. retinervis extracts are presented in tables 1 
and 2, respectively. 
 
Table 1  Extraction yields of X. villosa extracts 
Extract Mass (g) % yield 
Petroleum ether 0.76 1.9 
Dichloromethane 0.08 0.2 
Ethyl acetate 0.13 0.3 
Methanol 1.50 3.8 
 
The methanol extract was further separated into two fractions as described in Chapter 12 
(12.2).  Liquid-liquid extraction was performed on the methanol extract to separate the less 
polar compounds from the more polar compounds.  The yields of the aqueous and organic 
layers were 0.3 g and 1.1 g, respectively (0.1 g loss).  
 
Table 2  Extraction yields of X. retinervis extracts 
Extract Mass (g) % yield 
Petroleum ether 0.5 1.0 
Methanol 0.5 1.0 
 
The methanol extract was also separated into two groups using liquid-liquid extraction and 
is also described in Chapter 12 (12.2).  The yields of the aqueous and organic layers were 
0.1 g and 0.3 g, respectively (0.1 g loss).  
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2.3   Discussion 
The plant material was collected during the cold winter period in Mpumalanga, South 
Africa.  During this period the plants are in a dormant state as can be seen in the 
photographs presented in figure 9. 
 
X. villosa plant material was extracted sequentially with organic solvents of increasing 
polarities:  petroleum ether, dichloromethane, ethyl acetate and methanol.  The highest 
yield was observed in the methanol extract (3.8%).  X. retinervis plant material was 
extracted initially with petroleum ether, followed by methanol.  The extraction yields for 
both extracts were 1%.   
 
Previous work by Dianne Chen reported the presence of a novel flavonolignan (which 
showed moderate antiplasmodial activity during preliminary screening) in a methanol 
extract from X. retinervis.  It was reported that the compound precipitated out of solution 
after the methanol extract was dried and redissolved in ethyl acetate.  At this stage of the 
project it was decided to commence the search for antiplasmodial compounds in a similar 
chemical environment as was reported earlier [Chen, 1997].  The methanol extracts were 
therefore further subdivided into semi-polar and polar groups by liquid-liquid extraction.  
The organic fractions from the methanol extracts were considered potential sources for 
related antiplasmodial compounds.  These organic fractions of X. villosa and X. retinervis 
yielded 1.1 and 0.3 g material, respectively.      
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CHAPTER 3 
 
Antiplasmodial activity and cytotoxicity screening 
of X. villosa and X. retinervis extracts 
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3   Antiplasmodial activity and cytotoxicity screening of X. 
villosa and X. retinervis extracts 
 
 
3.1   Introduction 
Antiplasmodial activity screening of plant extracts is used to determine the potential of 
extracts as sources of antiplasmodial compounds [Clarkson et al., 2003; Clarkson et al., 
2004; Fischer et al., 2004; Chukwujekwu et al., 2005; De Monbrison et al., 2006; Pillay et 
al., 2007].  Antiplasmodial activity of crude extracts with IC50 values less than 10 μg/ml are 
considered to be potential sources of antiplasmodial compounds [Rasoanaivo, 2002; 
Willcox et al., 2004].  A good source of antiplasmodial compounds should also inhibit 
parasites selectively and cause no harm to other cells.  Cytotoxicity experiments are used 
to determine general toxic properties of plant extracts against living cells.  Antiplasmodial 
activity and cytotoxicity information are used to determine selectivity indexes, which are 
used as a guide to determine the potential of an extract for further investigation.  
Evaluation criteria on this subject varies, but according to a review article by Richard Pink 
and co-authors, an active antiplasmodial compound should be at least tenfold more active 
against the targeted organism than against mammalian cells to be considered for further 
testing.  It was decided to use this selectivity evaluation method as a guideline for extract 
evaluation [Pink et al., 2005].   
 
An antiplasmodial whole parasite screening system was used to test the antiplasmodial 
activity of these plant extracts.  The malaria parasites were cultured according to the 
method described by Trager and Jensen (with minor modifications) [Trager and Jensen, 
1976].  The parasite lactate dehydrogenase assay (pLDH) as described by Makler and co-
workers was used to determine parasite viability (with minor modifications) [Makler et al., 
1993].  Cytotoxicity was tested against Chinese hamster ovarian (CHO) cells.  The cells 
were cultured according to a standard operating procedure prepared by the Pharmacology 
Department at the University of Cape Town, South Africa.  The MTT assay as described 
by Mosmann (with minor modifications) was used to determine cell viability [Mosmann, 
1983].  These assay procedures are described in Chapter 12 (12.3 and 12.4). 
 
The organic fractions, from the methanol extracts, from X. villosa and X. retinervis were 
targeted as potential natural sources of new antiplasmodial compounds.  These extracts 
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were screened against a chloroquine sensitive P. falciparum strain (D10), and a 
chloroquine resistant P. falciparum strain (K1).  Cytotoxicity screening of these extracts 
were also performed. 
 
3.2   Results 
3.2.1   Antiplasmodial activity screening 
3.2.1.1   Antiplasmodial screening of the plant extracts against the D10 strain 
The antiplasmodial activities of the organic fractions, from the methanol extracts, from X. 
villosa and X. retinervis were determined against the chloroquine sensitive D10 strain.  
These experiments were done in duplicate and repeated two times on separate days.  
Chloroquine was used as an internal standard to monitor the experimental conditions and 
showed IC50 values within the acceptable range (6 - 20 ng/ml).  The IC50 values for the X. 
villosa and X. retinervis extracts were 6.0, and 1.4 µg/ml on average, respectively.  The 
parasite survival curves are presented in figures 11 and 12. 
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Figure 11  Dose response curves of the X. villosa extract on P. falciparum D10 parasites 
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Figure 12  Dose response curves of the X. retinervis extract on P. falciparum D10 
parasites 
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3.2.1.2   Antiplasmodial activity of the plant extracts against the K1 strain 
The antiplasmodial activities of the organic fractions from the methanol extracts from X. 
villosa and X. retinervis were determined in duplicate against the chloroquine resistant K1 
strain.  Chloroquine was used as an internal standard to monitor the experimental 
conditions and showed IC50 values within the acceptable range (150 - 250 ng/ml).  The 
IC50 values for the X. villosa and X. retinervis extracts were 5.4, and 2.2 µg/ml, 
respectively.  The parasite survival curves are presented in figures 13 and 14. 
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Figure 13  Dose response curve of the X. villosa extract on P. falciparum K1 parasites 
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Figure 14  Dose response curve of the X. retinervis extract on P. falciparum K1 parasites 
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Experiment 2 
3.2.2   Cytotoxicity assessment of the plant extracts 
Cytotoxicity of the organic fractions from the methanol extracts from X. villosa and X. 
retinervis were determined against CHO cells.  These experiments were done in triplicate 
and repeated two times on separate days.  Emetine was used as a quality control standard 
to monitor the experimental conditions and showed IC50 values within the acceptable 
range (40 – 60 ng/ml).  The cell viability curves of the organic fractions from the methanol 
extracts from X. villosa and X. retinervis are presented in figures 15 and 16 and show IC50 
values of 90.5 and 80.9 μg/ml on average, respectively.   
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Figure 15  Dose response curves of the X. villosa extract on CHO cells 
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Figure 16  Dose response curves of the X. retinervis extract on CHO cells 
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3.2.3   Selectivity Index 
In order to determine the specificity of an extract against the Plasmodium parasite the 
antiplasmodial activity and cytotoxicity are used to calculate a selectivity index value.  The 
cytotoxicity IC50 value of the extract is divided by the antiplasmodial IC50 value to obtain 
the selectivity index value.  These values are presented in table 3 (calculated for D10 
strain).   
 
Table 3  Selectivity index values of the X. villosa and X. retinervis extracts 
Extract Antiplasmodial activityD10 (IC50, μg/ml) 
Cytotoxicity 
(IC50, μg/ml) Selectivity Index 
a
X. villosa  6.0 90.5 15.1 
X. retinervis   1.4 80.9 57.8 
a Selectivity Index = cytotoxicity IC50/antiplasmodial D10 IC50 
 
 
3.3   Discussion 
The antiplasmodial activities of the extracts from both species were below 10 μg/ml, which 
according to Rasoanaivo, Willcox and co-authors are considered to be good potential 
sources of antiplasmodial compounds [Rasoanaivo, 2002; Willcox et al., 2004].  The 
selectivity index values for both extracts also indicated that the constituents from these 
extracts selectively inhibit parasite growth.  Both extracts are therefore considered to be 
good quality sources for potential antiplasmodial compounds.  The X. retinervis extract 
was superior to the X. villosa extract, regarding their antiplasmodial activity; however both 
extracts were considered good sources of potential antiplasmodial compounds and were 
taken further in the drug discovery process.   
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CHAPTER 4 
 
Isolation of pure compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 69
4   Isolation of pure compounds 
 
 
4.1   Introduction  
The flavonoid family, from the bioactive Xerophyta extracts as described in Chapters 2 and 
3, was targeted as a potential source of antimalarial compounds.  Flavonoids are one of 
the most numerous groups of natural products, and are important to humans because 
many are physiologically active [Harborne et al., 1975].  Flavonoids exist in plants as 
secondary metabolites as aglycones or glycosides.  The aglycones are usually absorbed 
from the gut by passive diffusion [Pong et al., 2005].  A general molecular structure of a 
flavonoid molecule is presented in figure 17.  It consists of 3 major rings (A, C and B) as 
indicated in the structure.  The double bonds in the flavonoid skeleton cause them to 
absorb visible light, and as a result, give them colour.  
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Figure 17  General molecular structure of flavonoids 
 
Hydroxyl groups are almost always present in the flavonoids and are usually attached to 
the B ring at positions 3’ and 4’ and to the 5 and 7 positions of the A ring [Harborne et al., 
1975]. 
 
Flavonoids consist of many different subgroups of which: flavones, isoflavones, 
flavanones, isoflavanones, flavonols and dihydroflavonols were targeted as potential 
antimalarial compounds during this project.  The general molecular structures of these 
subgroups are presented in figure 18. 
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Figure 18  General molecular structures of flavonoid subgroups 
 
Many different analytical techniques are described in the literature for the isolation of pure 
compounds from complex plant material.  The laboratory handbook for the fractionation of 
natural extracts was used as a guide to design a specific model to isolate compounds for 
this project [Houghton and Raman, 1998]. 
 
An automated, semi-preparative HPLC fraction collection system was used to analyse and 
fractionate the extracts [Preparative HPLC; Brandt and Kueppers, 2002; Miliauskas et al., 
2006].  The HPLC system produced milligram quantities of pure compounds in a relatively 
short period.  The methodology of this process is described in Chapter 12 (12.5).  
 
The bioactive methanol extract (organic phase) of X. villosa was analysed on HPLC to get 
a better understanding of the complexity of the extract.  The HPLC profile of this extract 
was also compared to the other two intermediate polar extracts (ethyl acetate and 
dichloromethane) to examine the similarities and differences in their profiles.  This extract 
was fractionated to obtain six semi-pure compounds.  Each of these fractions was further 
purified on HPLC to obtain pure compounds.  The methodology of this process is 
summarised in figure 19 and described in Chapter 12 (12.5). 
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Figure 19  Flow-diagram of X. villosa fractionation methodology 
 
The bioactive methanol extract (organic phase) of X. retinervis was also analysed on 
HPLC.  This extract was fractionated to obtain two semi-pure compounds.  Each of these 
fractions was further purified on HPLC to obtain single pure compounds.  The 
methodology is summarised in figure 20 and described in Chapter 12 (12.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20  Flow-diagram of X. retinervis fractionation methodology 
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4.2   Results 
4.2.1   X. villosa  
4.2.1.1   Methanol extract (organic phase) 
The HPLC chromatogram of this extract is presented in figure 21.  Six major peaks were 
observed at 7.1, 9.7, 12.3, 14.5, 18.2 and 20.0 minutes. 
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Figure 21  HPLC chromatogram of the X. villosa organic layer from the methanol extract 
 
4.2.1.2   Ethyl acetate extract 
The HPLC chromatogram of this extract is represented in figure 22.  The same major 
peaks (compared to the methanol extract, organic phase) were also observed for this 
extract at 7.1, 9.7, 12.2, 14.5, 18.1 and 19.9 minutes. 
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Figure 22  HPLC chromatogram of the X. villosa ethyl acetate extract 
 
4.2.1.3   Dichloromethane extract 
The HPLC chromatogram of this extract is represented in figure 23.   Peaks 4, 5 and 6 
(compared to the methanol extract, organic phase) were observed for this extract at 14.6, 
18.2 and 20.0 minutes. 
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Figure 23  HPLC chromatogram of the X. villosa dichloromethane extract 
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Peaks 4, 5 and 6 from the dichloromethane extract have the same retention time and UV 
spectra when compared to peaks 4, 5 and 6 from the ethyl acetate extract.  Peaks 1, 2, 3, 
4, 5 and 6 from the ethyl acetate extract have identical retention times and UV spectra 
when compared to peaks 1, 2, 3, 4, 5 and 6 from the organic fraction of the methanol 
extract. It was therefore decided to use the organic fraction of the methanol extract as a 
source for further fractionation.    
 
4.2.1.4   Fractionation of the 6 major peaks 
The HPLC system was optimised for the methanol extract (organic phase).  The HPLC 
chromatogram of the extract that was used for fractionation is presented in figure 24.  The 
methodology used to fractionate this extract is presented in Chapter 12 (12.5).   
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Figure 24  HPLC chromatogram of the X. villosa organic layer from the methanol extract 
 
The six major peaks (1, 2, 3, 4, 5 and 6) were collected into separate solvent bottles using 
an automated HPLC and fraction collector.  These fractions were further purified using 
specific HPLC methods for every fraction.  The methodology used to purify these fractions 
is presented in Chapter 12 (12.5).   
 
4.2.1.4.1 Fraction 1 
The HPLC chromatogram of this fraction is presented in figure 25.  The peak of interest 
eluted from the column at 7.1 minutes and was collected into a clean solvent bottle.  The 
isolated material was dried and stored at -20 °C. 
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Figure 25  HPLC chromatogram of fraction 1 
 
A small sample was analysed using the same HPLC conditions to test the purity of 
compound 1.  The HPLC chromatogram is presented in figure 26 and the purity according 
to HPLC was greater than 99%. 
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Figure 26  HPLC chromatogram of compound 1 
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4.2.1.4.2 Fraction 2 
The HPLC chromatogram of this fraction is presented in figure 27.  The peak of interest 
eluted from the column at 9.7 minutes and was collected into a clean solvent bottle.  The 
isolated material was dried and stored at -20 °C. 
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Figure 27  HPLC chromatogram of fraction 2 
 
A small sample was analysed using the same HPLC conditions to test the purity of 
compound 2.  The HPLC chromatogram is presented in figure 28 and the purity according 
to HPLC was greater than 99%.  The small peak at 15 minutes was also present in the 
blank chromatogram (figure 29), which was injected before this sample.  This peak is 
therefore not related to the test sample. 
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Figure 28  HPLC chromatogram of compound 2 
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Figure 29  HPLC chromatogram of blank (acetonitrile) 
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4.2.1.4.3 Fraction 3 
The HPLC chromatogram of this fraction is presented in figure 30.  The peak of interest 
eluted from the column at 17.5 minutes and was collected into a clean solvent bottle.  The 
isolated material was dried and stored at -20 °C. 
 
nm250.00
300.00 350.00
251.0
348.2
15.87
15.871
nm250.00
300.00 350.00
258.0
311.3
362.6
17.54
17.535
nm250.00
300.00 350.00
341.0
19.36
19.341
 
AU
0.00
0.05
0.10
0.15
0.20
Minutes
5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
15
.8
71
17
.5
35
19
.3
41
 
Figure 30  HPLC chromatogram of fraction 3 
 
A small sample was analysed using the same HPLC conditions to test the purity of 
compound 3.  The HPLC chromatogram is presented in figure 31 and the purity according 
to HPLC was greater than 99%. 
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Figure 31  HPLC chromatogram of compound 3 
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4.2.1.4.4 Fraction 4 
The HPLC chromatogram of this fraction is presented in figure 32.  The peak of interest 
eluted from the column at 21.3 minutes and was collected into a clean solvent bottle.  The 
isolated material was dried and stored at -20 °C. 
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Figure 32  HPLC chromatogram of fraction 4 
 
A small sample was analysed using the same HPLC conditions to test the purity of 
compound 4.  The HPLC chromatogram is presented in figure 33 and the purity according 
to HPLC was greater than 99%.  The small peak at 33 minutes was also present in the 
blank chromatogram (figure 34), which was injected before this sample.  This peak is 
therefore not related to the test sample.  
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Figure 33  HPLC chromatogram of compound 4 
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Figure 34  HPLC chromatogram of blank (acetonitrile) 
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4.2.1.4.5 Fraction 5 
The HPLC chromatogram of this fraction is presented in figure 35.  The peak of interest 
eluted from the column at 16.3 minutes and was collected into a clean solvent bottle.  The 
isolated material was dried and stored at -20 °C. 
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Figure 35  HPLC chromatogram of fraction 5 
 
A small sample was analysed using the same HPLC conditions to test the purity of 
compound 5.  The HPLC chromatogram is presented in figure 36 and the purity according 
to HPLC was greater than 99%. 
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Figure 36  HPLC chromatogram of compound 5 
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4.2.1.4.6 Fraction 6 
The HPLC chromatogram of this fraction is presented in figure 37.  The peak of interest 
eluted from the column at 17.0 minutes and was collected into a clean solvent bottle.  The 
isolated material was dried and stored at -20 °C. 
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Figure 37  HPLC chromatogram of fraction 6 
 
A small sample was analysed using the same HPLC conditions to test the purity of 
compound 6.  The HPLC chromatogram is presented in figure 38 and the purity according 
to HPLC was greater than 99%. 
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Figure 38  HPLC chromatogram of compound 6 
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4.2.2   X. retinervis  
4.2.2.1   Methanol extract (organic phase) 
The HPLC chromatogram of this extract is presented in figure 39.  Two major peaks were 
observed at 20.1 and 24.6 minutes. The methodology used to fractionate this extract is 
presented in Chapter 12 (12.5).   
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Figure 39  HPLC chromatogram of the X. retinervis organic layer from the methanol 
extract 
 
4.2.2.2   Fractionation of the 2 major peaks 
The two major peaks (A and B) were collected into separate solvent bottles using an 
automated HPLC and fraction collector.  The isolated material was dried and stored at 
-20 °C, until further analysis.  Small samples were analysed using a slightly modified 
HPLC system to test the purity of compounds A and B.  HPLC chromatograms are 
presented in figures 40 and 41.  The methodology used to purify these fractions is 
presented in Chapter 12 (12.5).   
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Figure 40  HPLC chromatogram of peak A 
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Figure 41  HPLC chromatogram of peak B 
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4.3   Discussion 
The compounds of interest belong to the flavonoid family of natural products and are 
probably flavones or flavonols.  The UV spectra of these compounds show 2 maximum 
absorbance bands, typical for flavonoids.  Many members of the flavonoid family are 
physiologically active, which would make these compounds a good source to search for 
antimalarial active compounds [Harborne et al., 1975].  These compounds form part of the 
plants defence system against insect herbivores and pathogens, and are stored in the 
central vacuoles of cells in relatively high amounts [Salisbury and Ross, 1992].   
 
Xerophyta species “hibernate” during winter, but still need protection against pathogens.  It 
is therefore hypothesised that the compounds of interest would have been present at 
relatively high concentrations during the time of collection.  The leave bases of the 
Xerophyta species are probably used to protect the inner stems against insect herbivores 
and pathogens, therefore the decision to start off with the leave bases.  The extraction 
methodology, as described in Chapter 12 (12.2), was used to target compounds with 
intermediate polarities.   
 
The two most abundant compounds isolated from X. retinervis were also present in the X. 
villosa extract, therefore the decision to fractionate the crude extract from X. villosa.  The 
methanol (organic phase) extract of X. villosa as described in 4.2.1.4 was targeted for 
antimalarial compounds.  An automated, semi-preparative reverse phase (C18) HPLC 
system was used to separate and collect the compounds of interest.  A sample of the 
crude extract at a concentration of 20 mg/ml in DMSO was originally used during 
fractionation, but yielded low amounts of semi-pure compounds per analytical run.  The 
concentration of the extract was increased to 200 mg/ml, which increased productivity 
tenfold.  With this “upscale approach”, about 1 gram crude extract could be fractionated 
per week to produce 6 semi-pure compounds (20 - 30 mg).  The extraction procedure 
(Chapter 2) was also repeated a few times to obtain enough material for the in vitro and in 
vivo animal experiments.  These semi-pure fractions were further purified using a second 
automated, analytical reverse phase HPLC system with different column technology (C16 -
amide).  The chromatography was optimised for each compound by using different mobile 
phase gradients.  Baseline separation between compound of interest and the “impurities” 
was reached for all applications.  
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This project not only deals with the isolation and structural elucidation of new 
antiplasmodial compounds, but also with bioavailability, metabolic and efficacy evaluation 
of antiplasmodial compounds in an animal model.  Animal testing requires relatively high 
amounts of pure material, so it was decided for practical reasons to focus the fractionation 
process on the compounds that were present at relatively high amounts.  The automated 
fractionation system as described in Chapter 12 (12.5) was run for a few weeks to obtain 
enough material for further testing:  in vitro antiplasmodial and cytotoxicity screening 
(Chapter 5), structural elucidation (Chapter 6), bioavailability evaluation (Chapter 8), 
metabolic investigation (Chapter 9) and in vivo antimalarial experiments (Chapters 7 and 
10).  Six compounds were isolated from the leave bases of X. villosa with purities above 
99% (according to HPLC).  Compounds 1 and 2 are light brown, compounds 3, 4 and 5 
are light yellow and compound 6 has a light orange colour.   
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CHAPTER 5 
 
Antiplasmodial activity and cytotoxicity screening 
of pure compounds isolated from X. villosa and X. 
retinervis  
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5   Antiplasmodial activity and cytotoxicity screening of pure 
compounds isolated from X. villosa and X. retinervis  
 
5.1   Introduction 
The six isolated compounds from X. villosa were targeted as potential selective 
antiplasmodial compounds. 
 
The same screening assay was used (as was used for screening the extracts) for testing 
the antiplasmodial activity of the six isolated compounds.  Cytotoxicity screening of the six 
pure compounds was also used to determine their general toxicity.  The methodology is 
described in Chapter 12 (12.3 and 12.4).  
 
5.2   Results 
5.2.1   Antiplasmodial activity screening 
5.2.1.1   Antiplasmodial screening of 6 pure compounds against the D10 strain 
The antiplasmodial activity of the six isolated compounds was determined for the 
chloroquine sensitive D10 strain.  These experiments were done in duplicate and repeated 
two times on separate days.  Chloroquine was used as an internal standard to monitor the 
experimental conditions and showed IC50 values within the acceptable range (6 - 20 
ng/ml).  The IC50 values were 11.1, 9.1, 22.5, 5.5, 2.5 and above 100 µg/ml on average, 
respectively (compounds 1, 2, 3, 4, 5 and 6). The parasite survival curves are presented in 
figures 42 - 47. 
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Figure 42  Dose response curves of compound 1 on P. falciparum D10 parasites 
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Figure 43  Dose response curves of compound 2 on P. falciparum D10 parasites 
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Figure 44  Dose response curves of compound 3 on P. falciparum D10 parasites 
 
 
 
Exp. 2 
Experiment   1 Experiment 2 
Experiment 1 Experiment 2 
Experiment 1 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 90
-1 0 1 2
0
25
50
75
100
IC50 = 5.1 ug/ml
Log [] ug/ml
%
 P
ar
as
ite
 s
ur
vi
va
l
-1 0 1 2
0
50
100
IC50 = 5.8 ug/ml
Log [] ug/ml
%
 P
ar
as
ite
 s
ur
vi
va
l
 
Figure 45  Dose response curves of compound 4 on P. falciparum D10 parasites 
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Figure 46  Dose response curves of compound 5 on P. falciparum D10 parasites 
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Figure 47  Dose response curves of compound 6 on P. falciparum D10 parasites 
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5.2.1.2   Antiplasmodial screening of compounds 4 and 5 against the K1 strain 
Compounds 4 and 5 showed the best antiplasmodial activity when tested against the 
chloroquine sensitive (D10) strain; consequently it was decided to further investigate their 
activity against the chloroquine resistant K1 strain.  These experiments were done in 
duplicate.  Chloroquine was used as an internal standard to monitor the experimental 
conditions and showed IC50 values within the acceptable range (150 - 250 ng/ml).  The 
IC50 values were 4.1 and 1.8 µg/ml, respectively.  The parasite survival curves are 
presented in figures 48 and 49. 
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Figure 48  Dose response curve of compound 4 on P. falciparum K1 parasites 
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Figure 49  Dose response curve of compound 5 on P. falciparum K1 parasites 
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5.2.2   Cytotoxicity assessment of the 6 isolated compounds 
Cytotoxicity assessment was performed on all 6 isolated compounds.  These experiments 
were done in triplicate and repeated two times on separate days.  Emetine was used as a 
quality control standard to monitor the experimental conditions and showed IC50 values 
within the acceptable range (40 – 60 ng/ml).  The IC50 values were >100, 18.5, >100, 88.3, 
95.4 and >100 µg/ml on average, respectively (compounds 1, 2, 3, 4, 5 and 6).  The cell 
viability curves are presented in figures 50 - 55. 
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Figure 50  Dose response curves of compound 1 on CHO cells 
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Figure 51  Dose response curves of compound 2 on CHO cells 
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Figure 52  Dose response curves of compound 3 on CHO cells 
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Figure 53  Dose response curves of compound 4 on CHO cells 
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Figure 54  Dose response curves of compound 5 on CHO cells 
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Figure 55  Dose response curves of compound 6 on CHO cells 
 
 
 
5.2.3   Selectivity Index 
The antiplasmodial activity and cytotoxicity results are summarised in table 4.  The 
selectivity index values were determined for each compound, using the D10 strain 
(explained in 3.2.3).  
  
Table 4  in vitro antiplasmodial activity, cytotoxicity and selectivity index values 
Compound 
Antiplasmodial 
activity 
D10 (IC50, μg/ml) 
Antiplasmodial 
activity 
K1 (IC50, μg/ml) 
Cytotoxicity 
 (IC50, μg/ml) Selectivity Index a 
1 11.1 - >100 > 9.0 
2 9.1 - 18.5 2.0 
3 22.5 - >100 > 4.4 
4 5.5 4.1 88.3 16.1 
5 2.5 1.8 95.4 38.2 
6 > 100 - >100 n/a 
a Selectivity Index = cytotoxicity IC50/antiplasmodial D10 IC50 
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5.3   Discussion 
The pure compounds were screened against the chloroquine sensitive (D10) P. falciparum 
strain.  Two of these compounds showed relatively good antiplasmodial activity, three 
showed mild activity, and one showed no activity.  The two most active compounds were 
further screened against a chloroquine resistant (K1) strain and showed similar activity 
compared to the sensitive strain.   This information indicates that these compounds are 
probably using a different parasite inhibitory mechanism than chloroquine. 
 
The pure compounds were also screened against mammalian cells to investigate their 
specificity to the malaria parasite.  The most active compound (5) showed relatively low 
cytotoxicity and the selectivity index value indicates that this compound selectively inhibits 
parasites compared to mammalian cells at the same concentration.  This compound fits 
well within the selectivity criteria set by Pink and co-authors and is therefore considered a 
good candidate for further animal testing [Pink et al., 2005].  
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CHAPTER 6 
 
Structural elucidation of antiplasmodial 
compounds extracted from Xerophyta species 
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6   Structural elucidation of antiplasmodial compounds 
extracted from Xerophyta species 
 
6.1   Introduction 
Ultraviolet spectroscopy was used to identify the class of compound.  UV spectra of 
flavonoids consist of two major absorption maxima bands at 240 – 285 nm and 300 – 400 
nm [Harborne et al., 1975].  High resolution mass spectrometry is used to determine the 
mass and atomic composition of a molecule [Clayden et al., 2004].  Unit resolution mass 
spectrometry is used complementary to high resolution mass spectrometry to determine 
molecular ions.  Nuclear magnetic resonance spectroscopy (1D and 2D) is used to identify 
all the proton and carbon atoms of a molecule [Clayden et al., 2004].  Numerous articles 
have been written about structural elucidation of flavones using NMR spectroscopy.  Some 
of these have been studied to get more insight on typical proton and carbon chemical 
shifts of this class of natural products [Sahin et al., 2004; Moon et al., 2005; Park et al., 
2006].   
 
Antiplasmodial screening and cytotoxicity testing of the 6 isolated compounds revealed 
that compound 5 would make the best candidate for further in vivo experimentation due to 
its relatively good and selective antiplasmodial activity.  At this stage of the project it was 
decided to do a feasibility study of compound 5 in vivo to determine the bioavailability of 
this compound in mice (Chapter 8).  Results from these initial experiments showed that 
compound 5 gets metabolised to form a product that is identical to compound 4.  This 
compound (4) was the second best candidate, and it was decided to include this 
compound during this phase of the project.  Compounds 1, 2 and 3 showed mild 
antiplasmodial activities and compound 6 was inactive against the parasites.  An internal 
standard was required for bioavailability experiments (Chapter 8).  Compound 2 was 
tested during initial bioavailability experiments as an internal standard for the assay 
method, and showed promising results.  Compound 2 was also the third most active 
compound against the malaria parasites.  For these reasons the inclusion here.  
 
UV spectroscopy, mass spectrometry and nuclear magnetic resonance spectroscopy (1D 
and 2D) techniques were used to resolve the structures.  The methodology is presented in 
Chapter 12 (12.6).   
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6.2   Structural elucidation of compound 2 
The proposed chemical structure of compound 2 (figure 56) resulted from ultraviolet 
spectroscopy, unit resolution mass spectrometry, high resolution mass spectrometry and 
nuclear magnetic resonance spectroscopy (1D and 2D). 
 
6.2.1   Chemical structure 
The proposed chemical structure of compound 2 (figure 56) consists of a 3 ring system 
with hydroxyl groups at position 5, 7, 3′ and 4′. 
 
OOH
O
OH
OH
OH
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6
7
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6'
 
Figure 56  Proposed chemical structure of compound 2 
 
6.2.2   Results  
6.2.2.1   Ultraviolet spectroscopy  
The UV spectrum of compound 2 is presented in appendix 1 (figure 127).  
 
6.2.2.2   Mass spectrometry 
6.2.2.2.1 Unit resolution mass spectrometry 
The unit resolution mass spectrum of compound 2 is presented in appendix 1 (figure 128) 
showing the molecular ion [M+H]+ at m/z 287.6. 
 
6.2.2.2.2 High resolution mass spectrometry 
The accurate mass spectrum of compound 2 is presented in appendix 1 (figure 129) 
showing the molecular ion [M+H]+ at m/z 287.0550, which corresponded to the molecular 
formula C15H10O6 of compound 2 (calculated mass 287.0556). 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 99
6.2.2.3   Nuclear magnetic resonance spectroscopy 
6.2.2.3.1 1H NMR spectrum 
The 1H NMR spectrum of compound 2 is presented in appendix 1 (figure 130).  Peak 
assignments according to 2D experiments are presented in figure131. 
 
6.2.2.3.2 13C NMR spectrum 
The 13C NMR spectrum of compound 2 is presented in appendix 1 (figure 132).  Peak 
assignments according to 2D experiments are presented in figure 133. 
 
6.2.2.3.3 COSY spectrum of compound 2 
Results from the proton correlation spectroscopy experiment are presented in appendix 1 
(figure 134), with detailed spectral information presented in figure 135. 
 
6.2.2.3.4 HSQC spectrum of compound 2 
Results from the heteronuclear single quantum proton correlation spectroscopy 
experiment are presented in appendix 1 (figure 136). 
 
6.2.2.3.5 HMQC spectrum of compound 2 
Results from the heteronuclear multiple bond quantum coherence experiment are 
presented in appendix 1 (figure 137).  Detailed spectral information is presented in figure 
138. 
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6.2.2.3.6 Summary of NMR spectral data 
Results from the NMR experiments are presented in table 5. 
 
Table 5  NMR data of compound 2 
Position δ 1H δ 13C COSY HMQC 
2 - 163.77 - - 
3 6.67 s 102.74 - C-1′, C-2, C-4, C-4a 
4 - 181.53 - - 
4a - 103.57 - - 
5-OH 12.97 s 157.17 - C-5 
6 6.19 d 93.72 - C-4a, C-5, C-7, C-8 
7 - 164.03 - - 
8 6.44 d 98.71 - C-4a, C-6, C-7, C-8a 
8a - 161.36 - - 
1′ - 121.36 - - 
2′ 7.39 d (1.75 Hz) 113.24 - C-2, C-3′, C-6′
3′ - 149.61 - - 
4′ - 145.62 - - 
5′ 6.89 d (8.30 Hz) 115.89 H-6′ C-1′, C-4′ 
6′ 7.41 dd (8.33Hz, 2.09 Hz) 118.87 H-2′ H-5′ C-2, C-2′ 
 
 
 
6.2.3   Discussion 
Two maximum absorbance bands were observed at 255 and 349 nm, which is typical for 
flavonoids.    
 
The high resolution mass spectrum of compound 2 suggested 15 carbons, 10 hydrogens 
and 6 oxygen atoms, which correlate well with the proposed chemical structure of 
compound 2 (figure 56). 
 
Spectral analysis of the 1H, 13C, COSY, HSQC and HMQC NMR spectra revealed the 
following structural information about compound 2: 
The 1H NMR spectrum showed two aromatic spin systems in the downfield region typical 
for aromatic signals (δ 6.0 – 8.0 ppm).  These coupling patterns suggested the presence of 
the following sub-structures: 
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Substructure 1 
The proton at position 6 is meta-coupled to the proton at position 8.  The proton at position 
8 is also meta-coupled to the proton at position 6.  Substructure 1 is presented in figure 57.  
4a
5
6
7
8
8a
H
H
 
Figure 57  H-6 and H-8 from substructure 1 
 
Substructure 2 
The proton at position 2′ is meta-coupled (1.75 Hz) to the proton at position 6′.  The proton 
at position 5′ is ortho-coupled (8.30 Hz) to the proton at position 6′.  The proton at position 
6′ is ortho-coupled (8.33 Hz) to the proton at position 5′ and meta-coupled (2.09 Hz) to the 
proton at position 2′.  Substructure 2 is presented in figure 58. 
1'
3'
4'
5'
6' H
H
H
2'
 
 Figure 58  H-2′, H-5′ and H-6′ from substructure 2 
 
The proton spectrum also indicated two singlets, an olefinic proton (figure 59) at δ 6.67 
which is typical for an α,β-unsaturated carbonyl system and a acidic phenolic proton 
(figure 60) which is in a close proximity to a carbonyl group at δ 12.97 ppm. 
  
C
O
H
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4
 
Figure 59  Substructure 3:  α,β-unsaturated carbonyl system  
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Figure 60   Substructure 4:  acidic phenolic proton  
 
The 13C NMR spectrum confirmed the presence of 15 carbon atoms which matches up 
with the suggested chemical formula that was revealed from the high resolution mass 
spectrum.  The COSY spectrum showed connectivities between the protons at positions 5′ 
and 6′.  Analysis of the HSQC spectrum revealed information about proton-carbon 
connectivities as can be seen in table 5.  The HMBC spectrum was used to assign the 
remaining carbons and the correlation information was used to connect the different 
substructures as follows: 
 
Connection of substructures 1, 2, 3 and 4 
H-6′ showed connectivity to C-2, H-3 showed connectivities to C-2, C-4, C-4a, and both H-
6 and H-8 showed connectivities to C-4a, and H-8 also showed connectivity to C-8a.  The 
following substructure is suggested:   
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Figure 61  Substructure X (connection of substructures 1, 2, 3 and 4)  
 
The chemical shifts of C-7, C-3′ and C-4′ (δ 164.03, 149.61 and 145.62, respectively) 
suggested the presence of three –OH groups.  The unknown atom at position 1 of 
substructure X was assigned an oxygen atom as suggested by chemical shifts of C-8a and 
C-2 (δ 161.36 and 163.77 ppm, respectively).   The proposed chemical structure is 
presented in figure 56. 
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6.3    Structural elucidation of compound 4 
The proposed chemical structure of compound 4 (figure 62) resulted from ultraviolet 
spectroscopy, unit resolution mass spectrometry, high resolution mass spectrometry and 
nuclear magnetic resonance spectroscopy (1D and 2D). 
 
6.3.1   Chemical structure 
The proposed chemical structure of compound 4 is presented in figure 62. 
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Figure 62  Proposed chemical structure of compound 4 
 
 
6.3.2   Results 
6.3.2.1   Ultraviolet spectroscopy  
The UV spectrum of compound 4 is presented in appendix 1 (figure 139).  
 
 
6.3.2.2   Mass spectrometry 
6.3.2.2.1 Unit resolution mass spectrometry 
The mass spectrum of compound 4 is presented in appendix 1 (figure 140) showing the 
molecular ion [M+H]+ at m/z 465.8. 
 
 
6.3.2.2.2 High resolution mass spectrometry 
The accurate mass spectrum of compound 4 is presented in appendix 1 (figure 141) 
showing the molecular ion [M+H]+ at m/z 465.1193, which corresponded to the molecular 
formula C25H20O9 of compound 4 (calculated mass 465.1186). 
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6.3.2.3   Nuclear magnetic resonance spectroscopy 
6.3.2.3.1 1H NMR spectrum 
The 1H NMR spectrum of compound 4 is presented in appendix 1 (figure 142).  Peak 
assignments according to 2D experiments are presented in figure 143. 
 
6.3.2.3.2 13C NMR spectrum 
The 13C NMR spectrum of compound 4 is presented in appendix 1 (figure 144).  Peak 
assignments according to 2D experiments are presented in figure 145. 
 
6.3.2.3.3 COSY spectrum of compound 4 
Results from the proton correlation spectroscopy experiment are presented in appendix 1 
(figure 146).  Detailed spectral information is presented in figure 147. 
 
6.3.2.3.4 HSQC spectrum of compound 4 
Results from the heteronuclear single quantum proton correlation spectroscopy 
experiment are presented in appendix 1 (figure 148).  Detailed spectral information is 
presented in figure 149. 
 
6.3.2.3.5 HMQC spectrum of compound 4 
Results from the heteronuclear multiple bond quantum coherence experiment are 
presented in appendix 1 (figure 150).  Detailed spectral information is presented in figure 
151. 
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6.3.2.3.6 Summary of NMR spectral data 
Results from the NMR experiments are presented in table 6. 
 
Table 6  NMR data of compound 4 
Position δ 1H δ 13C COSY HMQC 
2 - 162.81 - - 
3 6.89 s 103.83 - C-2, C-4, C-4a, C-1′ 
4 - 181.67 - - 
4a - 103.67 - - 
5 12.91 s 161.32 - - 
6 6.20 d (2.02 Hz) 98.82 -  C-5, C-8, C-4a 
7 - 164.22 - - 
8 6.53 d (2.01 Hz) 94.00 - C-6, C-7, C-8a C-4a 
8a - 157.24 - - 
9α, 9β 4.12 m 59.96 H-9, H-10 - 
10 4.28 m 76.26 H-9, H-11 - 
11 5.03 d (7.85 Hz) 77.89 H-10 C-11, C-12, C-13, C-17 
12 - 126.84 - - 
13 7.04 d (1.88 Hz) 111.68 - C-10, C-14, C-17 
14 - 147.05 - - 
15 - 147.54 - - 
16 6.81 d (8.00 Hz) 115.23 H-17 C-12, C-14 
17 6.85 m 120.50 H-16 C-12, C-14, C-15 
18 (OMe) 3.78 s 55.61 - C-14 
1′ - 123.60 - - 
2′ 7.61 dd (8.20 Hz, 2.10 Hz) 119.80 H-3′ - 
3′ 7.09 d (8.53 Hz) 117.42 H-2′ C-1′, C-5′, C-4′ 
4′ - 146.99 - - 
5′ - 143.56 - - 
6′ 7.68 d (2.24 Hz) 114.73 - C-2, C-5′, C-4′, C-2′ 
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6.3.3   Discussion 
Two maximum absorbance bands were observed at 271 and 340 nm, which is typical of 
flavonoids.    
 
The high resolution mass spectrum of compound 4 suggested 25 carbons, 20 hydrogens 
and 9 oxygen atoms, which correlate well with the proposed chemical structure of 
compound 4 (figure 62). 
 
Spectral analysis of the 1H, 13C, COSY, HSQC and HMQC NMR spectra revealed the 
following structural information about compound 4: 
The 1H NMR spectrum showed three aromatic spin systems in the downfield region typical 
for aromatic signals (δ 6.0 – 8.0 ppm).  These coupling patterns suggested the presence of 
the following sub-structures: 
 
Substructure 1 
The proton at position 6 is meta-coupled (2.02 Hz) to the proton at position 8.  The proton 
at position 8 is also meta-coupled (2.01 Hz) to the proton at position 6.  Substructure 1 is 
presented in figure 63.  
4a
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7
8
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Figure 63  H-6 and H-8 from substructure 1 
 
Substructure 2 
The proton at position 2′ is ortho-coupled (8.20 Hz) to the proton at position 3′ and meta-
coupled (2.10 Hz) to the proton at position 6′.  The proton at position 3′ is ortho-coupled 
(8.53 Hz) to the proton at position 2′.  The proton at position 6′ is meta-coupled (2.24 Hz) 
to the proton at position 2′.  Substructure 2 is presented in figure 64. 
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 Figure 64  H-2′, H-3′ and H-6′ from substructure 2 
 
 
Substructure 3 
The proton at position 13 is meta-coupled (1.88 Hz) to the proton at position 17.  The 
proton at position 16 is ortho-coupled (8.00 Hz) to the proton at position 17.  A multiplet 
signal at 6.85 ppm suggested the presence of a proton at position 17, which shows 
connectivities to the protons at positions 11, 13 and 16.  Substructure 3 is presented in 
figure 65. 
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Figure 65  H-13, H-16 and H-17 from substructure 3 
 
 
The proton spectrum also revealed a fourth spin system of protons attached to oxygenated 
aliphatic carbons.  Two multiplet signals at 4.12 and 4.28 ppm, and a doublet signal at 
5.03 ppm which is ortho-coupled (7.85 Hz) to the proton at position 10 suggested 
substructure 4 (figure 66).   
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Figure 66  H-9’s, H-10 and H-11 from substructure 4 
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The proton spectrum also indicated three singlets.  A methoxyl group (figure 67) at δ 3.78, 
an olefinic proton (figure 68) at δ 6.89 which is typical for an α,β-unsaturated carbonyl 
system and an acidic phenolic proton (figure 69) which is in a close proximity to a carbonyl 
group at δ 12.91 ppm. 
 
  
O CH3
18  
Figure 67  Substructure 5:  methoxyl group 
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Figure 68  Substructure 6:  α,β-unsaturated carbonyl system  
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Figure 69   Substructure 7:  acidic phenolic proton  
 
The 13C NMR spectrum confirmed the presence of 25 carbon atoms which matches up 
with the suggested chemical formula that was revealed from the high resolution mass 
spectrum.  The COSY spectrum showed connectivities between the protons at positions 2′ 
and 3′; 16 and 17; 9, 10 and 11 which confirm the presence of substructures 1, 2, 3 and 4.  
Analysis of the HSQC spectrum revealed information about proton-carbon connectivities 
as can be seen in table 6.  The HMBC spectrum was used to assign the remaining 
carbons and the correlation information was used to connect the different substructures as 
follows: 
 
Connection of substructures 1, 2, 6 and 7 
H-6′ showed connectivity to C-2, H-3 showed connectivities to C-2, C-4, C-4a and C-1, and 
both H-6 and H-8 showed connectivities to C-4a, and H-8 also showed connectivity to C-
8a.  The following substructure is suggested:   
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Figure 70  Substructure X (connection of substructures 1, 2, 6 and 7)  
 
Connection of substructures 3 and 4 
H-13 and H-17 were long ranged coupled to C-11; H-11 showed connectivities to C-10,  
C-12, C-13 and C-17.  The following substructure is suggested:   
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Figure 71  Substructure Y (connection of substructures 3 and 4) 
 
Connection of substructures X and Y 
Substructure X was connected at C-4′ and C-5′ to substructure Y’s two oxygen atoms as 
suggested by its chemical shifts of δ 146.99 and δ 143.56 ppm respectively.  The chemical 
shifts of C-5, C-7 and C-15 (δ 161.32, 164.22 and 147.54, respectively) suggested the 
presence of three –OH groups.  C-14’s chemical shift (δ 147.05) also indicated an oxygen 
bond; in this case C-14 was bound to a methoxy-group.  The methyl protons were 
observed as a strong singlet at δ 3.78 which is typical of methoxyl protons.  The unknown 
atom at position 1 of substructure X was assigned to an oxygen atom as suggested by 
chemical shifts of C-8a and C-2 (δ 157.24 and 162.81 ppm, respectively).  The proposed 
structure for compound 4 is presented in figure 62. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 110
6.4   Structural elucidation of compound 5 
The proposed chemical structure of compound 5 (figure 72) resulted from ultraviolet 
spectroscopy, unit resolution mass spectrometry, high resolution mass spectrometry and 
nuclear magnetic resonance spectroscopy (1D and 2D). 
 
The chemical structure of this compound has not been published previously, therefore the 
inclusion of the optical rotation (6.4.2.1) and melting point (6.4.2.2) data.  The methodology 
is presented in Chapter 12 (12.6).   
 
6.4.1   Chemical structure 
The proposed chemical structure of compound 5 is presented in figure 72. 
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Figure 72  Proposed chemical structure of compound 5 
 
 
6.4.2   Results 
6.4.2.1   Optical rotation 
Optical rotation: +0.201  
 
6.4.2.2   Melting point 
Melting point: 255.5 – 256.0 °C 
 
6.4.2.3   Ultraviolet spectroscopy  
The UV spectrum of compound 5 is presented in appendix 1 (figure 152).  
 
 
6.4.2.4   Mass spectrometry 
6.4.2.4.1 Unit resolution mass spectrometry 
The mass spectrum of compound 5 is presented in appendix 1 (figure 153) showing the 
molecular ion [M+H]+ at m/z 507.7. 
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6.4.2.4.2 High resolution mass spectrometry 
The accurate mass spectrum of compound 5 is presented in appendix 1 (figure 154) 
showing the molecular ion [M+H]+ at m/z 507.1298, which corresponded to the molecular 
formula C27H22O10 of compound 5 (calculated mass 507.1291). 
 
6.4.2.5   Nuclear magnetic resonance spectroscopy 
6.4.2.5.1 1H NMR spectrum 
The 1H NMR spectrum of compound 5 is presented in appendix 1 (figure 155).  Peak 
assignments according to 2D experiments are presented in figure 156. 
 
 
6.4.2.5.2 13C NMR spectrum 
The 13C NMR spectrum of compound 5 is presented in appendix 1 (figure 157).  Peak 
assignments according to 2D experiments are presented in figure 158. 
 
6.4.2.5.3 COSY spectrum of compound 5 
Results from the proton correlation spectroscopy experiment are presented in appendix 1 
(figure 159).  Detailed spectral information is presented in figure 160. 
 
6.4.2.5.4 HSQC spectrum of compound 5 
Results from the heteronuclear single quantum proton correlation spectroscopy 
experiment are presented in appendix 1 (figure 161).  Detailed spectral information is 
presented in figure 162. 
 
6.4.2.5.5 HMQC spectrum of compound 5 
Results from the heteronuclear multiple bond quantum coherence experiment are 
presented in appendix 1 (figure 163).  Detailed spectral information is presented in figure 
164. 
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6.4.2.5.6 Summary of NMR spectral data 
Results from the NMR experiments are presented in table 7. 
 
Table 7  NMR data of compound 5 
Position δ 1H δ 1H** δ 13C δ 13C** COSY HMQC
2 - - 162.64 162.66 - - 
3 6.91 s 6.82 s 103.96 103.99 - C-2, C-4, C-4a, C-1′ 
4 - - 181.67 181.69 - - 
4a - - 103.67 103.73 - - 
5 12.90 s 12.90 s 161.30 161.35 - - 
6 6.20 d (2.02 Hz) 6.20 d (2.08 Hz) 98.84 98.87 -  C-5, C-7, C-8, C-4a 
7 - - 164.26 164.25 - - 
8 6.54 d (2.02 Hz) 6.53 d (1.98 Hz) 94.05 94.07 - C-6, C-7, C-8a, C-4a 
8a - - 157.25 157.28 - - 
9α, 9β 4.11 m, 3.97 m 4.03 m 62.37 62.41 H-9, H-10 C-10, C-11, C-19 
10 4.6 m 4.6 m 74.82 74.89 H-9, H-11 - 
11 5.06 d (7.99 Hz) 5.05 d (8.12 Hz) 76.19 76.25 H-10 C-10, C-12, C-13, C-17 
12 - - 125.96 126.01 - - 
13 7.06 d (1.91 Hz) 7.03 d (1.92 Hz) 111.65 111.72 - C-11, C-13, C-17 
14 - - 147.33* 147.38* - - 
15 - - 147.66* 147.71* - - 
16 6.82 d (8.02 Hz) 6.81 d (8.12 Hz) 115.36 115.42 H-17 C-12, C-14, C-15 
17 6.89 m 6.87 d (8.12 Hz) 120.59 120.63 H-16 C-11, C-13, C-14 
18 (OMe) 3.78 s 3.78 s 55.59 55.65 - - 
19 (OCO) - - 169.92 169.98 - - 
20 (OMe) 2.05 s 2.04 s 20.36 20.38 - - 
1′ - - 123.87 123.89 - - 
2′ 7.64 dd (8.53 Hz, 2.16 Hz) 7.58 dd (8.55 Hz, 2.35 Hz) 120.12 120.13 H-3′ C-4′ 
3′ 7.13 d (8.56 Hz) 7.07 d (8.54 Hz) 117.59 117.59 H-2′ C-1′, C-5′, C-4′ 
4′ - - 146.87 146.89 - - 
5′ - - 143.00 143.02 - - 
6′ 7.74 d (2.22 Hz) 7.65 d (2.35 Hz) 114.91 114.91 - C-2, C-5′, C-4′, C-2′ 
 
δ 1H** and δ 13C** [Chen, 1997] 
* indicates assignments interchangeable 
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6.4.3   Discussion 
Two maximum absorbance bands were observed at 270 and 340 nm, which is typical of 
flavonoids.    
 
The high resolution mass spectrum of compound 5 suggested 27 carbons, 22 hydrogens 
and 10 oxygen atoms, which correlate well with the proposed chemical structure of 
compound 5 (figure 72). 
 
Spectral analysis of the 1H, 13C, COSY, HSQC and HMQC NMR spectra revealed the 
following structural information about compound 5. 
 
The 1H NMR spectrum showed three aromatic spin systems in the downfield region typical 
for aromatic signals (δ 6.0 – 8.0 ppm).  These coupling patterns suggested the presence of 
the following substructures: 
 
Substructure 1 
The proton at position 6 is meta-coupled (2.02 Hz) to the proton at position 8.  The proton 
at position 8 is also meta-coupled (2.02 Hz) to the proton at position 6.  Substructure 1 is 
presented in figure 73.  
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Figure 73  H-6 and H-8 from substructure 1 
 
Substructure 2 
The proton at position 2′ is ortho-coupled (8.53 Hz) to the proton at position 3′ and meta-
coupled (2.16 Hz) to the proton at position 6′.  The proton at position 3′ is ortho-coupled 
(8.56 Hz) to the proton at position 2′.  The proton at position 6′ is meta-coupled (2.22 Hz) 
to the proton at position 2′.  Substructure 2 is presented in figure 74. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 114
H
H
H
1'
2'
3'
4'
5'
6'
 
 Figure 74  H-2′, H-3′ and H-6′ from substructure 2 
 
 
Substructure 3 
The proton at position 13 is meta-coupled (1.91 Hz) to the proton at position 17.  The 
proton at position 16 is ortho-coupled (8.02 Hz) to the proton at position 17.  A multiplet 
signal at 6.89 ppm suggested the presence of a proton at position 17, which shows 
connectivities to the protons at positions 11, 13 and 16.  Substructure 3 is presented in 
figure 75. 
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Figure 75  H-13, H-16 and H-17 from substructure 3 
 
 
The proton spectrum also rev aled a fourth spin system of protons attached to oxygenated 
aliphatic carbons.  Three multiplet signals at 3.97, 4.11 and 4.6 ppm, and a doublet signal 
at 5.06 ppm which is ortho-coupled (7.99 Hz) to the proton at position 10 suggested 
substructure 4 (figure 76).   
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Figure 76  H-9’s, H-10 and H-11 from substructure 4 
 
The proton spectrum also indicated four singlets.  An o-acetyl group at δ 2.05 (figure 77), a 
methoxyl group (figure 78) at δ 3.78, an olefinic proton (figure 79) at δ 6.91 which is typical 
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for an α,β-unsaturated carbonyl system and an acidic phenolic proton (figure 80) which is 
in a close proximity to a carbonyl group at δ 12.90 ppm. 
  
C
CH3
O
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Figure 77  Substructure 5:  O-acetyl group  
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Figure 78  Substructure 6:  methoxyl group 
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Figure 79  Substructure 7:  α,β-unsaturated carbonyl system  
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Figure 80   Substructure 8:  acidic phenolic proton  
 
The 13C NMR spectrum confirmed the presence of 27 carbon atoms which matches up 
with the suggested chemical formula that was revealed from the high resolution mass 
spectrum.  The COSY spectrum showed connectivities between the protons at positions 2′ 
and 3′; 16 and 17; 9, 10 and 11 which confirm the presence of substructures 1, 2, 3 and 4.  
Analysis of the HSQC spectrum revealed information about proton-carbon connectivities 
as can be seen in table 7.  The HMBC spectrum was used to assign the remaining 
carbons and the correlation information was used to connect the different substructures as 
follows: 
 
Connection of substructures 1, 2, 7 and 8 
H-6′ showed connectivity to C-2, H-3 showed connectivities to C-2, C-4, C-4a and C-1, and 
both H-6 and H-8 showed connectivities to C-4a, and H-8 also showed connectivity to C-
8a.  The following substructure is suggested:   
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Figure 81  Substructure X (connection of substructures 1, 2, 7 and 8)  
 
Connection of substructures 3, 4 and 5 
H-13 and H-17 were long ranged coupled to C-11; H-11 showed connectivities to C-10,  
C-12, C-13 and C-17; the two H-9 protons showed connectivities to C-10 and C-11; and 
the protons in the OCOMe group showed connectivities to C-9,  The following substructure 
is suggested: 
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Figure 82  Substructure Y (connection of substructures 3, 4 and 5) 
 
Connection of substructures X and Y 
Substructure X was co nected at C-4′ and C-5′ to substructure Y’s two oxygen atoms as 
suggested by its chemical shifts of δ 146.87 and δ 145.00 ppm respectively.  The chemical 
shifts of C-5, C-7 and C-15 (δ 161.30, 164.26 and 147.66, respectively) suggested the 
presence of three –OH groups.  C-14’s chemical shift also indicated an oxygen bond; in 
this case C-14 was bound to a methoxy-group.  The methyl protons were observed as a 
strong singlet at δ 2.05 which is typical of methoxyl protons.  The unknown atom at 
position 1 of substructure X was assigned to an oxygen atom as suggested by chemical 
shifts of C-8a and C-2 (δ 157.25 and 162.64 ppm, respectively).  The proposed structure 
for compound 5 is presented in figure 72. 
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6.5   Conclusion 
Structural elucidation of compounds 2, 4 and 5 revealed the following information about 
their structures: 
Compound 2 is a known flavonoid, luteolin [Boersma et al., 2002].  Mild antiplasmodial 
activity was observed for this compound (Chapter 5).  This compound was only used as an 
internal standard during initial bioavailability experiments (Chapter 8).   
Compound 4 is a known flavonolignan, hydnocarpin [Antus et al., 1982; Sharma and Hall, 
1991; Stermitz et al., 2000; Stermitz et al., 2001].  This compound showed relatively good 
and selective antiplasmodial activity (Chapter 5).  This is however the first study that 
shows the presence of hydnocarpin in X. villosa and X. retinervis.  The bioavailability of 
this compound was also studied in a mouse model (Chapter 8). 
Spectral data of compound 5 were identical to a flavonolignan isolated by Chen [Chen, 
1997].  This compound showed relatively good and selective antiplasmodial activity and 
further in vivo experiments were conducted on this compound (Chapters 7, 8, 9 and 10).  
This is the first study that shows the presence of 9-O-acetylhydnocarpin in X. villosa.  
 
Structural analysis of compounds 1, 3 and 6 were not discussed during this phase of the 
project, however analysis was performed on compounds 1 and 3 and revealed the 
following information: 
 
The accurate mass spectrum of compound 1 is showing the molecular ion [M+H]+ at m/z 
271.0613.  The proposed chemical formula of compound 1 is:  C15H10O5.  Spectral 
analysis of the 1H, 13C, COSY, HSQC and HMQC spectra revealed the following structural 
information about compound 1:  compound 1 is a small flavone with hydroxyl groups at 
position 7, 2′ and 3′.  
 
The accurate mass spectrum of compound 3 is showing the molecular ion [M+H]+ at m/z 
525.1560.  The proposed chemical formula of compound 3 is:  C31H24O8.  Spectral 
analysis of the 1H, 13C, COSY, HSQC and HMQC spectra could not reveal the structure of 
the compound at this stage of the project, and it was decided not to continue with the 
structural elucidation of this compound, because of its mild activity. 
 
Compound 6 was inactive against the malaria parasites, therefore the decision to not 
perform spectral analysis on this compound.   
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Compounds 1 and 2 are small flavones with similar antiplasmodial activity (11.1 µg/ml and 
9.1 µg/ml, respectively, D10 strain).  Compounds 4 and 5 are related flavonolignans, 
compound 4 was about two times more active compared to the two small flavones, and 
compound 5 was about four times more active compared to the two small flavones.   
It appears that the lignan component of the flavonolignans is responsible for a 2 fold 
improvement in the antiplasmodial activity when compared to the small flavones.  The 
acetyl group at position 9 (figure 72) improved activity twofold. 
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CHAPTER 7 
 
Antimalarial assessment of 9-O-acetylhydnocarpin 
in mice 
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7   Antimalarial assessment of 9-O-acetylhydnocarpin in mice 
 
7.1   Introduction 
The next phase of this project was to evaluate the activity of the most promising 
antiplasmodial compound in an animal model.  There are different animal models available 
for antimalarial drug testing, i.e. the P. berghei parasite mouse model and the P. 
falciparum or P. vivax parasite Aotus monkey model.  The mouse model is usually used for 
the initial in vivo screening of antiplasmodial compounds, and those that perform well 
during these early tests could be further tested in the primate model.  There are many 
different dosing strategies discussed in the literature, and the most frequently used 
technique is the 4 day suppressive treatment strategy.  Mice are infected with P. berghei 
parasites and treatment starts after 24 hours, once a day for 4 days [Peters et al., 1975, 
1993; Herrera et al., 2002; Gumede et al., 2003; Waako et al., 2005; Muthaura et al., 
2007; Ojo-Amaize et al., 2007; Portet et al., 2007]. 
 
The P. berghei mouse model was selected for the initial efficacy study of 9-O-
acetylhydnocarpin.  According to a review article by Richard Pink and co-authors, potential 
lead antimalarial compounds should show parasite inhibition when administered at 
concentrations below 100 mg/kg to test animals, consequently it was decided to begin 
treatment at a concentration of 100 mg/kg (DMSO : water, 1:9 v/v) [Pink et al., 2005].   
 
Isolating pure compounds from natural products is a laborious and expensive process.  An 
amount of 2.91 mg pure compound per mouse per treatment is required for dosing at a 
concentration of 100 mg/kg (average weight of mouse = 29.1 g).  The amount of pure 
material was limited, hence the decision to include three mice per group.  The animals 
were infected with P. berghei parasites as described in Chapter 12 (12.9).  The 4 day 
suppressive treatment strategy, with minor modifications, was followed to evaluate the 
antimalarial activity of 9-O-acetylhydnocarpin in mice.  The positive control group was 
infected with P. berghei parasites and treated with chloroquine at a concentration of 10 
mg/kg.  The negative control group was also infected with P. berghei parasites, and was 
treated with placebo samples which consisted of a solution of DMSO and water (1:9, v/v), 
without the test compound.  The test compound group was also infected with P. berghei 
parasites, and was treated with 9-O-acetylhydnocarpin at a concentration of 100 mg/kg in 
a solution of DMSO and water (1:9, v/v), once a day on days 2, 3, 4 and 5. 
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The use of animals in research is a controversial and complicated subject in modern times; 
consequently it was essential to obtain ethical approval for this part of the project by the 
ethics committee of the University of Cape Town.  A manuscript prepared by the South 
African Medical Research Council about guidelines on ethics for medical research and the 
use of animals in research was used as a reference source when compiling the application 
[Austin et al., 2004]. Ethical approval was granted by the Animal Research Ethics 
Committee, Faculty of Health Sciences, University of Cape Town (Project number:  
006/034) for studying the antimalarial activity of 9-O-acetylhydnocarpin in a mouse model. 
 
Figure 83 summarises the allocation of the experimental groups, treatment schedule, 
sampling and the endpoint of the experiment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 83  Flow-diagram of the antimalarial assessment animal model, which included the 
experimental groups, treatment schedule, sampling and the endpoint of the experiment 
 
 
 
 
 
 
 
 
 
Negative control group 
infection 
treatment 
sampling/weighing 
endpoint 
Day 1 
Days 2, 3, 4 and 5  
Days 3, 5, 7, 9 
Day 9 
Test group Positive control group 
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7.2   Results 
The following parameters were evaluated: Body weight, %Parasitaemia and %Chemo 
suppression.  The body weight and percentage parasitaemia data of the mice is presented 
in appendix 2 (tables 50 and 51) and is summarised in figures 84 and 85.  The mean 
%Parasitaemia and %Chemo suppression data is presented in table 8.  The %Chemo 
suppression of the test compound in a polar formulation (water : DMSO, 90:10, v/v) was 
determined on day 7 using the following formula:  
 
%Chemo suppression = ((A-B)/A) x 100 
 
A was the mean parasitaemia in the negative control and B was the parasitaemia in the 
test group.  Compound activity was determined by the %reduction of parasitaemia in the 
treated group compared to untreated group [Tona et al., 2001]. 
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Figure 84  Body weight vs. Time graph of mice treated with a polar 100 mg/kg 9-O-
acetylhydnocarpin formulation using the 4 day suppressive treatment strategy (control 
groups included) 
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Figure 85  % Parasitaemia vs. Time graph of mice treated with a polar 100 mg/kg 9-O-
acetylhydnocarpin formulation using the 4 day suppressive treatment strategy (control 
groups included) 
 
Table 8  Mean %Parasitaemia and %Chemo suppression data  
Treatment %Parasitaemia %Chemo suppression 
Test group (polar) 12.0 ± 3.4 38.1 
Negative control 19.4 ± 1.3 0 
Positive control 0.0 ± 0 100 
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7.3     Discussion 
A 38.1% reduction of parasitaemia was observed on day 7 in the group that was treated 
with the test compound compared to the placebo group, and the weight loss of the test 
group was comparable with the placebo group.  The test compound showed a reasonable 
degree of parasite inhibition, but could not provide complete protection.  Chemo 
suppression is normally measured around day 5, but because of relatively low 
parasitaemia levels (in both the test and placebo groups), it was decided to measure the 
reduction of parasitaemia on day 7.    
 
The test compound was not doing that well in the animal model, and it was hypothesised 
that it may be a bioavailability problem due to inadequate formulation, or that the test 
compound was metabolised extensively to inactive metabolites by CYP450 enzymes.  
 
Pink and co-workers have shown the importance of conducting bioavailability and 
metabolism investigation during early development.  These studies aim to improve 
treatment formulations and are also vital when compounds are selected for in vivo activity 
testing [Pink et al., 2005].   
 
The next objective of this project was to evaluate the test compounds absorption, 
distribution, metabolism and excretion properties in the same mouse model as was used 
during the efficacy study.   
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CHAPTER 8 
 
Bioavailability investigation of 9-O-
acetylhydnocarpin in mice 
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8   Bioavailability evaluation of 9-O-acetylhydnocarpin in mice 
 
8.1   Introduction 
Bioavailability evaluation of active in vitro compounds in animals is one of the most 
important secondary screening procedures in drug development and should also be 
included on a larger scale in preliminary antimalarial screening.  Drug formulation plays an 
important part during this phase of the development process.  Drug formulation is a 
comprehensive field and numerous articles have been written on this subject.  A few 
relevant examples are presented below [Rieckmann et al., 1996; Shearer et al., 2005; 
Guidance for Industry, 2007]. 
 
Morazzoni and co-workers have studied the pharmacokinetics of structurally related 
compounds (to 9-O-acetylhydnocarpin) in rats.  The structurally related compound, silybin, 
was formulated with a phosphatidylcholine complex and was administered orally to rats.  
Silybin was also administered in a control formulation, using the natural silymarin extract.  
An HPLC method was used to analyse the samples.  Pharmacokinetic profiles were 
constructed and the two formulations compared.  The silybin-phosphatidylcholine complex 
showed a 10-fold increase in relative bioavailability compared to the control formulation 
[Morazzoni et al., 1993]. 
 
Hitte and co-authors have described general formulation strategies for oral delivery of 
poorly soluble drugs.  Oral administration is the preferred method of administration for 
antimalarial drugs, but is unfortunately restricted to compounds that could cross the gastric 
mucosa.  Compounds that have the potential to cross these membranes should be at least 
moderately water-soluble.  Many of the compounds that are discovered during in vitro 
screening programmes are poorly water-soluble, thus limiting their use as potential drug 
candidates.  There are many methods that could improve solubility, thereby improving 
bioavailability.   Accelerating agents, such as surfactants, wetting agents and dispersants 
are used to facilitate dissolution or dispersion.  Polyethylene glycol (PEG) is an example of 
a dispersion-enhancing agent that is also used as a precipitation prevention solvent of 
poorly aqueous soluble compounds.  Polar materials, such as gelatine and lecithin are 
used to improve the “wetability” of hydrophobic compounds through polar interaction.  
Polar materials are also used as emulsifying agents.  Controlled-release matrix 
technologies have also been developed for these poorly soluble compounds.  The use of 
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alkalising agents in electrolyte-based systems is also well established in the 
pharmaceutical field [Hite et al., 2003]. 
 
Kuentz and co-workers have showed the relevance of using “in silico” pharmacokinetic 
tools for preclinical formulation development.  These new technologies could improve the 
formulation development process [Kuentz et al., 2006]. 
 
Monodiglycerides and their derivatives are widely used in the food industry as emulsifiers.  
These molecules form a range of various liquid crystalline structures when present in an 
aqueous environment.  The structures could potentially dissolve active ingredients and act 
as drug delivery vehicles.  Some of these structures have also been shown to protect 
compounds against degradation [Sagalowicz et al., 2006]. 
 
The development of sustained delivery systems for herbal medicines is challenging 
because of its complexity in composition.  Lu and co-workers have developed a 
synchronized and sustained release glyceryl monostearate matrix system for the silymarin 
compounds (taxifolin, silychristin, silydianin, isosilybin and silybin) [Lu et al., 2007]. 
 
A multi-unit floating gel bead delivery system was synthesized with calcium alginate, 
sunflower oil and the drug of interest through an emulsification process.  Tang and co-
workers have tested both hydrophobic and hydrophilic drugs and have observed a 
sustained release of the drugs for more than 12 hours [Tang et al., 2007]. 
 
Various analytical techniques are described in the literature for analysing samples from 
pharmacokinetic studies.  These techniques can be summarized in two main groups:  
firstly, HPLC coupled with fluorescence, UV, electrochemical, MS or MS/MS detectors; 
and secondly, GC coupled with NPD, ECD, FID, MS or MS/MS detectors.  The physical 
and chemical properties of the test compound as well as the biological model are used to 
decide which analytical system will be appropriate.  [Chu et al., 2006; Mackie et al., 2005; 
Jia et al., 2005; Somers et al., 2003; Choi et al., 2004; Anupongsanugool et al., 2005; 
DuPont et al., 2004; Zhang and Brodbelt, 2004; Schmidt, 2004; Ward et al., 2001].  
 
The P. berghei mouse model was selected for efficacy testing; therefore the same animal 
model was required for bioavailability testing.  The limited blood volume makes it rather 
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challenging to study the bioavailability of antiplasmodial compounds in mice.  Literature on 
this subject is limited, so it was clear that new methodology had to be developed to study 
the bioavailability of antiplasmodial compounds in mouse blood.  The aim was to use one 
animal for all the sampling points.  This would require a sensitive and selective analytical 
method that could measure trace amounts of the test compound in only 10 μl of blood.  A 
highly sensitive and selective analytical system was required, so it was decided to use 
triple quadrupole mass spectrometry coupled with HPLC.  New, specific and sensitive LC-
MS/MS methodology was developed to analyse mouse blood samples, which were 
generated during bioavailability studies.  The method development phase of this part of the 
project is described and presented in Chapter 12 (12.7).  
 
One of the main focus areas of this project is to show the importance of conducting 
bioavailability studies (using different administration routes and f rmulations) during early 
drug development.  Information that results from such studies should give the investigator 
more insight about the biological availability of the test compound at the target site, and 
should also be used to design an optimised formulation and dosing strategy during further 
efficacy studies.   
 
A comprehensive bioavailability study of the most active antiplasmodial compound (9-O-
acetylhydnocarpin) was conducted in a mouse model, using different administration routes 
and formulations.   
 
Ethical approval was granted by the Animal Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (Project number:  006/034) for this project.   
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8.2   Initial bioavailability study of 9-O-acetylhydnocarpin in mice 
 
8.2.1   Introduction 
A preliminary investigation of the bioavailability of 9-O-acetylhydnocarpin in mice was 
performed using LC-MS/MS analysis.  A highly selective, sensitive and consistent 
bioanalytical method for analysing animal samples was developed.  The methodology is 
described and presented in Chapter 12 (12.7.1 and 12.7.2).   
9-O-Acetylhydnocarpin was administered orally at a concentration of 200 mg/kg in a 
solution which consisted of water and DMSO (9:1, v/v) to healthy mice.  Blood samples 
were collected at 0, 1, 2, 3 and 5 hours after administration.  One animal per sampling 
point was used at this stage of the project.    
 
8.2.2   Results 
The study samples and calibration standards were analysed according to the method 
described in Chapter 12 (12.7.2).  The calibration curve and the back-calculated results of 
the standards are presented in appendix 3 (figure 165 and table 56).  A quadratic 
regression weighted 1/x was used for the statistical analyses.  Representative 
chromatograms are presented in appendix 3 (figure 166).  The back-calculated results of 
study samples are presented in table 9.   
 
Table 9  Back-calculated concentrations of 9-O-acetylhydnocarpin  
Sample 
(hours) 
Peak 
Area 
Calculated conc. 
(ng/ml) 
0 0 No Peak 
1 0 No Peak 
2 0 No Peak 
3 2400 29.8 
5 0 No Peak 
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8.2.3   Discussion 
The analytical method performed well and 9-O-acetylhydnocarpin could be detected at 
very low amounts.  In most of the samples 9-O-acetylhydnocarpin was below the limit of 
quantification, except for the sample that was collected at 3 hours after administration, but 
was only present at very low levels.  9-O-Acetylhydnocarpin was administered at relatively 
high concentrations (200 mg/kg) and one expected to observe high levels in the samples, 
but this was not the case.  9-O-Acetylhydnocarpin has an acetyl group at carbon 9, which 
is probably hydrolysed under low pH conditions or hydrolysed by esterase enzymes in the 
blood.  It seems that 9-O-acetylhydnocarpin is metabolised rapidly, but may form 
metabolites that are still active.   
 
The next phase of this project was to search for these metabolites by making use of 
precursor ion experiments [Applied Biosystems MDS Sciex].   
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8.3   Metabolite investigation 
8.3.1   Introduction 
LC-MS technology is the analytical option of choice in the search for metabolites.  Some of 
these experiments include LC-MS scans, precursor ion experiments and neutral loss 
scans.  At this stage of the project it was thought that the acetyl group of 9-O-
acetylhydnocarpin was hydrolysed under low pH conditions in the stomach or by esterase 
enzymes in the blood to form a hydrolysed product which would have the identical 
structure of hydnocarpin (Chapter 6).  This hydrolysed product would have the same 
carbon backbone as the parent compound.  The product ion mass spectra of 9-O-
acetylhydnocarpin and hydnocarpin should have similar product ions.  An Applied 
Biosystems API 2000 mass spectrometer was used to search for this hydrolysed product.  
The monoisotopic masses of 9-O-acetylhydnocarpin and hydnocarpin are 506.1213 and 
464.1107, respectively.  The experiments were carried out in the positive ion mode, and 
[M+H]+ ions were expected (507 for the 9-O-acetylhydnocarpin ion and 465 for the 
hydrolysed product, hydnocarpin).  The precursor ion scan methodology is described and 
presented in Chapter 12 (12.7.3). 
 
8.3.2   Results 
The total ion chromatogram is presented in appendix 3 (figure 167).  Mass spectra of the 
peaks at 0.8, 2.4 and 3.5 minutes are also presented in appendix 3 (figures 168 to 170).  
 
 
8.3.3   Discussion  
The peak at 0.8 minutes resulted in stable precursor ions with masses of 499.5 and 540.0 
which may be metabolites.  The peak at 2.4 minutes resulted in a stable precursor ion with 
a mass of 465, which matches up with the proposed molecular ion of the hydrolysed 
product.  The peak at 3.5 minutes resulted in a few stable precursor ions, including 507, 
which is the molecular ion of 9-O-acetylhydnocarpin.  These peaks represent trace 
amounts of the parent compound.  The hydrolysis reaction probably occurs in the stomach 
of the mice where pH conditions are relatively low or in the blood by esterase enzymes.  
The mass spectrum of the hydrolysed compound is identical to the mass spectrum of 
compound 4 (Chapter 6).  Their MS/MS spectra are also identical.  This compound was 
the second most active antiplasmodial compound (Chapter 5), therefore the inclusion of 
the hydrolysed product during the following bioavailability experiments. 
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8.4   Bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed 
product in mice using different formulations and administration routes 
 
8.4.1   Introduction 
The precursor ion experiments showed that the hydrolysed product of 9-O-
acetylhydnocarpin is present in the study samples.  The LC-MS/MS method was modified 
to also detect the hydrolysed product of 9-O-acetylhydnocarpin and was used to study the 
bioavailability of this product in a mouse model.  The bioavailability of 9-O-
acetylhydnocarpin and its hydrolysed product was relatively low when administered in a 
polar chemical environment as was reported previously.  The test compound is poorly 
water soluble which may be the reason for the low blood levels that were measured.  A 
drug delivery system was required that could carry the test drug across membranes.  
Formulation plays an important role in delivering drugs to the target site and is an 
important part of early drug development. 
 
At this stage of the project it was decided to study the effect of different administration 
routes and formulations to get a better understanding about the bioavailability properties of 
the test compound under the different experimental conditions.   
An oral vs. subcutaneous comparison study was conducted using a polar and non polar 
formulation to examine the bioavailability of these compounds under different chemical 
and administration environments. 
 
A further objective was to develop an assay method that was more sensitive and used less 
sample, so that one a imal was used for all sampling periods.  The mice would not be 
sacrificed at every time point, and could be reused after a recovery period of about two 
weeks.  The intent was to develop methodology that uses 10 μl of blood per sampling point 
with six sampling times per animal.  Less than 10% of an animal’s blood is removed by this 
methodology, which should not affect the animal’s health in any negative way.  It should 
also not have a significant impact on bioavailability results. 
 
The low levels of 9-O-acetylhydnocarpin and the hydrolysed product that were observed 
during the previous animal experiments may be due to low absorption from the 
gastrointestinal tract, which may be a matter of formulation [Yanyu et al., 2006 Yanyu et 
al., 2006].   
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A second possibility may be that 9-O-acetylhydnocarpin is absorbed, but undergoes 
extensive metabolism by the CYP450 enzymes that occur predominantly in the liver 
[Katzung, 2004]. 
 
Surfactants, e.g. PEG and Tween® 80 are often used in formulations to improve 
bioavailability by enhancing the solubility of test compounds [Hite et al., 2003]. 
 
Tween® 80 was chosen as a possible delivery vehicle for the test compound.  It consists of 
fatty acid esters of sorbitan polyethoxylates [Tween® 80 by LC-MS]. 
 
Experiments used here are intended to give more insight into the matters raised above.  
Two experiments were designed, the first should have answers to the first topic and the 
second should answer the metabolism topic.   
 
For the first experiment, Tween® 80 was used as a delivery vehicle and was orally 
administered to mice.  A control group of mice was included, with the test compound was 
administered in the standard polar format (water : DMSO; 90:10, v/v).   
 
For the second experiment, Tween® 80 was also used as a delivery vehicle but was 
subcutaneously administered to mice.  A control group of mice was included, with the test 
compound was administered in the standard polar format (water : DMSO; 90:10, v/v).  
The experimental design is presented in Chapter 12 (12.7.4). 
 
8.4.2   Results 
The calibration standards were extracted and analysed in duplicate.  The calibration 
curves are presented in appendix 3 (9-O-acetylhydnocarpin:  figure 171, hydrolysed 
product:  figure 172).  The back-calculated results are presented in appendix 3 (9-O-
acetylhydnocarpin:  table 57, hydrolysed product:  table 58).  A quadratic regression 
weighted 1/x was used for the statistical analyses.  Representative chromatograms of 
calibration standards at the LLOQ and Cmax are presented in appendix 3 (figures 173 and 
174).  Representative chromatograms of a study sample are presented in appendix 3 
(figure 175).  Results of the animal samples are presented in sections 8.4.2.1 and 8.4.2.2.  
The results of the oral dose experiments are summarised in tables 10, 11, 12 and 13.  The 
results of the subcutaneous dose experiments are summarised in tables 14, 15, 16 and 
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17.  Concentration vs. Time graphs of 9-O-acetylhydnocarpin and the hydrolysed product 
as obtained after a single subcutaneous dose of 9-O-acetylhydnocarpin in the test 
formulation (100 mg/kg) are presented in figures 86 and 87. 
 
8.4.2.1   Oral dose experiment 
8.4.2.1.1 Test formulation 
Table 10  Whole blood concentrations of 9-O-acetylhydnocarpin            
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
 0 0 0 0 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
3 BLQ BLQ BLQ 
5 BLQ 0.346 0.318 
7 BLQ BLQ BLQ 
BLQ = below limit of quantification 
Table 11  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 0.317 BLQ BLQ 
2 BLQ BLQ BLQ 
3 BLQ BLQ BLQ 
5 BLQ BLQ BLQ 
7 BLQ BLQ BLQ 
 
8.4.2.1.2 Control formulation 
Table 12  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
3 BLQ BLQ BLQ 
5 BLQ BLQ BLQ 
7 BLQ BLQ BLQ 
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Table 13  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
3 BLQ BLQ BLQ 
5 BLQ BLQ BLQ 
7 BLQ BLQ BLQ 
 
 
8.4.2.2   Subcutaneous dose experiment 
8.4.2.2.1 Test formulation 
Table 14  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 0.632 1.03 0.351 
2 0.430 0.512 BLQ 
3 0.333 0.731 0.835 
5 BLQ 1.18 BLQ 
7 BLQ BLQ 0.0812 
 
Table 15  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 0.937 0.855 1.18 
2 0.598 0.757 0.778 
3 0.491 0.801 0.740 
5 0.397 1.32 BLQ 
7 0.368 BLQ BLQ 
 
8.4.2.2.2 Control formulation 
Table 16  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
3 BLQ BLQ BLQ 
5 BLQ BLQ BLQ 
7 BLQ BLQ BLQ 
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Table 17  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3
(μg/ml)
0 0 0 0 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
3 BLQ BLQ BLQ 
5 BLQ BLQ BLQ 
7 BLQ BLQ BLQ 
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Figure 86  Concentration vs. Time graph of 9-O-acetylhydnocarpin as obtained after a 
single subcutaneous dose of 9-O-acetylhydnocarpin in the test formulation (100 mg/kg) 
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Figure 87  Concentration vs. Time graph of the hydrolysed product as obtained after a 
single subcutaneous dose of 9-O-acetylhydnocarpin in the test formulation (100 mg/kg) 
 
8.4.3   Discussion 
An improved LC-MS/MS method for the determination of 9-O-acetylhydnocarpin and its 
hydrolysed product in mice whole blood was developed, by making use of a more sensitive 
mass spectrometer.  A micro liquid-liquid filter paper extraction method was developed to 
extract the compounds of interest from the whole blood samples and was followed by C18 
reversed phase HPLC and tandem mass spectrometry.  The calibration range for both 
compounds was between 0.313 and 5.0 μg/ml.  This assay method was used to quantify 
9-O-acetylhydnocarpin and its hydrolysed product in mice whole blood.    
 
Blood levels for 9-O-acetylhydnocarpin and its hydrolysed product obtained during the oral 
dose experiment were lower than the LLOQ for both the test and control formulations.  
These results indicate that 9-O-acetylhydnocarpin is poorly absorbed from the 
gastrointestinal tract or probably metabolised extensively by CYP450 enzymes.   
 
Blood levels for 9-O-acetylhydnocarpin and its hydrolysed product obtained during the 
subcutaneous dose experiment were relatively high for the Tween® 80 formulation.  Blood 
levels above the LLOQ could be determined for both compounds up to 7 hours after dose.  
Blood levels in the control group were below the LLOQ for both compounds.  These results 
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show that 9-O-acetylhydnocarpin is bioavailable after subcutaneous dose in the Tween® 
80 formulation, and is probably protected against first pass metabolism to some degree.  
The compounds in the control group should be available after subcutaneous 
administration, but no levels for both compounds were detected, which is an indication that 
the compounds were extensively metabolised by probably the CYP450 enzymes. 
 
Results from these experiments show that the test compound is most likely absorbed from 
the gastrointestinal tract but is extensively metabolised by the liver enzymes. 
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8.5   Method development and validation of an improved assay method  
8.5.1   Introduction 
The analytical method that was used during the previous section had a relatively high 
LLOQ.  At this stage of the project a more sensitive method was required to be able to 
answer some of the questions that were raised previously.   A more sensitive analytical 
model for quantifying the compounds of interest was developed by including an internal 
standard and improving the extraction method.  Compound 2 was selected as an internal 
standard (6.2).  The method development methodology of the new improve analytical 
model is presented in Chapter 12 (12.7.5).   
 
8.5.2   Validation results 
Van Zoonen and co-workers described the importance of method validation in the 
analytical laboratory [Van Zoonen et al., 1999]. 
 
This is the final test to demonstrate that the bioassay method is fit to be used as a “tool” to 
quantify study samples.  Shah and co-workers have described the fundamental 
parameters that are required for validation [Shah et al., 2000].  The validation process is 
also performed to objectively demonstrate the specificity, reliability, sensitivity and 
suitability of the assay method for the purposes of assaying study samples.  A 
comprehensive method validation is required for analytical methods that are used for 
analysing samples that are generated during clinical and preclinical studies.  This project is 
about the discovery of selective antiplasmodial compounds, as well as the evaluation of 
the most active compound in an animal model, keeping this in context, it was decided to 
develop an accurate and precise analytical method and also show the validity of the 
method.   
 
8.5.2.1   Analysis of calibration standards 
The calibration standards were analysed according to the method described in Chapter 12 
(12.7.5).  The calibration curves are presented in appendix 3 (9-O-acetylhydnocarpin:  
figure 176, hydrolysed product:  figure 177).  The back-calculated results are presented in 
appendix 3 (9-O-acetylhydnocarpin:  table 59, hydrolysed product:  table 60).  A quadratic 
regression weighted 1/x was used for the statistical analyses.   
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8.5.2.2   Stability  
Stability information is assessed to ensure that all necessary precautions are taken to 
ensure that the compound concentration is not affected by internal and external conditions 
such as matrix-interactions, chemical properties, storage conditions of the drug and the 
container system.  These stability procedures should evaluate the stability of the 
compound during sample collection and handling, after long-term (frozen at the intended 
storage temperature) and short-term storage, and after going through freeze and thaw 
cycles and the analytical process.  These experiments should reflect situations likely to be 
encountered during actual sample handling and analysis [Van Zoonen et al., 1999; Shah 
et al., 2000]. 
 
8.5.2.2.1 Long term matrix stability 
Long term stability should be determined by storing at least three aliquots of each of the 
low and high concentrations under the same conditions as the study samples.  The time 
that the samples are stored should exceed the time between the date of first sample 
collection and the date of last sample analysis.  The samples that were used to test long 
term matrix stability were prepared on the sixteenth of March 2007.  The standards that 
were used to construct the calibration curve were prepared on the third of May 2007. 
These samples were analysed and peak areas and means as well as the calculated 
differences between the two sets of aliquots are summarised in appendix 3 (tables 61 and 
62).  Both compounds were found to be stable for at least 48 days when stored at – 20 °C.   
 
8.5.2.2.2 On bench and Freeze-thaw stability 
The FDA Guidance suggested that three freeze and thaw cycles should be determined to 
ensure compound stability for analytical methods used for clinical sample analysis.  They 
also indicated that at least three aliquots at each of the low and high concentrations should 
be stored at the intended storage temperature for 24 hours and thawed unassisted at room 
temperature.  After the samples have been thawed completely, they should be refrozen for 
12 to 24 hours at the same conditions.  This cycle should be repeated two more times, and 
analysed after the third cycle.  If it is found that an analyte is unstable at the intended 
temperature, these stability samples should be frozen at –70 °C and tested again as 
described above [Guidance for Industry, 2001]. 
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Spiked solutions of 9-O-acetylhydnocarpin and the hydrolysed product in whole blood at 
two different concentrations (10 and 0.625 μg/ml) were frozen at -20°C and put through 
three freeze and thaw cycles.  The samples were also left on ice for 2 hours after being 
thawed.  These samples were analysed and peak areas and means as well as the 
calculated differences between the two sets of aliquots are summarised in appendix 3 
(tables 63 and 64). 
 
9-O-Acetylhydnocarpin was found to be stable at high and low concentrations as indicated 
in table 63.  The hydrolysed product was also found to be stable when tested at high 
concentrations and a slight decrease in measured concentration was observed when 
tested at low concentrations as indicated in table 64. 
The animal samples and calibration standards were only thawed once on ice to prevent 
degradation.   
 
 
8.5.2.3   Specificity 
Specificity of a method is the ability to differentiate nd quantify the compound of interest 
in the presence of other components in the sample.  There are potential interfering 
substances in a biological matrix that include endogenous matrix components, 
metabolites, decomposition products and other xenobiotics [Van Zoonen et al., 1999; Shah 
et al., 2000].   
 
The very high specificity of th  LC-MS/MS assay procedure precludes the detection of any 
compounds that do not possess the capability to produce the specific molecular ion 
followed by formation of the specific product ion produced and monitored in the mass 
spectrometer. 
 
Blank sample extracts were positioned in the injection sequence immediately after the 
highest calibration standard in order to assess possible carry-over effects.  The 
autosampler needle was rinsed with acetonitrile after every injection for 5 seconds.  No 
significant carry-over was observed.  An example of a chromatogram of a blank whole 
blood extract injected after the highest standard is presented in appendix 3 (figure 178). 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 142
8.5.2.4   Limit of quantification 
The lower limit of quantification (LLOQ) of a method should have a signal/noise value 
greater than 5 [Van Zoonen et al., 1999; Shah et al., 2000].  The LLOQ of this method was 
set at 0.078 μg/ml (concentration of lowest STD) for both compounds.  The signal/noise 
values for both compounds were much higher than 5.  The LLOQ chromatograms are 
presented in appendix 3 (figure 179). 
 
8.5.2.5   Recovery 
The recovery of a compound is the detector response obtained from an amount of 
compound added to and extracted from the biological matrix, compared to the detector 
response obtained for the true concentration of the pure authentic standard.  The recovery 
should be consistent, precise and reproducible, and need not be 100% [Van Zoonen et al., 
1999; Shah et al., 2000].  
 
Recovery is the measure of the compounds losses incurred during sample processing, 
and is defined as:  Recovery (%) = (peak area of standard/peak area of sample spiked in 
mobile phase) x 100 
 
Peak areas of a standard and theoretical peak areas obtained from the samples spiked in 
mobile phase are used in calculating the recovery of the compounds according to the 
above mentioned formula.  
 
The concentration of the standard was 10 μg/ml for 9-O-acetylhydnocarpin and the 
hydrolysed product spiked in whole blood.  The concentration of the sample spiked in 
mobile phase was 1 μg/ml for 9-O-acetylhydnocarpin and the hydrolysed product.  The 
extracted samples were diluted ten times during the extraction process (10 μl sample, 100 
μl extract) to give an effective concentration of 1 μg/ml in the final extracted sample, 
therefore no dilution factor needs to be taken into account. 
 
The concentration of the internal standard in the organic solvent used during the extraction 
of the standard was 1 μg/ml.  The internal standard gets concentrated 2.5 times during the 
extraction (250 μl organic solvent gets concentrated to 100 μl in the mobile phase).  The 
concentration of the sample spiked in mobile phase was 1 μg/ml for the internal standard.  
A 2.5 x concentrating factor was included for calculating the internal standards recovery.    
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Recovery (9-O-acetylhydnocarpin) = (196000/234500) * 100 
               = 84% 
 
 
Recovery (hydrolysed product)   = (87100 / 78950) x 100 
               = 110% 
 
Recovery (internal standard)   = ((25600 x 2.5) / 76450) x 100 
               = 84% 
 
8.5.3   Discussion 
A reliable, accurate and more sensitive analytical method was developed for determining 
9-O-acetylhydnocarpin and its hydrolysed product in mice whole blood.  This method was 
used as a quantification “tool” during the next section of this project.   
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8.6   Bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed 
product in mice using a self-microemulsifying drug delivery system 
 
8.6.1   Introduction 
A lipid based self-microemulsifying drug delivery system (SMEDDS) improved the 
bioavailability of silymarin compounds significantly in a study conducted by Wu and co-
workers [Wu et al., 2006].  These compounds are structurally related to 9-O-
acetylhydnocarpin; consequently it was decided to investigate this drug delivery system as 
a possible vehicle to improve the bioavailability of the compounds investigated in this 
study.  This formulation consists of silymarin, Tween® 80, ethyl linoleate and ethanol.  The 
authors tested different compositions and found the optimal formulation as follows:  
silymarin (8.5%), ethanol (9.2%), Tween® 80 (54.9%) and ethyl linoleate (27.4%).  The 
bioavailability of silymarin was studied in rabbits by making use of the optimal SMEDDS 
formulation.  It was found that the bioavailability of the silymarin compounds was improved 
49 fold when compared to the usual suspension.  
 
The test compound was formulated using the SMEDDS formulation Chapter 12 (12.7.6).  
The SMEDDS formulation was tested orally and subcutaneously as follow: 
 
Oral dose experiment  
9-O-Acetylhydnocarpin was administered orally at a concentration of 200 mg/kg (SMEDDS 
formulation) to three healthy mice (male, C57BL6).   Blood samples (10 μl) were collected 
just before, and at 0.5, 1, 2, 5 and 7 hours after administration. 
 
Subcutaneous dose experiment 
9-O-Acetylhydnocarpin was administered subcutaneously at a concentration of 200 mg/kg 
(SMEDDS formulation) to three healthy mice (male, C57BL6).  Blood samples (10 μl) were 
collected just before, and at 0.5, 1, 2, 5 and 7 hours after administration. 
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8.6.2   Results 
The study samples and calibration standards were analysed according to the method 
described in Chapter 12 (12.7.5).  Two additional standards were included at the lower end 
of the calibration curve, and 10 μl was injected onto the column. 
 
Although the internal standard technique is widely used in chromatography, this does not 
inevitably improve the precision of an assay method; in fact it may even impair the 
precision of the assay, as was observed during this phase of the project [Haefelfinger, 
1981].  The internal standard was found to be unstable in the organic solvent when it was 
left on the bench for 24 hours, therefore the decision to exclude the internal standard. 
 
Calibration curves (analysed in duplicate) are presented in appendix 3 (9-O-
acetylhydnocarpin:  figure 180, hydrolysed product:  figure 181).  The back-calculated 
results are presented in appendix 3 (9-O-acetylhydnocarpin:  table 65, hydrolysed product:  
table 66).  A quadratic regression weighted 1/x was used for the statistical analyses.  
Representative chromatograms of calibration standards at the LLOQ and Cmax are 
presented in appendix 3 (figures 182 and 183, respectively).  Representative 
chromatograms of a study sample are also presented in appendix 3 (figure 184). 
 
The results of the oral dose experiments are summarised in tables 18 and 19.  
Concentration vs. Time graphs of 9-O-acetylhydnocarpin and the hydrolysed product as 
obtained after a single oral dose of 9-O-acetylhydnocarpin in the SMEDDS formulation 
(200 mg/kg) are presented in figures 88 and 89. 
 
The results of the subcutaneous dose experiments are summarised in tables 20 and 21.  
Concentration vs. Time graphs of 9-O-acetylhydnocarpin and the hydrolysed product as 
obtained after a single subcutaneous dose of 9-O-acetylhydnocarpin in the SMEDDS 
formulation (200 mg/kg) are presented in figures 90 and 91. 
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8.6.2.1   Oral dose experiment 
Table 18  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
0.5 0.243 0.469 0.388 
1 BLQ  0.526 BLQ 
2 BLQ BLQ BLQ 
5 BLQ BLQ 0.396 
7 - 0.537 - 
BLQ = below limit of quantification 
 
Table 19  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
0.5 0 0 0 
1 0 0 0 
2 0 0 0 
5 0 0 0 
7 0 0 0 
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Figure 88  Concentration vs. Time graph of 9-O-acetylhydnocarpin as obtained after a 
single oral dose of 9-O-acetylhydnocarpin in the SMEDDS formulation (200 mg/kg) 
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Figure 89  Concentration vs. Time graph of the hydrolysed product as obtained after a 
single oral dose of 9-O-acetylhydnocarpin in the SMEDDS formulation (200 mg/kg) 
 
 
 
 
8.6.2.2   Subcutaneous dose experiment  
Table 20  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
0.5 0.262 0.451 0.433 
1 0.149 0 0.303 
2 0.0961 0 0.363 
5 0.415 0 0.108 
7 0.152 0.374 0 
 
Table 21  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
0.5 0.119 0.109 0.104 
1 0.149 0.108 0.122 
2 0.135 0.102 0.126 
5 0.194 0.127 0.153 
7 0.0869 0.127 0.0867
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Figure 90  Concentration vs. Time graph of 9-O-acetylhydnocarpin as obtained after a 
single subcutaneous dose of 9-O-acetylhydnocarpin in the SMEDDS formulation (200 
mg/kg) 
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Figure 91  Concentration vs. Time graph of the hydrolysed product as obtained after a 
single subcutaneous dose of 9-O-acetylhydnocarpin in the SMEDDS formulation (200 
mg/kg) 
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8.6.3   Discussion 
The same LC-MS/MS method was used as described in 8.5.  The calibration range for 
both compounds was between 0.0781 and 10.0 μg/ml.  This assay method was used to 
quantify 9-O-acetylhydnocarpin and its hydrolysed product in mice whole blood, using the 
SMEDDS drug delivery system.    
 
Relatively high levels for 9-O-acetylhydnocarpin could be determined for up to 7 hours, 
using the SMEDDS oral dose formulation.  An enterohepatic circulation effect was 
observed for the test compound.  These results indicate that 9-O-acetylhydnocarpin is 
absorbed from the gastrointestinal tract, but is rapidly metabolised by the CYP450 
enzymes in the liver to probably glucuronidated metabolites.  These conjugated 
metabolites are reintroduced back into the blood system as free molecules as observed by 
the enterohepatic circulation effect.  No levels were detected for the hydrolysed product, 
which indicates that this formulation protects the test compound against the hydrolysis 
reaction. 
 
The concentration of the test compound was relatively high after 30 minutes, using the 
SMEDDS subcutaneous dose formulation, but reached almost steady state after an hour, 
and lasted for up to seven hours.  The hydrolysed product was also observed after 30 
minutes but at lower concentrations, and could also be followed for up to seven hours.  
The SMEDDS formulation also protects the compound against hydrolysis, but to a lesser 
extent than was observed for the oral dose experiment.  The SMEDDS formulation, 
administered subcutaneously delivered the test compounds at almost steady state.   
 
The SMEDDS formulation improved bioavailability drastically for the oral dose experiment, 
however higher blood levels of the test compound were expected, if the relatively high 
dose of 200 mg/kg is brought in context.  This indicates that the test compound and its 
hydrolysed product are extensively metabolised by the CYP450 liver enzymes to probably 
glucuronidated metabolites. 
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8.7   Bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed 
product in mice using Pheroid technology as a drug delivery system 
after oral administration  
 
8.7.1   Introduction 
Pheroid technology is a novel universal drug delivery and carrier system that enhances 
bioavailability and efficacy.  It has also been suggested that the system most likely 
protects compounds from Phase I and II metabolism.  The intellectual property of the 
Pheroid technology was purchased by the North-West University of South Africa from 
MeyerZall (Pty) Ltd in 2003.  It was tested for a broad range of drugs and showed 
promising results.  The department of Pharmaceutics at the North-West University has 
granted permission (in writing by Anne Grobler) for testing the Pheroid drug delivery 
system in this project.  The Pheroid system is a colloidal system of modified essential fatty 
acids with stable lipid-based vesicular structures, known as Pheroids, with size ranging 
from 200 to 440 nm.  These vesicles are distributed uniformly in a dispersion medium 
which may be modified depending on the application.   The Pheroids consist mainly of 
ethylated and pegylated polyunsaturated fatty acids.  Omega-3 and omega-6 are included 
but arachidonic acid is excluded.  The fatty acids are in the cis-conformation and therefore 
compatible with the orientation of human fatty acids [Grobler et al.]. 
 
It was decided to investigate this drug delivery system as a possible vehicle to improve 
bioavailability of the test compound under investigation.  9-O-Acetylhydnocarpin was 
formulated using the pheroid system, at a concentration of 10 mg/ml.  This 9-O-
acetylhydnocarpin pheroid formulation was administered orally to three healthy mice 
(male, C57BL6), at 2 mg per mouse (200 µl of a 10 mg/ml formulation).   Blood samples 
(10 μl) were collected just before, and at 0.5, 1, 2, 5 and 7 hours after administration. 
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8.7.2   Results 
The study samples and calibration standards were analysed according to the method 
described in Chapter 12 (12.7.5).  A new set of calibration standards was prepared, with 
the LLOQ set at 0.0780 μg/ml, and the highest standard set at 2.5 μg/ml, for 9-O-
acetylhydnocarpin and its hydrolysed product.  Representative chromatograms of 
calibration standards at the LLOQ and Cmax are presented in appendix 3 (figures 185 and 
186, respectively).  Representative chromatograms of a study sample are presented in 
appendix 3 (figure 187).   
 
The calibration curves of 9-O-acetylhydnocarpin and its hydrolysed product are presented 
in appendix 3 (figures 188 and 189, respectively).  The back-calculated results and 
calibration curve statistics are presented in appendix 3 (tables 67 and 68 for 9-O-
acetylhydnocarpin and the hydrolysed product, respectively).  A quadratic regression 
weighted 1/x was used for the statistical analyses. 
 
The results of the oral dose experiments are summarised in tables 22 and 23.  A 
Concentration vs. Time graph of 9-O-acetylhydnocarpin obtained after a single oral dose 
of 9-O-acetylhydnocarpin in the Pheroid formulation (2 mg/mouse) is presented in figure 
92. 
 
Table 22  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mous  2 
(μg/ml) 
Average 
(μg/ml) 
0 0 0 0 
0.5 BLQ 0.0862 BLQ 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
5 0.337 BLQ 0.1685 
7 0.909 0.533 0.721 
BLQ = below limit of quantification 
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Table 23  Whole blood concentrations of the hydrolysed product 
Time 
(hours) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
0.5 BLQ BLQ BLQ 
1 BLQ BLQ BLQ 
2 BLQ BLQ BLQ 
5 BLQ BLQ BLQ 
7 BLQ BLQ BLQ 
BLQ = below limit of quantification 
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Figure 92  Concentration vs. Time graph of 9-O-acetylhydnocarpin obtained after a single 
oral dose of 9-O-acetylhydnocarpin in the Pheroid formulation (2 mg/mouse) 
 
 
8.7.3   Discussion 
The same LC-MS/MS method was used as described in 8.5.  The calibration range for 
both compounds was between 0.0781 and 2.5 μg/ml.  This assay method was used to 
quantify 9-O-acetylhydnocarpin and its hydrolysed product in mice whole blood, using the 
Pheroid drug delivery system.    
 
Relatively high levels for 9-O-acetylhydnocarpin could be determined at 5 and 7 hours, 
using the Pheroid formulation.  A relatively long absorption delay was observed for the test 
compound.   
 
These results indicate that 9-O-acetylhydnocarpin is absorbed from the gastrointestinal 
tract, when administered in the Pheroid formulation, but at a much later stage than was 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 153
previously observed for the SMEDDS formulation.  A glimpse of the enterohepatic effect 
was observed for one animal, but is considered insignificant, because of the low level that 
was reached at 0.5 hours after dose.  
 
No levels were detected for the hydrolysed product, which indicates that the Pheroid 
formulation protects the test compound against hydrolysis. 
 
The Pheroid formulation delayed the absorption of the test compound considerably, and it 
was probably absorbed from the latter part of the gastrointestinal tract.  Bioavailability was 
improved significantly if compared to the SMEDDS formulation.  Less of the test 
compound was administered and higher levels were reached at 7 hours (2 mg for Pheroid 
and 5 mg for SMEDDS).  The Pheroid drug carrier and delivery system thus proved to be 
superior to the others that were tested.   
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8.8   Bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed 
product in mice after intravenous administration  
 
8.8.1   Introduction 
Results of the preceding experiments indicated that the test compound undergoes 
extensive metabolism soon after absorption from the gastrointestinal tract.   It was decided 
to study the test compound’s clearance rate after intravenous injection (IV) to prove this 
theory.  Results from this experiment should give more insight about the compounds 
metabolism.   
     
The Pheroid delivery system was the most promising formulation tested; consequently it 
was decided to use this formulation as the injection vehicle for the IV experiments.  A 
control group was also included which consisted of the test compound in a polar 
environment.   
 
Test formulation 
9-O-Acetylhydnocarpin was administered intravenously (200 μl) at a concentration of 100 
μg/ml in a pheroid-saline solution to 3 healthy mice (male, C57BL6).  The mice were 
anesthetised for this procedure.  Blood samples (10 μl) were collected just before, and at 
2, 10, 30, 60, 120 and 240 minutes after administration. 
 
Control formulation 
9-O-Acetylhydnocarpin was administered intravenously (200 μl) at a concentration of 100 
μg/ml in a saline solution to 3 healthy mice (male, C57BL6).  The mice were also 
anesthetised for this procedure.  Blood samples (10 μl) were collected just before, and at 
2, 10, 30, 60, 120 and 240 minutes after administration. 
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8.8.2   Results 
The study samples and calibration standards were analysed according to the method 
described in 8.5.  A new set of calibration standards was prepared, with the LLOQ set at 
0.0195 μg/ml, and the highest standard set at 1.25 μg/ml, for 9-O-acetylhydnocarpin and 
its hydrolysed product.  The standards were analysed in four-fold.   
 
Representative chromatograms of calibration standards at the LLOQ and Cmax are 
presented in appendix 3 (figures 190 and 191, respectively).  Representative 
chromatograms of a study sample are presented in appendix 3 (figure 192).  The 
calibration curves of 9-O-acetylhydnocarpin and its hydrolysed product are presented in 
appendix 3 (figures 193 and 194, respectively).  The back-calculated results and 
calibration curve statistics are presented in appendix 3 (tables 69, 70, 71 and 72 for 9-O-
acetylhydnocarpin and the hydrolysed product, respectively).  A linear regression weighted 
1/x was used for the statistical analyses. 
 
The results of the IV dose experiments of the Pheroid formulation are summarised in 
tables 24 and 25.  Concentration vs. Time graphs of 9-O-acetylhydnocarpin and the 
hydrolysed product obtained after single IV injections of 9-O-acetylhydnocarpin in the 
Pheroid formulation (20 μg/mouse) are presented in figure 93 and 94, respectively. 
 
The results of the IV dose experiments of the control formulation are summarised in tables 
26 and 27.  Concentration vs. Time graphs of 9-O-acetylhydnocarpin and the hydrolysed 
product obtained after single IV injections of 9-O-acetylhydnocarpin in the control 
formulation (20 μg/mouse) are presented in figure 95 and 96, respectively. 
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8.8.2.1.1 Test formulation 
Table 24  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(min) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
2 0.432 0.272 0.653 
10 0.0501 0.0275 0.0699 
30 0.0329 0.0558 0.0499 
60 0.0407 BLQ 0.0320 
120 BLQ BLQ 0.0314 
240 BLQ 0.0219 0.0414 
BLQ = below limit of quantification 
 
Table 25  Whole blood concentrations of the hydrolysed product 
Time 
(min) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
2 0.214 0.130 0.304 
10 0.0226 0.0248 0.0348 
30 BLQ 0.0288 BLQ 
60 BLQ BLQ BLQ 
120 BLQ BLQ BLQ 
240 BLQ BLQ BLQ 
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Figure 93  Concentration vs. Time graph of 9-O-acetylhydnocarpin as obtained after 
single intravenous injections of 9-O-acetylhydnocarpin in the Pheroid formulation (20 
μg/mouse) 
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Figure 94  Concentration vs. Time graph of the hydrolysed product obtained after single 
intravenous injections of 9-O-acetylhydnocarpin in the Pheroid formulation (20 μg/mouse)  
 
 
 
8.8.2.1.2 Control formulation 
Table 26  Whole blood concentrations of 9-O-acetylhydnocarpin 
Time 
(min) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
2 0.161 0.113 0.134 
10 0.0382 0.0416 0.0307 
30 BLQ BLQ 0.0231 
60 0.0196 BLQ BLQ 
120 BLQ BLQ BLQ 
240 BLQ BLQ BLQ 
 
Table 27  Whole blood concentrations of the hydrolysed product 
Time 
(min) 
Mouse 1 
(μg/ml) 
Mouse 2 
(μg/ml) 
Mouse 3 
(μg/ml) 
0 0 0 0 
2 0.418 0.316 0.381 
10 0.0621 0.0626 0.0434 
30 BLQ 0.0295 0.0215 
60 BLQ BLQ BLQ 
120 BLQ BLQ BLQ 
240 BLQ BLQ BLQ 
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Figure 95  Concentration vs. Time graph of 9-O-acetylhydnocarpin as obtained after 
single intravenous injections of 9-O-acetylhydnocarpin in the control formulation (20 
μg/mouse) 
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Figure 96  Concentration vs. Time graph of the hydrolysed product obtained after single 
intravenous injections of 9-O-acetylhydnocarpin in the control formulation (20 μg/mouse) 
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8.8.3   Discussion 
The intravenous experimental results showed fast clearance of the test compound, as 
about 90% of the compound is metabolised within 10 minutes.  These results prove that 
extensive metabolism occurs after absorption by probably the CYP450 liver enzymes. 
The initial level of the test compound in the Pheroid group was about three times higher 
than for the control group, which indicates some level of protection against the CYP450 
liver enzymes by the Pheroid formulation.  The initial level of the hydrolysed product in the 
Pheroid group was lower than for the control group, which indicates some level of 
protection against the esterase enzymes by the Pheroid formulation.   
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8.9   Conclusion 
A comprehensive bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed product 
was conducted in mice using LC-MS/MS analysis.  
 
A new micro extraction technique that uses only 10 μl of sample was developed.  The test 
compound and hydrolysed product were selectively extracted from mice blood with 
consistent recoveries above 80%.  This technique made it possible to study bioavailability 
in one animal over a period of six sampling points.  It also reduced the number of animals 
that are usually required for these kinds of experiments. 
 
A highly sensitive, selective and accurate LC-MS/MS method was developed and 
validated, and was used as a quantitative tool for sample analysis.  The final method could 
accurately detect levels as low as 20 ng/ml for both compounds in 10 μl samples. 
 
Results from these experiments showed that the test compound is absorbed from the 
gastrointestinal tract if administered in the right formulation.  Relatively high blood levels 
were observed for the SMEDDS and Pheroid oral formulations. 
 
The Pheroid and SMEDDS oral formulations improved bioavailability significantly, but 
because of rapid metabolism, levels were lower than expected.   
 
A comparison of the test compounds blood levels and in vitro IC50 values indicate that the 
test compound will probably not reach high enough blood levels for curing infected 
animals, although parasite inhibition may still be observed at these levels.  One should 
also keep in mind that different Plasmodium species were used for in vitro and in vivo 
testing and would probably have different IC50 values.  Metabolites may also be active and 
present at high enough levels to inhibit parasite growth in vivo.      
    
Bioavailability (biological availability) can be described as the extent to which a compound 
is utilized pharmacologically.  Pharmacokinetics on the other hand is the science of the 
mathematical assessment of drug distribution in terms of model systems, of rate constants 
of transfer, of rate constants of metabolism and excretion, and of apparent volumes of 
distribution compartments.  It was intended to study the test compounds biological 
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availability in a mouse model, and to use this information to construct concentration vs. 
time graphs, and ultimately to construct a pharmacokinetic model for the test compound 
that was evaluated.  The outcome of the bioavailability studies, which were performed by 
using different formulations and administration routes, unfortunately resulted in relatively 
poor bioavailability profiles.  Therefore it was decided not to construct a pharmakocinetic 
model for the test compound [Curry, 1977]. 
 
The outcome of these findings led to the following logical step in the early development 
process, which is the search for metabolites in vivo as well as investigating the metabolism 
of structurally related compounds. 
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CHAPTER 9 
 
Metabolite study of 9-O-acetylhydnocarpin 
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9   Metabolite study of 9-O-acetylhydnocarpin 
 
9.1   Introduction 
Metabolite studies are vital in the drug discovery process, but are expensive and time 
consuming.  The pharmaceutical industry has shown the importance of conducting 
metabolite studies before drug candidates are selected during the drug development 
process.  Results from these studies should give more insight on drug candidate selection. 
 
During the last few years mass spectrometry has emerged as the analytical instrument of 
choice used for the identification of metabolites.  Tandem mass spectrometers have 
become the keystone of metabolite identification.  Tandem quadrupole mass 
spectrometers generally consist of an isolation stage and fragmentation stage within the 
same instrument.  There are numerous different tandem MS experiments that can be used 
to identify metabolites, even though the same basic series of events are followed.  The ion 
of interest is first isolated on the basis of its mass/charge ratio and is then passed into the 
collision cell, which is filled with an inert gas such as helium or argon, and a potential 
difference is applied.  The energized ions collide with the gas molecules resulting in 
fragment ions, which moves out of the cell and hit the detector.  The product ions 
correspond to part of the unknown molecule.  The product ion mass spectrum contains the 
“puzzle pieces” of the unknown molecule.   Interpretation of this spectrum is supported by 
infusing the parent compound and performing the same fragmentation experiment as was 
used for the unknown metabolite.  Comparing the product ion mass spectrum of the 
unknown metabolite with the product ion mass spectrum of the known parent compound 
an experienced operator can identify the overall structure and would be able to indicate the 
changes in the molecule. 
 
Metabolite identification using LC-MS instruments is a systematic approach.  The first step 
in metabolite identification is LC-MS experiments, the second step is precursor ion 
experiments, the third step is neutral loss scans, the fourth step is LC-MS/MS experiments 
and the fifth step is MRM experiments.  The last step is accurate mass measurement, 
which should result in the empirical formula of the unknown metabolite [Applied 
Biosystems MDS Sciex; Clarke et al., 2001; Willoughby et al., 2002; Gangl et al., 2002]. 
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The metabolism of structurally related compounds was studied to get a better 
understanding about general metabolic routes of this group of compounds.  The 
pharmacology of silybin, which is structurally related to 9-O-acetylhydnocarpin, is 
described in the literature [Pharmacology of Silymarin].  Silybin is isolated from the seeds 
of the milk thistle Silybin marianum.  Silybin, which is a flavonolignan, is the main 
compound in the silymarin extract.  Silybin is an important hepatoprotective drug 
(Flavobiom™, Legalon™) used to treat liver damage and is also used as a liver-protecting 
drug [Morazzoni and Bombardelli, 1995; Kren et al., 1997; Flora et al., 1998; Alikaridis et 
al., 2000; Dvorak et al., 2003; Kvasnicka et al., 2003; Davis-Searles et al., 2005; Kren and 
Walterova, 2005].    
 
The chemical structures of 9-O-acetylhydnocarpin, hydnocarpin (hydrolysed product) and 
silybin are presented in figure 97.  These compounds are structurally related and would 
probably have similar pharmacokinetic properties.  Th se compounds are known as 
flavonolignans, with 9-O-acetylhydnocarpin and hydnocarpin belonging to the flavone 
subgroup and silybin to the flavonol subgroup.  General chemical structures of these 
compounds are presented and discussed in Chapter 4 (4.1).  
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Figure 97  Chemical structures of 9-O-acetylhydnocarpin, hydnocarpin and silybin 
 
Silybin is poorly water soluble and is generally administered as a plant extract.  
Bioavailability of silybin is relatively low after oral administration, with highest plasma 
concentrations reached between 4 and 6 hours in humans.  Silybin and related 
compounds of the silymarin extract are quickly conjugated with glucuronic acid and 
sulphate in the liver. These conjugated metabolites are extracted from the blood into the 
bile, and are found in levels corresponding to 80% of the total dose that was administered.  
A small fraction is extracted in the urine [Pharmacology of Silymarin].  Kren and co-authors 
9-O-acetylhydnocarpin silybin hydnocarpin 
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showed that the main silybin conjugate in humans is its 20β-D-glucuronate [Kren et al., 
2000]. 
 
The following enterohepatic circulation of the silymarin compounds is suggested after oral 
administration of silymarin:  intestinal absorption, conjugation in the liver, excretion in the 
bile, hydrolysis by the intestinal flora, and reuptake in the intestine. 
 
Cytochrome P450 enzymes play an important role in the metabolism of the silymarin 
compounds.  9-O-Acetylhydnocarpin is structurally related to these compounds and has 
the same functional groups which points towards a similar metabolic pathway.  The study 
of the metabolic pathway of drugs is a comprehensive field and advanced analytical 
instrumentation is required to study these metabolites qualitatively and quantitatively [Glue 
and Clement, 1999; Kumar and Clark, 2006; Petushkova et al., 2006; Yao et al., 2007].  
Bioavailability of flavonoids has been found to be lower than expected from its favourable 
lipophilicity, because of its extensive metabolic effect in the small intestine.  The major 
metabolic pathway for flavonoids is Phase II metabolism such as glucuronidation and 
sulphatation [Pong et al., 2005; Han et al., 2005]. 
 
LC-MS/MS technology was used to search for metabolites of 9-O-acetylhydnocarpin in a 
mouse model.  The methodology is presented in Chapter 12 (12.8).  
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9.2   Metabolite study of 9-O-acetylhydnocarpin in mice 
The target site for activity testing of the test compound was the animal’s blood system, and 
for that reason it was decided to target this matrix for metabolite discovery.  Metabolites 
end up in the urine and faeces eventually, therefore the addition of these two matrixes in 
the metabolite search.  An Applied Biosystems 3200 Q-Trap mass spectrometer was used 
for the metabolite search.  It was decided to focus on the discovery of potential metabolites 
for this project.  The identification of metabolites is a much more involved process and 
would fall outside the scope of this project.  Different tests were conducted in the search 
for these potential metabolites, which include LC-MS, precursor ion, neutral loss and LC-
MS/MS experiments. 
 
9.2.1   LC-MS analysis 
An oral dose (200 μl) of 9-O-acetylhydnocarpin (200 mg/kg), using the SMEDDS 
formulation, was administered to a mouse.  Blood, urine and faeces samples were 
collected and prepared for LC-MS analysis as described in Chapter 12 (12.8.1).  The LC-
MS analysis methodology is also described in Chapter 12 (12.8.2). 
 
9.2.1.1   Results 
9.2.1.1.1 Blood samples 
The total ion chromatograms of the control (red) and test (blue) blood samples are 
presented in figure 98.  The retention times of the test compound and its hydrolysed 
product could not be identified with the relatively unspecific LC-MS scan experiment, 
therefore a more sensitive and selective MRM experiment was conducted to illustrate the 
retention times of these compounds using the HPLC gradient as described in Chapter 12 
(12.8.2).  The test compound and its hydrolysed product eluted at 11.8 and 10.7 minutes, 
respectively (figure 99). 
 
The mass spectrum of each of the peaks was subtracted from the background.  TIC 
chromatograms, showing background (green selection) subtraction, as well as mass 
spectra (blue selection) of each of the peaks are presented in appendix 4 (figures 195 to 
208).      
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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Figure 98  Total ion chromatograms of the control and test blood samples 
 
XIC of +MRM (2 pairs): 507.2/257.2 amu from Sample 1 (Sample005) of 1005.wiff (Turbo Spray) Max. 7466.7 cps.
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Figure 99  MRM chromatogram of 9-O-acetylhydnocarpin and its hydrolysed product 
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9.2.1.1.2 Urine samples 
The total ion chromatograms of the control (red) and test (blue) urine samples are 
presented in figure 100.  Mass spectra of peak groups 1 and 2 are also presented in 
appendix 4 (figures 209 and 210, background subtraction was performed).   
  
TIC of +Q1: from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 8.8e8 cps.
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Figure 100  Total ion chromatograms of the control and test urine samples 
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9.2.1.1.3 Faeces samples 
The total ion chromatograms of the control (red) and test (blue) faeces samples are 
presented in figure 101.  Mass spectra of the most prominent peak groups 1, 2, 3 and 4 
are presented in appendix 4 (figures 211 to 214, background subtraction was performed).   
 
TIC of +Q1: from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 8.9e8 cps.
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Figure 101  Total ion chromatograms of the control and test faeces samples 
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9.2.1.2   Discussion 
9.2.1.2.1 Blood sample 
The retention times of 9-O-acetylhydnocarpin and its hydrolysed product were 11.8 and 
10.7 minutes, respectively (figure 99).  9-O-Acetylhydnocarpin and its hydrolysed product 
were present in the blood, but at relatively low concentrations compared to the potential 
metabolites.  These two compounds could not be identified in LC-MS scan mode, 
therefore the inclusion of the more sensitive and specific MRM chromatogram.  This 
chromatogram is included to illustrate the retention times of 9-O-acetylhydnocarpin and its 
hydrolysed product, using the HPLC gradient system as described in Chapter 12 (12.8.2). 
 
The total ion chromatogram of the test sample showed additional peaks compared to the 
control sample (figure 98).  These peaks are considered potential metabolite peaks, 
because of their absence in the control sample.  Five of these peak groups were observed 
in the chromatogram.  The first group eluted at the front of the chromatogram at 0.6 
minutes.  The second group eluted between 5.5 and 7.0 minutes.  A third group was 
observed at about 9.9 minutes, a fourth group at 11.8 minutes, and a fifth peak at 14.1 
minutes. 
 
The mass spectrum of the frontal peak (figure 195) contained quite a few ion peaks, which 
suggested the presence of more than one metabolite.  These potential metabolites are 
extremely polar and are difficult to separate under reverse phase HPLC conditions. 
 
The second group consisted of 8 well separated peaks.  The mass spectra of these peaks 
(figures 196 to 203) contained less ion peaks, which suggested the possibility of single 
metabolites. 
 
The third group consisted of 2 partially separated peaks.  The mass spectra of these 
peaks (figures 204 and 205) also suggested the possibility of single metabolites. 
 
The fourth group also consisted of 2 partially separated peaks.  The mass spectra of these 
peaks (figures 206 and 207) also suggested the possibility of single metabolites. 
 
The fifth group contained a single peak and the mass spectrum (figure 208) also 
suggested the possibility of a single metabolite. 
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The outcome of this experiment suggested the presence of quite a few metabolites in 
blood, which are present at relatively high concentrations. 
 
9.2.1.2.2 Urine sample 
The total ion chromatogram of the test sample showed two additional peak groups 
compared to the control sample (figure 100).  A relatively large frontal peak was observed 
at 0.6 minutes, similar to the blood sample.  A second, very large and broad peak group 
eluted between 5.5 and 8.0 minutes, similar to the blood sample. 
 
The mass spectra (figure 209 and 210) of both peak groups consisted of many peak ions, 
which suggested the presence of many metabolites in the urine.   
 
These results suggested that both polar and intermediate polar metabolites are effectively 
extracted from the blood into the urine at relatively high concentrations.   
 
9.2.1.2.3 Faeces sample 
The total ion chromatogram of the test sample showed a number of additional peak groups 
compared to the control sample (figure 101).  A relatively large frontal peak was observed 
at 0.6 minutes, similar to the blood sample.  A second, very large and broad peak group 
eluted between 5.5 and 8.5 minutes, similar to the blood sample.  A third peak eluted at 
11.9 minutes.  A fourth peak eluted at 17.8 minutes.  A series of minor peaks eluted 
between 9 and 19 minutes. 
 
The mass spectra (figure 211 and 212) of peak groups 1 and 2 consisted of many peak 
ions, which is similar to the blood and urine sample.  The mass spectrum (figure 213) of 
peak 3 showed the molecular ion of the test compound, which therefore suggested the 
presence of the test compound in the faeces at relatively high concentrations.  The mass 
spectrum (figure 214) of peak 4 suggested the possibility of a single metabolite.  These 
results suggested that the unchanged test compound, polar, intermediate polar and non 
polar metabolites are effectively removed from the gastrointestinal and blood systems and 
end up in the faeces at relatively high concentrations. 
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9.2.2   Precursor ion scan analysis 
The same samples that were used for LC-MS analysis were also used for precursor 
experiments.  The methodology is described in Chapter 12 (12.8.3). 
 
9.2.2.1   Results 
9.2.2.1.1 Blood samples 
The precursor ion chromatograms of the control (red) and test (blue) blood samples are 
presented in figure 102.  A precursor ion chromatogram, showing background (green 
selection) subtraction, as well as the mass spectrum (blue selection) of peak 1 is 
presented in appendix 4 (figure 215).      
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Figure 102  Precursor ion chromatograms of the control and test blood samples 
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9.2.2.1.2 Urine samples 
The precursor ion chromatograms of the control (red) and test (blue) urine samples are 
presented in figure 103.  Precursor ion chromatograms, showing background (green 
selection) subtraction, as well as mass spectra (blue selection) of peaks 1 and 2 are 
presented in appendix 4 (figures 216 and 217).      
 
TIC of +Prec (257.20): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 1.4e5 cps.
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Figure 103  Precursor ion chromatograms of the control and test urine samples 
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9.2.2.1.3 Faeces samples 
The precursor ion chromatograms of the control (red) and test (blue) faeces samples are 
presented in figure 104.  Precursor ion chromatograms, showing background (green 
selection) subtraction, as well as mass spectra (blue selection) of peaks 1, 2 and 3 are 
presented in appendix 4 (figure 218, 219 and 220).      
 
TIC of +Prec (257.20): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 5.4e6 cps.
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Figure 104  Precursor ion chromatograms of the control and test faeces samples 
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9.2.2.2   Discussion 
9.2.2.2.1 Blood sample 
The precursor ion chromatogram of the test sample showed one additional peak (14.06 
minutes) compared to the control sample (figure 102).  The mass spectrum (figure 215) of 
this peak showed two major ion peaks at 567.2 Da and 589.1 Da.  The ion peak at 589 Da 
is probably the sodium adduct of 567, which suggest the presence of a single metabolite.   
 
9.2.2.2.2 Urine sample 
The precursor ion chromatogram of the test sample showed two additional peaks (9.2 and 
9.6 minutes) compared to the control sample (figure 103).  The mass spectrum (figure 
216) of the peak at 9.2 minutes showed two major ion peaks at 464.9 and 641.3.  A mass 
shift of 176 Da is observed, which suggest the presence of a glucuronidated metabolite.  
The mass spectrum (figure 217) of the peak at 9.6 minutes als  showed two major ion 
peaks at 465.3 Da and 640.6 Da.  A mass shift of about 176 Da is also observed, which 
suggests the presence of another glucuronidated metabolite, probably an isomer.     
 
9.2.2.2.3 Faeces sample 
The precursor ion chromatogram of the test sample showed three additional peaks (10.1, 
10.7 and 11.9 minutes) compared to the control sample (figure 104). 
 
The mass spectrum (figure 218) of the first peak at 10.1 minutes showed a major peak at 
451.5 Da.  A mass difference of about 14 Da from the hydrolysed product is observed, 
which is probably an O-dealkylation (R-O-CH3 => R-OH) metabolite of the hydrolysed 
product.  The methoxyl group at position 14 (figure 72) is probably metabolised to a 
hydroxyl group.  
 
The mass spectrum (figure 219) of the second peak at 10.7 minutes showed a major peak 
at 465.3 Da.  This ion peak matches up well with the molecular ion of the hydrolysed 
product of 9-O-acetylhydnocarpin.  This information suggests the presence of the 
hydrolysed product of 9-O-acetylhydnocarpin in the faeces at relatively high 
concentrations. 
 
The mass spectrum (figure 220) of the third peak at 11.9 minutes showed a major peak at 
507.4 Da.  This ion peak matches up well with the molecular ion of 9-O-acetylhydnocarpin.  
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This information suggests the presence of the test compound in the faeces at relatively 
high concentrations. 
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9.2.3   Neutral loss scan analysis 
The same samples that were used for LC-MS and precursor ion scan analysis were also 
used for neutral loss experiments.  The methodology is described in Chapter 12 (12.8.4). 
 
9.2.3.1   Results 
9.2.3.1.1 Blood samples 
The neutral loss chromatograms of the control (red) and test (blue) blood samples are 
presented in figure 105.  A neutral loss chromatogram, showing background (green 
selection) subtraction, as well as the mass spectrum (blue selection) of peak 1 (potential 
metabolite) is presented in appendix 4 (figure 221).   
    
TIC of +NL (176.00): from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 1.1e5 cps.
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Figure 105  Neutral loss chromatograms of the control and test blood samples 
 
 
 
1
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 178
9.2.3.1.2 Urine samples 
Neutral loss chromatograms of the control (red) and test (blue) urine samples are 
presented in figure 106.  Neutral loss chromatograms, showing background (green 
selection) subtraction, as well as their mass spectra (blue selection) of peaks 1 to 5 
(possible metabolites) are presented in appendix 4 (figures 222 to 226).   
 
TIC of +NL (176.00): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.2e5 cps.
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Figure 106  Neutral loss chromatograms of the control and test urine samples 
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9.2.3.1.3 Faeces samples 
Neutral loss chromatograms of the control (red) and test (blue) faeces samples are 
presented in figure 107.  Neutral loss chromatograms, showing background (green 
selection) subtraction, as well as their mass spectra (blue selection) of peak groups 1, 2 
and 3 (possible metabolites) are presented in appendix 4 (figures 227 to 229).   
 
TIC of +NL (176.00): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 4.0e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
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Figure 107  Neutral loss chromatograms of the control and test faeces samples 
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9.2.3.2   Discussion 
9.2.3.2.1 Blood 
The neutral loss chromatogram of the test sample showed one additional peak at 10.0 
minutes, compared to the control sample (figure 105).   
 
The mass spectrum (figure 221) of this peak showed three major peak ions, 425.2, 441.2 
and 458.2 Da.  The masses of these peak ions are relatively low, which makes the 
suggestion of a potential glucuronidated metabolite inconclusive.   
 
9.2.3.2.2 Urine 
The neutral loss chromatogram of the test sample showed five additional peaks at 0.6, 6.1, 
6.3, 6.4 and 9.3 minutes, compared to the control sample (figure 106).   
 
The mass spectrum (figure 222) of the first peak at 0.6 minutes showed a number of peak 
ions, with relatively high masses, which suggested th  presence of probably a few 
glucuronidated polar metabolites. 
 
The mass spectrum (figure 223) of the second peak at 6.1 minutes showed a major peak 
ion of 657.3 Da, which suggested the presence of a glucuronidated metabolite. 
 
The mass spectrum (figure 224) of the third peak at 6.3 minutes showed a major peak ion 
of 701.4 Da, which suggested the presence of another glucuronidated metabolite. 
 
The mass spectrum (figure 225) of the fourth peak at 6.4 minutes showed a major peak 
ion of 745.5 Da, which suggested the presence of another glucuronidated metabolite. 
 
The mass spectrum (figure 226) of the fifth peak at 9.3 minutes showed a major peak ion 
of 641.3 Da, which suggested the presence of a glucuronidated metabolite of the 
hydrolysed product (465 + 176). 
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9.2.3.2.3 Faeces 
The neutral loss chromatogram of the test sample showed three additional peak groups at 
0.6, 5.5 - 8.5 and 17.8 minutes, compared to the control sample (figure 107).   
 
The mass spectrum (figure 227) of the first peak at 0.6 minutes showed a number of peak 
ions, with relatively high masses, which suggested the presence of probably a few 
glucuronidated polar metabolites. 
 
The mass spectrum (figure 228) of the second peak group at 5.5 – 8.5 minutes showed a 
number of peak ions, with relatively high masses, which suggested the presence of 
probably a few glucuronidated polar metabolites. 
 
The mass spectrum (figure 229) of the third peak at 17.8 minutes showed a major peak ion 
of 593.2 Da, which suggested the presence of another glucuronidated metabolite. 
 
9.2.4   LC-MS/MS analysis 
The same samples that were used for LC-MS, precursor ion scan and neutral loss scan 
analysis were also used for LC-MS/MS analysis.  The methodology is described in 
Chapter 12 (12.8.5). 
 
9.2.4.1   Results and discussion 
The quality of the product ion mass spectra was not sufficient to identify the metabolites; 
therefore it was decided not to include the spectra.  The amount of metabolite ions was not 
adequate to obtain good quality MS/MS spectra.  Much more material would be required 
and more specific extraction methods needed to obtain higher concentrations of the 
metabolites.  This would fall outside the scope of this project and it was decided not to 
pursue this subject any further.   
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9.3   Conclusion  
LC-MS, precursor ion scan and neutral loss scan experiments were conducted in mouse 
blood, which resulted in the discovery of several polar and semi-polar metabolites. 
 
The results of the urine sample showed the presence of these and other metabolites, 
which include the following glucuronidated species:  isomers of 641 Da (glucuronidated 
metabolites of the hydrolysed product; 465 + 176), 657.3 Da, 701.4 Da, and 745.5 Da.    
 
The faeces sample spectra also indicated the presence of many of the above mentioned 
metabolites, as well as an O-dealkylated metabolite of 451.5 Da.  The test compound and 
hydrolysed product were also present at relatively high concentrations.   
 
9-O-Acetylhydnocarpin is metabolised extensively by the liver enzymes and is removed 
from the blood system, via the liver and kidneys.   
 
The test compound and its hydrolysed product could not be detected with these methods 
in the blood.  A more sensitive MRM method was required to detect these compounds in 
the blood.  The metabolites are present at higher concentrations in the blood compared to 
the test and hydrolysed compounds.  These metabolites are present at the target site and 
may also be active against the P. berghei parasites. 
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CHAPTER 10 
 
Antimalarial assessment of 9-O-acetylhydnocarpin 
in mice using SMEDDS and Pheroid formulations 
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10   Antimalarial assessment of 9-O-acetylhydnocarpin in mice 
using SMEDDS and Pheroid formulations 
 
10.1   Introduction 
The antimalarial assessment of 9-O-acetylhydnocarpin (polar formulation, presented in 
Chapter 7) indicated limited protection for the mice against the parasites.  One of the 
significant outcomes of the bioavailability studies, presented in Chapter 8, is the 
introduction of improved drug delivery systems.  The SMEDDS and Pheroid formulations 
were used as delivery and carrier systems for the antimalarial assessment of 9-O-
acetylhydnocarpin.  The 4 day suppressive treatment strategy, with minor modifications, 
was followed as described in Chapter 7 [Peters et al., 1975]. 
 
Ethical approval was granted by the Animal Research Ethics Committee, Faculty of Health 
Sciences, University of Cape Town (Project number:  006/034) for studying the 
antimalarial activity of 9-O-acetylhydnocarpin in mice.  The same experimental procedure 
was followed as was presented in Chapters 7 and 12 (12.9).  
 
The test compound was tested using the SMEDDS and Pheroid formulations at a 
concentration of 100 mg/kg.   The animals were treated once a day on days 2, 3, 4, 5 and 
6.  The negative control groups received placebo treatment (formulation without test drug).  
The positive control group received chloroquine at 10 mg/kg for 5 days (once per day on 
days:  D2, D3, D4, D5 and D6). 
 
Figure 108 summarises the allocation of the experimental groups, treatment schedule, 
sampling and the endpoint of the experiment.   
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Figure 108  Flow-diagram of the antimalarial assessment animal model using the 
SMEDDS and Pheroid formulations, which included the experimental groups, treatment 
schedule, sampling and the endpoint of the experiment 
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10.2   Results 
The following parameters were evaluated: Body weight, %Parasitaemia and %Chemo 
suppression.  The body weight and percentage parasitaemia data of the mice is presented 
in appendix 2 (tables 52 - 55) and is summarised in figures 109 - 112.  The %Chemo 
suppression of the test compound in the SMEDDS and Pheroid formulations are presented 
in tables 28 and 29, respectively. The %Chemo suppression determination was done on 
day 7, as described in Chapter 7. 
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Figure 109  Body weight vs. Time graph of mice treated with a 100 mg/kg 9-O-
acetylhydnocarpin SMEDDS formulation using a 5 day suppressive treatment strategy 
(control groups included)  
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Figure 110  % Parasitaemia vs. Time graph of mice treated with a 100 mg/kg 9-O-
acetylhydnocarpin SMEDDS formulation using a 5 day suppressive treatment strategy 
(control groups included)  
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Figure 111  Body weight vs. Time graph of mice treated with a 100 mg/kg 9-O-
acetylhydnocarpin Pheroid formulation using a 5 day suppressive treatment strategy 
(control groups included) 
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Figure 112  % Parasitaemia vs. Time graph of mice treated with a 100 mg/kg 9-O-
acetylhydnocarpin Pheroid formulation using a 5 day suppressive treatment strategy 
(control groups included) 
 
Table 28  Mean %Parasitaemia and %Chemo suppression data 
Treatment %Parasitaemia %Chemo suppression 
Test group (SMEDDS) 18.6 ± 2.6 38.2 
Negative control 30.1 ± 7.4 0 
Positive control 0.4 ± 0.3 98.7 
 
Table 29  Mean %Parasitaemia and %Chemo suppression data 
Treatment %Parasitaemia %Chemo suppression 
Test group (Pheroid) 18.3 ± 3.3 41.7 
Negative control 31.4 ± 3.2 0 
Positive control 0.4 ± 0.3 98.7 
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10.3   Discussion 
Chemo suppression is normally measured around day 5, but because of relatively low 
parasitaemia levels on day 5 (in both the test and placebo groups), it was decided to 
measure the reduction of parasitaemia on day 7.    
 
10.3.1   SMEDDS formulation 
The P. berghei infected mice were treated with 9-O-acetylhydnocarpin at a concentration 
of 100 mg/kg formulated with SMEDDS.  The body weight of the group that received the 
test compound decreased over time in a similar way as the placebo group.  It appears that 
the animals discontinue feeding when parasitaemia gets to about 5%.  The test compound 
formulated with SMEDDS at the tested concentration showed parasite reduction of 38.2%, 
but could not provide complete protection against the parasites. 
 
10.3.2   Pheroid formulation 
The P. berghei infected mice were treated with 9-O-acetylhydnocarpin at a concentration 
of 100 mg/kg formulated with Pheroid as described in Chapter 12 (12.9).  The body weight 
of the group that received the test compound also decreased over time in a similar way as 
the placebo group.  The test compound formulated with Pheroid at the tested 
concentration also showed a similar degree of parasite inhibition compared to the 
SMEDDS formulation. 
 
The outcome of these experiments showed similar parasite reduction compared to the 
polar formulation (Chapter 7).  The improved drug delivery systems were not effective 
enough to deliver 9-O-acetylhydnocarpin to its target site at high enough levels.  The poor 
bioavailability properties (Chapter 8) and extensive metabolism (Chapter 9) of 9-O-
acetylhydnocarpin in mice are probably the major reasons for its limited protection ability 
against the malaria parasites (in vivo). 
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CHAPTER 11 
 
Research summary, final thoughts and research 
prospects, presentations and manuscripts 
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11   Research summary, final thoughts and research prospects, 
presentations and manuscripts 
 
11.1   Research summary 
A new class of antiplasmodial compounds was discovered from the Xerophyta genus.  
These compounds fit into the flavonoid natural class of compounds, and are known as 
flavones.  The most promising compound (9-O-acetylhydnocarpin) isolated from this 
group, selectively killed P. falciparum parasites of both chloroquine sensitive (D10) and 
resistant (K1) strains at fairly low concentrations.  This compound was considered to be a 
selective antiplasmodial compound because of its favourable antiplasmodial activity and 
cytotoxicity properties. 
 
The activity of 9-O-acetylhydnocarpin was tested in a polar formulation using the P. 
berghei mouse model.  The test compound showed some protection for the mice against 
the parasites, but could not inhibit all parasites.  At this stage of the projects many 
questions came to mind about why the compound did not perform as well as was seen 
during the in vitro experiments.  For this reason it was decided to conduct a bioavailability 
investigation in a similar mouse model to find answers to some of the questions raised.  
Results from these experiments showed that 9-O-acetylhydnocarpin is poorly absorbed 
from the gastrointestinal tract in a polar formulation.  Many different formulations and 
administration routes were tested.  The outcome of these investigations showed that if the 
correct formulation is used relatively high blood levels could be reached.  The 
concentration of the test compound was still lower than expected.  Milligram quantities 
were administered and low microgram maximum levels were reached in the blood.  
Literature indicated high microgram levels for drugs that are absorbed well and which are 
not metabolised rapidly [Curry, 1977; Creasey, 1979].  The results of these bioavailability 
experiments indicated that the compound may be metabolised quite rapidly.   
 
The test compound was injected intravenously and the outcome of this experiment showed 
that 9-O-acetylhydnocarpin is metabolised rapidly.  These results led to the metabolite 
study.  Results from these experiments showed that the test compound is quickly 
metabolised once it enters the bloodstream by the liver enzymes, and is extracted into the 
urine and faeces.  These metabolites are present at higher concentrations at the target 
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site, compared to 9-O-acetylhydnocarpin.  The results of the bioavailability and metabolite 
studies were used to develop an improved dosing strategy for in vivo antimalarial testing 
on P. berghei infected mice.  The improved formulations of the test compound did not 
reach high enough blood levels for curing the infected animals, however a reasonable 
degree of parasite inhibition was observed. 
  
The work presented in this thesis showed an improved evaluation system for plant derived 
antimalarial products.  It is also proposed that in vitro active antiplasmodial compounds be 
examined for its bioavailability and metabolic properties before or parallel to evaluation of 
its activity in animal models.  Compounds with poor pharmacokinetic properties will not 
make good candidates for further animal testing and should not be taken further in animal 
efficacy studies.  The usual approach in antimalarial compound evaluation is direct animal 
efficacy testing after in vitro activity and cytotoxicity testing.  The new, improved evaluation 
system introduced a secondary screening test before or at least parallel to in vivo efficacy 
testing in a mouse model.  This model should give investigators better insight in selecting 
compounds for further testing.   
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11.2   Final thoughts and research prospects 
The work presented in this thesis suggested that the sequence in evaluating 
antiplasmodial compounds in animal testing be altered as follows:  Firstly, administer the 
test compound intravenously to mice and study the compounds clearance rate.  This 
experiment will only require small amounts of pure material and would give the investigator 
valuable information about the compounds stability in the animal’s bloodstream.  Secondly, 
if the outcome of this experiment is favourable, administer the test compound orally in a 
polar and non-polar formulation to mice and study the compounds blood levels.  If the 
outcome of both the intravenous and oral experiments are favourable, bioavailability can 
be calculated which would give a good indication of the potential of a compound to be 
considered for further animal testing (metabolic, efficacy and toxicity studies).  The 
introduction of bioavailability and metabolic studies before, or at least parallel to efficacy 
studies should give more focus to antimalarial screening programmes, and would assist in 
selecting better drug candidates for further animal testing. 
 
The proposed antimalarial evaluation model would result in less animal’s being sacrificed 
unnecessarily for compounds that would in any case not make good pharmacological 
compounds.  The initial phases of this screening system would also require small amounts 
of the test compound, which is often a challenging factor in isolating pure compounds from 
plants.   
 
The most active compound, 9-O-acetylhydnocarpin, showed moderate in vitro activity 
against P. falciparum parasites when compared to chloroquine; however the activity of this 
compound was fairly specific to the malaria parasites as was indicated during the toxicity 
tests.  9-O-Acetylhydnocarpin did not dissolve well in the aqueous test solution that was 
used for the in vitro screening assays due to its hydrophobic nature.  More water-soluble 
derivatives could be synthesised that will improve water-solubility, which could improve 
activity.  Kren and co-authors have shown that glycosylation of silybin, which is structurally 
related to 9-O-acetylhydnocarpin, increased water-solubility up to 30 times.  A similar 
synthetic chemical modification approached could probably be followed for 9-O-
acetylhydnocarpin, which would improve water-solubility [Kren et al., 1997]. 
 
9-O-Acetylhydnocarpin showed an approximate 38% reduction of parasitaemia (Chapters 
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7 and 10), but could not protect the animals entirely.  It has been shown in Chapters 8 and 
9 that 9-O-acetylhydnocarpin is metabolised rapidly by the liver enzymes in mice to mainly 
glucuronidated metabolites, due to the hydroxyl functional groups.  These metabolites 
were removed quite rapidly from the blood.  The bioavailability of 9-O-acetylhydnocarpin 
and its metabolites were not sufficient to protect the animals against the malaria parasites. 
 
9-O-Acetylhydnocarpin is a good candidate for synthetic structural modification, because 
of its selective activity against P. falciparum parasites.  The hydroxyl functional groups are 
recognised by Phase II liver enzymes and should therefore be modified to more stable 
groups.  The 9-O-acetyl group should also be removed by acidic hydrolysis and the 
resulting hydroxyl group should then be modified to a more stable group.  The general 
antiplasmodial activity of 9-O-acetylhydnocarpin may also be improved if the hydroxyl 
groups are replaced with relatively small active groups.  9-O-Acetylhydnocarpin is present 
in relatively high concentrations in the Xerophyta genus, which makes it feasible to obtain 
enough starting material for chemical modification.   
 
The work suggested above falls outside the scope of this project and should be considered 
for future projects. 
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11.3   Presentations 
Parts of the work presented in this thesis have been presented as oral presentations at the 
Pharmacology department (University of Cape Town) and at the South African 
Pharmacology and Toxicology Congress, 2007. 
 
JL Wiesner, WE Campbell and PJ Smith 
Bioavailability Study of 9-O-acetylhydnocarpin in mice 
UCT Pharmacology, Medical Research Council of South Africa, Traditional Medicine 
Research Committee, 1 October 2007 
 
JL Wiesner, WE Campbell and PJ Smith 
Antimalarial Study of Bioactive Compounds Isolated from Xerophyta species 
South African Pharmacology and Toxicology Congress, North West Province, South 
Africa, 2-5 October 2007 
 
 
11.4   Manuscripts in preparation 
The following manuscripts are currently being prepared for submission to journals for 
publication.  
 
JL Wiesner, WE Campbell and PJ Smith 
Antiplasmodial compounds isolated from X. villosa and X. retinervis  
 
JL Wiesner, WE Campbell and PJ Smith 
Antimalarial study of 9-O-acetylhydnocarpin in mice 
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CHAPTER 12 
 
Materials and methods 
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12   Materials and methods & methodology development 
New methodologies have been developed for the work presented in Chapters 8 and 9, 
therefore the addition of a comprehensive and descriptive section about the method 
development process that was required to investigate the biological availability and 
metabolism of the test compound in a mouse model (12.7 and 12.8).   
 
The methodologies of Chapters 2, 3, 4, 5, 6, 7 and 10 are presented in sections 12.1, 12.2, 
12.3, 12.4, 12.5, 12.6 and 12.9.   
 
12.1   Collection and preparation of plant material 
Two different Xerophyta species were collected by Dr. P.C. Zietsman (collector No.  4350).   
 
X. villosa was collected on the first of June, 2006.  A voucher specimen (NMB 22615) was 
also collected and is kept at the herbarium of the national museum in Bloemfontein, South 
Africa.  The plant material was collected at Claremont, Blyde River Canyon Nature 
Reserve, Mpumalanga, South Africa (Latitude:  24 degrees, 32 minutes, 56.4 seconds; 
Longitude:  30 degrees, 45 minutes, 8.6 seconds). 
 
X. retinervis was collected on the tenth of July, 2006.  A voucher specimen (NMB 22616) 
was also collected and is kept in the herbarium of the national museum in Bloemfontein, 
South Africa.  The plant material was collected on a farm at Hoedspruit, Mpumalanga, 
South Africa (Latitude:  24 degrees, 20 minutes, 6.9 seconds; Longitude:  30 degrees, 51 
minutes, 4.9 seconds). 
 
The plant material was dried at room temperature for 3 weeks.  The leave bases were 
removed and macerated to a fine powder using a blender.  The powder was stored at  
-20 °C. 
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12.2   Solvent extraction 
12.2.1   X. villosa 
The plant powder (40 g) was extracted with petroleum ether (500 ml) on a horizontal 
shaker for 24 hours.  This solvent extraction with petroleum ether was repeated until no 
further colour change was observed.   The petroleum ether extract was filtered using paper 
filters (3HW, 320 mm, Lasec SA) and the organic solvent was separated from the extract 
using a Büchi rotavapor R-200/205 (Büchi Labortechnik AG Schweiz).  The dried powder 
that remained after petroleum ether extraction was further extracted using 
dichloromethane (500 ml), followed by ethyl acetate and finally methanol and the same 
methodology was performed as was used for the petroleum ether extraction.  The 
methanol extract was further separated into two fractions using solvent partioning.  The 
methanol extract was dried and dissolved in ethyl acetate (300 ml), and water (100 ml, 
Millipore water) was added to a separation funnel and shaken for 10 minutes.  The funnel 
was left on the bench for 30 minutes for the two layers to separate completely.  The 
aqueous phase was separated from the organic phase.  The aqueous phase was dried 
using a DURA-DRV II freeze-drying instrument (FTS SYSTEMS, NY USA).  Ethyl acetate 
was separated from the extracted material using a rotary evaporation system.  
 
12.2.2   X. retinervis  
The plant powder (50 g) was extracted with petroleum ether (1 litre) on a horizontal shaker 
for 24 hours.  The solvent extraction with petroleum ether was repeated until no further 
colour change was observed.   The petroleum ether extract was filtered and the organic 
solvent was separated from the extract using a rotor evaporating system.  The dried 
powder that remained after the petroleum ether extraction was further extracted using 
methanol (1 litre) until no further colour change was observed and the same methodology 
was performed as was used for the petroleum ether extraction.  The methanol extract was 
further separated into two groups using liquid-liquid extraction.  The methanol extract was 
dried and dissolved in ethyl acetate (300 ml) and water (100 ml, Millipore water) was 
added to a separation funnel and shaken for 10 minutes.  The funnel was left on the bench 
for 30 minutes for the two layers to separate completely.  The aqueous phase was 
separated from the organic phase.  The aqueous phase was dried using a freeze-drying 
instrument.  The ethyl acetate was separated from the extracted material using a rotary 
evaporation system.  
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12.3   Antiplasmodial screening assay  
12.3.1   Cultivation of malaria parasites 
The chloroquine sensitive D10 strain (derived from Papua New Guinea) [Ekong et al., 
1993] of P. falciparum was cultured according to the method described by Trager and 
Jensen, with minor modifications [Trager and Jensen, 1976].  A standard operating 
procedure, prepared by the Pharmacology Department at the University of Cape Town, 
was followed and is described below.  
 
“The parasites were sustained with RPMI 1640 (Biowhittaker) medium at a 5% 
haematocrit.  Albumax II (lipid rich bovine serum albumin) (GibcoBRL) (25 g/l), 
hypoxanthine (44 mg/l), HEPES (6 g/l), sodium bicarbonate (2.1 g/l) and gentamycin (50 
mg/l) were added as supplement reagents.  O+ RBC (Western Province Blood Transfuse 
Service, Groote Schuur Hospital, Cape Town, South Africa) was added regularly to the 
medium to keep the parasitaemia between 5 and 10%.  Parasitaemia was determined on a 
daily basis along with changing the medium.  The cultures were kept at 37 °C in an 
incubator with an atmosphere of 93% N2, 3% O2 and 4% CO2.” [Clarkson, 2002] 
 
The parasites were synchronised with D-sorbital [Lambros and Vanderberg, 1979]. 
 
12.3.2   Lactate dehydrogenase assay  
The parasite lactate dehydrogena e assay (pLDH) as described by Makler and co-workers 
was used to determine parasite viability, with minor modifications [Makler et al., 1993].  A 
standard operating procedure, prepared by the Pharmacology Department at the 
University of Cape Town, was followed and is described below. 
 
“This is a specific method that distinguish parasite LDH from host LDH by using 3-
acetylpyridine adenine dinucleotide (APAD).  The pLDH uses APAD as a coenzyme in the 
conversion of pyruvate to lactate and reduces it to APADH.  The formation of APADH can 
be calorimetrically measured by the reduction of a yellow nitroblue tetrazolium (NBT) salt 
to a blue formazan product.  The amount of blue formazan product is proportional to the 
pLDH activity.  The pLDH activity can therefore be monitored by using the Malstat reagent 
which contains:  triton (1 ml/l), APAD (0.33 g/l), TRIS buffer (3.3 g/l) and 1.96 mM NBT 
with 0.24 mM PES (Sigma) solution in Millipore water.   The test plates were incubated for 
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48 hours.  The malstat reagent (100 μl) and NBT/PES (25 μl) solution were added to new 
micro titre plates.  The test plates were removed from the incubator and the parasites were 
re-suspended within the original test plates before transferring 15 μl of the parasites with a 
multi-channel pipette into the corresponding well of the plates containing the Malstat 
reagents and NBT/PES solution.  The absorbance of the formed formazan salts was then 
measured at a wavelength of 620 nm using a 7520 microplate reader (Cambridge 
Technology).  The absorbance data were transformed into percentage viability using an 
excel spreadsheet and a non-linear regression analysis model in GraphPad Prism 4 was 
used to determine the 50% inhibitory concentration (IC50) of the extracts or compounds 
against the parasites.” [Clarkson, 2002] 
 
A representative example of samples tested in a 96 well plate is presented in figure 113. 
 
 
 
Figure 113  A representative example of a 96 well plate 
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12.4   Cytotoxicity assay 
12.4.1   Cell culture  
A standard operating procedure, prepared by the Pharmacology Department at the 
University of Cape Town, was followed and is described, next.  “The cells were routinely 
maintained as adherent monolayers in 75 cm3 culture flasks in complete medium 
consisting of Dulbecos Modified Eagles Medium (Highveld Biologicals, Lyndhurst, South 
Africa) : Hams F-12 medium (Sigma, St Louis, MO, USA) (1:1), and was supplemented 
with 10% heat inactivated fetal bovine serum (Highveld Biologicals, Lyndhurst, South 
Africa).  The cells were incubated in a 5% CO2 – air humidified atmosphere at 37 °C.  The 
culture medium was changed every 3 days and the cells sub-cultured, which involved 
digestion of the cellular matrix with 1% trypsin solution.” [Clarkson, 2002] 
 
12.4.2   MTT cytotoxicity assay 
The MTT assay as described by Mosmann, with minor modifications was used to 
determine cell viability [Mosmann, 1983].  This is a reliable method to measure metabolic 
activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values 
and cell survival [Sieuwerts et al., 1995].  A standard operating procedure, prepared by the 
Pharmacology Department at UCT, was followed and is described below.  
 
“The assay method distinguishes living cells from dead ones, and the signal generated is 
dependent on the level of activation of the cells.  It can be used to measure cytotoxicity, 
proliferation or activation.  This assay measure the formation of a water insoluble purple 
formazan product, once yellow water soluble tetrazolium salt is metabolized by living cells. 
The intensity of the formazan product is measured by a microplate reader and is 
proportional to the metabolic activity and number of cells in each microplate well.  MTT (25 
μl) at a concentration of 5 mg/ml in PBS was added to each well after initial incubation.  
The plates were incubated again for 4 hours at 37 °C.  The plates were centrifuged for 10 
minutes at 2050 rpm, and the supernatant washed from the wells without disturbing the 
formazan crystals.  DMSO (100 μl) was added to each well and the plate was shaken for 5 
minutes to dissolve the crystals.  The absorbance of the formazan salt was measured at 
540 nm.  
 
The following formula was used to calculate the cell viability: 
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% Viability = ((Aλ540 test well “cells + drug”) / (Aλ540 cell control well “cells + no drug”)) x 
100 
 
Dose response curves were constructed using nonlinear dose response analysis with 
GraphPad Prism 4 software and Microsoft Excel.”   
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12.5   HPLC fractionation 
12.5.1   X. villosa 
12.5.1.1   Methanol extract (organic phase) 
The extract was dried and reconstituted in a mixture of acetonitrile and DMSO (2:1, v/v) at 
a concentration of 20 mg/ml and 50 μl was injected onto a semi preparative C18 analytical 
HLPC column (SUPELCO Discovery® C18, 25 cm x 10 mm, 5 μm).  The chromatogram 
was recorded at 330 nm and a gradient (table 30) was used at a flow-rate of 3 ml/min.    
 
Table 30  HPLC gradient of semi-preparative HPLC system 
Time % acetonitrile % water 
0 30 70 
20 70 30 
21 100 0 
24 100 0 
25 30 70 
30 30 70 
 
12.5.1.2   Ethyl acetate extract 
The dried ethyl acetate extract was dissolved in acetonitrile at a concentration of 10 mg/ml, 
and the same HPLC system, as was used for the methanol (organic phase) extract, was 
used to analyse this extract.   
 
12.5.1.3   Dichloromethane extract 
The dried dichloromethane extract was dissolved in acetonitrile at a concentration of 8 
mg/ml, and the same HPLC system, as was used for the methanol (organic phase) extract, 
was used to analyse this extract.   
 
12.5.1.4   Fractionation of the 6 major peaks 
The dried organic phase (liquid-liquid extraction) from the methanol extract was dried and 
reconstituted in DMSO at a concentration of 200 mg/ml.  The mobile phase gradient (table 
31) was slightly changed to improve the separation on column.   
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Table 31  HPLC gradient of semi-preparative HPLC system 
Time % acetonitrile % water 
0 30 70 
25 70 30 
26 90 10 
28 90 10 
29 30 70 
37 30 70 
 
The six major peaks (1, 2, 3, 4, 5 and 6) were collected in separate solvent bottles using 
an automated HPLC and fraction collector.  These fractions were further purified using 
specific HPLC methods for every fraction. 
 
12.5.1.4.1 Fraction 1 
The dried material from fraction 1 was dissolved in DMSO at a concentration of 5 mg/ml 
and 50 μl was injected onto a C16 amide analytical HLPC column (SUPELCO, Discovery 
Amide C16, 15 cm x 4.6 mm i.d. x 5 μm).  The chromatogram was recorded at 330 nm and 
an isocratic mobile phase was used at a flow-rate of 1 ml/min, which consisted of 
acetonitrile and water (25:75, v/v).  The column was cleaned after each injection by 
increasing acetonitrile to 90% for 5 minutes, and equilibrated for 5 minutes using the 
isocratic mobile phase as described above.  The peak of interest eluted from the column at 
7.1 minutes and was collected in a clean solvent bottle using an automated HPLC and 
fraction collector.  Acetonitrile was removed using a Büchi rotary evaporator and the water 
was removed using a freeze-drying instrument.  The dried material was stored at -20 °C. 
 
12.5.1.4.2 Fraction 2 
The dried material from fraction 2 was dissolved in DMSO at a concentration of 5 mg/ml 
and 50 μl was injected onto the same C16 amide analytical HLPC column as was used for 
fraction 1.  The chromatogram was also recorded at 330 nm and an isocratic mobile phase 
was used at a flow-rate of 1 ml/min, which consisted of acetonitrile and water (30:70, v/v).  
The peak of interest eluted from the column at 9.7 minutes and was collected in a clean 
solvent bottle using an automated HPLC and fraction collector.  The column was cleaned 
and equilibrated as described in table 32.  Fraction 2 was dried and stored at -20 °C. 
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Table 32  HPLC mobile phase 
Time % acetonitrile % water 
0 30 70 
12 30 70 
13 90 10 
17 90 10 
18 30 70 
25 30 70 
 
12.5.1.4.3 Fraction 3 
The dried material from fraction 3 was dissolved in DMSO at a concentration of 1 mg/ml 
and 20 μl was injected onto the same C16 amide analytical HLPC column as was used for 
fraction 1.  The chromatogram was also recorded at 330 nm and a gradient mobile phase 
was used at a flow-rate of 1 ml/min, which consisted of acetonitrile and water (table 33).  
The peak of interest eluted from the column at 17.5 minutes and was collected in a clean 
solvent bottle using an automated HPLC and fraction collector.  Fraction 3 was dried and 
stored at -20 °C. 
 
Table 33  HPLC gradient of analytical HPLC system 
Time % acetonitrile % water 
0 25 75 
30 45 55 
31 90 10 
33 90 10 
34 25 75 
40 25 75 
 
12.5.1.4.4 Fraction 4 
The dried material from fraction 4 was dissolved in DMSO at a concentration of 5 mg/ml 
and 40 μl was injected onto the same C16 amide analytical HLPC column as was used for 
fraction 1.  The chromatogram was recorded at 330 nm and a gradient mobile phase was 
used at a flow-rate of 1 ml/min, which consisted of acetonitrile and water (table 34).  The 
peak of interest eluted from the column at 21.3 minutes and was collected in a clean 
solvent bottle using an automated HPLC and fraction collector.  Fraction 4 was dried and 
stored at -20 °C. 
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Table 34  HPLC gradient of analytical HPLC system 
Time % acetonitrile % water 
0 25 75 
30 50 50 
31 90 10 
33 90 10 
34 25 75 
40 25 75 
 
12.5.1.4.5 Fraction 5 
The dried material from fraction 5 was dissolved in DMSO at a concentration of 5 mg/ml 
and 50 μl was injected onto the same C16 amide analytical HLPC column as was used for 
fraction 1.  The chromatogram was also recorded at 330 nm and a gradient mobile phase 
was used at a flow-rate of 1 ml/min, which consisted of acetonitrile and water (table 35).  
The peak of interest eluted from the column at 16.3 minutes and was collected in a clean 
solvent bottle using an automated HPLC and fraction collector.  Fraction 5 was dried and 
stored at -20 °C. 
 
Table 35  HPLC gradient of analytical HPLC system 
Time % acetonitrile % water 
0 30 70 
20 60 40 
21 90 10 
23 90 10 
24 30 70 
30 30 70 
 
12.5.1.4.6 Fraction 6 
The dried material from fraction 6 was dissolved in DMSO at a concentration of 5 mg/ml 
and 50 μl was injected onto the same C16 amide analytical HLPC column as was used for 
fraction 1.  The chromatogram was recorded at 330 nm and a gradient mobile phase was 
used at a flow-rate of 1 ml/min, which consisted of acetonitrile and water (table 36).  The 
peak of interest eluted from the column at 17.0 minutes and was collected in a clean 
solvent bottle using an automated HPLC and fraction collector.  Fraction 6 was dried and 
stored at -20 °C. 
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Table 36  HPLC gradient of analytical HPLC system 
Time % acetonitrile % water 
0 20 80 
20 60 40 
21 90 10 
23 90 10 
24 20 80 
30 20 80 
 
 
12.5.2   X. retinervis  
12.5.2.1   Methanol extract (organic phase) 
The extract was dried and reconstituted in a mixture of acetonitrile and DMSO (2:1, v/v) at 
a concentration of 20 mg/ml and 50 μl was injected onto a semi preparative C18 analytical 
HLPC column (SUPELCO Discovery® C18, 25 cm x 10 mm, 5 μm).  The chromatogram 
was recorded at 330 nm and a gradient (Table 37) was used at a flow-rate of 2 ml/min.   
 
Table 37  HPLC gradient of semi-preparative HPLC system 
Time % acetonitrile % water 
0 30 70 
25 70 30 
26 30 70 
30 30 70 
 
 
The two major peaks were collected in separate solvent bottles using an automated HPLC 
connected to a fraction collector.  Fractions A and B were dried and stored at -20 °C.  The 
dried fractions were dissolved in acetonitrile and analysed using a C18 analytical column 
(Phenomenex, C18, 15 cm x 4.6 i.d. x 5 μm) to test the purity of the collected peaks.   The 
chromatograms were recorded at 330 nm and the same gradient (table 37) was used at a 
flow-rate of 1 ml/min.   
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12.6   Structural elucidation 
12.6.1   Ultraviolet spectroscopy  
A Waters 996 photodiode array detector was used to obtain UV spectra of compounds 2, 4 
and 5.  These spectra are presented in appendix 1.  
 
12.6.2   Mass spectrometry 
A unit resolution mass spectrometer was used to search for the molecular ions of interest; 
once these ions were detected a high resolution mass spectrometer was used to 
accurately determine the masses of the molecular ions.   
 
12.6.2.1   Unit resolution mass spectrometry 
An Applied Biosystems API 3200 linear ion trap mass spectrometer was used to determine 
the molecular ions of compounds 2, 4 and 5.  Small samples of these compounds were 
dissolved in acetonitrile and 0.1% formic acid (1:1, v/v) at a concentration of 500 ng/ml and 
infused into the mass spectrometer at 5 μl/min in the positive ion mode.  The mass spectra 
of these compounds are presented in appendix 1, showing the molecular ions. 
 
 
12.6.2.2   High resolution mass spectrometry 
A Waters Q-TOF mass spectrometer was used to determine the accurate mass of 
compounds 2, 4 and 5.  Small samples of these compounds were dissolved in acetonitrile 
and 0.1% formic acid (1:1, v/v) at a concentration of 500 ng/ml and infused into the mass 
spectrometer at 5 μl/min in the positive ion mode.  The accurate mass spectra of these 
compounds are presented in appendix 1, showing the molecular ions.   
 
12.6.3   Nuclear magnetic resonance spectroscopy 
A Varian Inova 600 mHz NMR instrument was used to analyse compounds 2, 4 and 5.  1H, 
13C and 2D experiments (COSY, HSQC and HMQC) were conducted and are presented in 
appendix 1. 
 
12.6.4   Optical rotation 
The optical rotation of compound 5 was measured at 25 °C on a Perkin-Elmer 241 
polarimeter at 598 nm (Na D-line) using a 1,001 dm cell.  The compound was dissolved in 
DMSO at a concentration of 5.0 mg/ml. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 209
12.6.5   Melting point 
The melting point of compound 5 was measured on a SANYO Gallenkamp variable 
electrical apparatus (supplied by United Scientific, Cape Town).   
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12.7   Bioavailability investigation of 9-O-acetylhydnocarpin in mice 
12.7.1   Mice 
Mice (male, 8 to 12 weeks old, C57BL6)  were obtained from the University of Cape 
Town’s Animal Unit and kept at the animal laboratory of the liver research group (Groote 
Schuur Hospital, Old main building, level K).  
 
12.7.2   Initial bioavailability study of 9-O-acetylhydnocarpin in mice 
9-O-Acetylhydnocarpin was administered orally (figure 114) at a concentration of 200 
mg/kg in a solution which consisted of water and DMSO (9:1, v/v) to healthy mice.  Blood 
samples were collected at 0, 1, 2, 3 and 5 hours after administration.  One animal per 
sampling point was used at this stage of the project.    
 
Figure 114  Example of a mouse receiving oral treatment 
 
12.7.2.1   Method development of an assay method for the determination of 9-O-
acetylhydnocarpin in mice whole blood 
An analytical method was needed to quantitatively determine the concentration of 9-O-
acetylhydnocarpin in whole blood samples to follow the concentration vs. time profile for 5 
hours after a 200 mg/kg single dose was given to healthy mice.  Blood samples (100 μl) 
were taken before administration of the study medication and thereafter at the following 
time periods:  0, 1, 2, 3, and 5 hours.  A relatively high volume of sample was required at 
this point of the project; therefore one mouse per sample point was used to obtain average 
initial bioavailability information.  The samples were stored at – 20 °C until analysed.  An 
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Applied Biosystems API-2000 mass spectrometer (MS) coupled to a high performance 
liquid chromatography (HPLC) system was used to analyse the samples.   
 
12.7.2.1.1 Mass Spectrometer optimisation 
Infusion experiments of 9-O-acetylhydnocarpin were conducted in acidic, neutral and basic 
chemical environments in both the positive and negative ESI modes to select the 
molecular ion of interest.  The best result was obtained when infused in an acidic chemical 
environment (0.1% formic acid : methanol, 1:1, v/v) at a flow rate of 10 μl/min.  A 
protonated molecular ion [M+H]+ was found at m/z 507 (figure 115), which correlates with 
the high resolution data presented in Chapter 6 and appendix 1.  
 
The molecular ions were selected in the first mass filter and fragmented in the collision cell 
to form product ions (figure 116).  The most abundant product ion (257) was selected and 
the MS set at the multiple reaction monitoring mode (MRM). 
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Figure 115  Mass spectrum of 9-O-acetylhydnocarpin showing the [M+H]+ ion  
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 +MS2 (507.18) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Ester-hydnocarpin_InitProduct_Pos.wiff (Turbo Spray) Max. 1.7e6 cps.
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Figure 116  Product ion mass spectrum of the protonated molecular ion and the product 
ions 
 
The mass spectrometer was set to detect 9-O-acetylhydnocarpin (507  257) in the MRM 
mode.  Detection was performed on an API 2000 mass spectrometer (ESI in the positive 
ion mode, MRM) and the settings on the apparatus are summarised in tables 38 and 39. 
 
Table 38  ESI settings 
Nebulizer gas (arbitrary value) 50 
Turbo spray (arbitrary value) 50 
Curtain gas (arbitrary value) 10 
Heated nebulizer (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
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Table 39  MS/MS settings 
 9-O-acetylhydnocarpin 
Average mass 506.4656 
Exact mass 506.1213 
Protonated molecular ion (m/z) 507.2 
Product ion (m/z) 257.2 
Dwell time (ms) 150 
Declustering potential (V) 71 
Entrance potential (V) 11 
Collision cell entrance potential (V) 22 
Collision energy (eV) 55 
Collision cell exit potential (V) 4 
Collision activated dissociation gas medium 
Scan type MRM 
Polarity positive 
Pause time 5 ms 
 
 
12.7.2.1.2 Chromatography development 
A primary stock solution of 9-O-acetylhydnocarpin was prepared in acetonitrile at a 
concentration of 2 mg/ml.  A secondary stock solution was prepared by spiking the primary 
stock solution in acetonitrile : 0.1% formic acid (1:1, v/v) to obtain a concentration of 1 
µg/ml.  Mobile phase was prepared consisting of acetonitrile and a 0.1% formic acid 
solution (70:30, v/v).  A Phenomenex® C18 (15 cm x 4.6 mm, 5 μm) column was set up and 
equilibrated for 20 minutes by pumping the mobile phase at a constant flow rate of 0.3 
ml/min through the column.  The injection volume was 10 μl.  This mobile phase resulted in 
very good chromatography.  The retention time was 3.2 minutes for 9-O-acetylhydnocarpin 
(figure 117). 
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XIC of +MRM (1 pair): 507.1/257.1 amu from Sample 1 (STD 1) of 1001.wiff (Turbo Spray) Max. 6146.7 cps.
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Figure 117  LC-MS/MS chromatogram of 9-O-acetylhydnocarpin 
 
12.7.2.1.3 Extraction  
A specific extraction method was needed to extract 9-O-acetylhydnocarpin from blood.  
Liquid-liquid extraction is often used to extract drugs from samples in clinical testing 
laboratories, so it was decid d to commence the extraction development process with 
solvent extraction.  Different organic solvents and buffers were tested and the best 
repeatable recovery (70%) was obtained with ethyl acetate and a 0.1 M carbonate buffer 
at pH 10.2.  The blood samples were thawed in a water bath at 37 °C, briefly vortexed and 
centrifuged for 1 minute at 1300 G.  Blood samples (100 µl) were pipetted in glass tubes.  
The sodium carbonate buffer (200 µl, 0.1 M, pH 10.2) and ethyl acetate (2 ml) organic 
solvent were added and the samples vortexed for 1 minute and centrifuged at 1300 G for 1 
minute.  The organic phase was transferred to clean glass tubes.  The organic solvent was 
evaporated under a gentle stream of nitrogen at room temperature.  The dried samples 
were reconstituted with mobile phase and vortexed for 15 seconds.  The extracts were 
transferred to autosampler vials and 5 µl was injected onto the HPLC column. 
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12.7.2.1.4   Preparation of calibration standards 
Whole blood was collected and cooled on ice before spiking with the reference standard to 
prevent hydrolysis by the esterase enzymes.  A stock solution with a concentration of 1 
mg/ml 9-O-acetylhydnocarpin was prepared in DMSO.  A pool of blank whole blood was 
spiked with the stock solution to obtain a standard with a concentration of 1 μg/ml.  This 
standard was serially diluted with blank whole blood to attain standards with the following 
concentrations:  500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9 and 1.95 ng/ml.  The calibration 
standards were aliquoted in polypropylene tubes and stored at approximately -20°C. 
 
12.7.3   Metabolite investigation 
12.7.3.1   Precursor ion experiment 
The mass spectrometer was set in the precursor ion mode and Q3 was set to stabilise the 
most abundant product ion of 9-O-acetylhydnocarpin and hydn carpin, which was 257.  
Q1 was set to scan between 400 and 600 to search for the hydrolysed product.  The 
extracted blood samples that were used during the previous experiment (12.7.2) were 
combined and analysed here.  The same analytical column was used as described in 
12.7.2.1.2.  A gradient mobile phase was used which consisted of acetonitrile and 0.1% 
formic acid.  The organic phase was increased from 50% to 70% over a period of 4 
minutes. 
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12.7.4   Bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed product in 
mice using different formulations and administration routes 
 
12.7.4.1   Experimental design 
12.7.4.1.1 Oral dose experiment 
Test formulation:  9-O-Acetylhydnocarpin was administered orally at a concentration of 
100 mg/kg in Tween® 80 (Aldrich, Cat.:  27,436-4) to three healthy mice.  Blood (10 μl) was 
collected just before, and at 1, 2, 3, 5 and 7 hours after administration. 
 
Control formulation:  9-O-Acetylhydnocarpin was administered orally at a concentration 
of 100 mg/kg in 10% DMSO (water : DMSO; 90:10, v/v) to three healthy mice.  Blood (10 
μl) was collected just before, and at 1, 2, 3, 5 and 7 hours after administration. 
 
12.7.4.1.2 Subcutaneous dose experiment 
Test formulation:  9-O-Acetylhydnocarpin was administered subcutaneously (figure 118) 
at a concentration of 100 mg/kg in Tween® 80 (Aldrich, Cat.:  27,436-4) to three healthy 
mice.  Blood (10 μl) was collected just before, and at 1, 2, 3, 5 and 7 hours after 
administration. 
 
Control formulation:  9-O-Acetylhydnocarpin was administered subcutaneously at a 
concentration of 100 mg/kg in 10% DMSO (water : DMSO; 90:10, v/v) to three healthy 
mice.  Blood (10 μl) was collected just before, and at 1, 2, 3, 5 and 7 hours after 
administration. 
 
 
Figure 118  Example of a mouse receiving subcutaneous treatment  
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12.7.4.2   Method development of a more sensitive assay method  
An analytical method was needed to quantitatively determine the concentration of 9-O-
acetylhydnocarpin and the hydrolysed product in whole blood samples to follow the 
concentration vs. time profile for 7 hours after a 100 mg/kg single dose was given to 
healthy mice.  Blood samples (10 μl) were taken before administration of the study 
medication and thereafter at the following time periods:  0, 1, 2, 3, 5, 7 hours.  The 
samples were spotted onto filter paper (Whatman® 3 filters) and left to dry at room 
temperature.  The filter paper was stored at – 20 °C until analysed.  An Applied 
Biosystems 3200 Q-trap mass spectrometer coupled to a high performance liquid 
chromatography system was used to analyse the samples.   
 
12.7.4.2.1 Mass Spectrometer optimisation 
The previous sample analysis was done on an Applied Biosystems API 2000 instrument.  
During those experiments, 100 μl of sample was used for analysis and one animal per time 
point was used.  A more sensitive detection method was needed to study the 
bioavailability of these compounds per animal, only 10 μl blood was collected per time 
point, and 6 samples were collected per animal.  The proposed range for the 10 µl 
extraction method was 0.313 to 5 μg/ml.  An Applied Biosystems 3200 Q-trap mass 
spectrometer, which is a much more sensitive instrument, was used for analysing these 
study samples.  
 
12.7.4.2.1.1. 9-O-Acetylhydnocarpin 
Infusion experiments of 9-O-acetylhydnocarpin were conducted in acidic, neutral and basic 
chemical environments (at a concentration of 100 ng/ml) in both the positive and negative 
ESI modes to select the molecular ion of interest.  The best result was obtained when 
infused in an acidic chemical environment (0.1% formic acid : methanol, 1:1, v/v) at a flow 
rate of 10 μl/min.  A protonated molecular ion [M+H]+ was found at m/z 507 (figure 119).  
The molecular ion was selected in the first mass filter and fragmented in the collision cell 
to form product ions (figure 120).  The most abundant product ion (257) was selected and 
the MS set in the multiple reaction monitoring mode (MRM). 
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 +Q1: 0.025 min from Sample 1 (TuneSampleID) of MT20061101104603.wiff (Turbo Spray) Max. 7.9e5 cps.
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Figure 119  Mass spectrum of 9-O-acetylhydnocarpin showing the [M+H]+ ion  
 +MS2 (507.18) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Ester-hydnocarpin_InitProduct_Pos.wiff (Turbo Spray) Max. 1.7e6 cps.
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Figure 120  Product ion mass spectrum of the protonated molecular ion and the product 
ions 
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12.7.4.2.1.2. Hydrolysed compound 
The same methodology was used to optimise the mass spectrometer for the hydrolysed 
product.  The mass spectrum of the hydrolysed product is presented in figure 121 and the 
product ion mass spectrum in figure 122.  The most abundant product ion (257) was 
selected and the MS set in the multiple reaction monitoring mode (MRM). 
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Figure 121  Mass spectrum of the hydrolysed product showing the [M+H]+ ion (m/z 465) 
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 +MS2 (465.17) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Hydnocarpin_InitProduct_Pos.wiff (Turbo Spray) Max. 1.2e6 cps.
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Figure 122  Product ion mass spectrum of the protonated molecular ion and the product 
ions 
 
The mass spectrometer was set to detect 9-O-acetylhydnocarpin (507  257) and its 
hydrolysed product (465  257) in the MRM mode.  Detection was performed using an 
Applied Biosystems 3200 Q-trap mass spectrometer (ESI in the positive ion mode, MRM) 
and the settings on the apparatus are summarised in tables 40 and 41.   
 
Table 40  ESI settings 
Nebulizer gas (arbitrary value) 50 
Turbo spray (arbitrary value) 50 
Curtain gas (arbitrary value) 10 
Heated nebulizer (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
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Table 41  MS/MS settings 
 9-O-acetylhydnocarpin Hydrolysed product 
Average mass 506.4656 464.4284 
Exact mass 506.1213 464.1107 
Protonated molecular ion (m/z) 507.2 465.2 
Product ion (m/z): 257.2 257.2 
Dwell time (ms) 150 150 
Declustering potential (V) 71 71 
Entrance potential (V) 11 10.5 
Collision cell entrance potential (V) 22 26 
Collision energy (eV) 55 51 
Collision cell exit potential (V) 4 4 
Collision activated dissociation gas medium medium 
Scan type MRM MRM 
Polarity positive positive 
Pause time 5 ms 5 ms 
 
 
12.7.4.2.2 Chromatography development 
A primary stock solution of 9-O-acetylhydnocarpin and its hydrolysed product was 
prepared in acetonitrile at a concentration of 2 mg/ml.  A secondary stock solution was 
prepared by spiking the primary stock solution in acetonitrile : 0.1% formic acid (1:1, v/v) to 
obtain a concentration of 1 ug/ml of both compounds.  Mobile phase was prepared 
consisting of acetonitrile and a 0.1% formic acid solution (70:30, v/v).  A Phenomenex® 
Gemini™ C18 (5 cm x 2 mm, 5 μm) column was set up and equilibrated for 20 minutes by 
pumping the mobile phase at a constant flow rate of 0.3 ml/min through the column.  The 
injection volume was 10 μl.  This mobile phase resulted in very good chromatography.  
The retention time was 1.05 minutes for 9-O-acetylhydnocarpin and 0.75 minutes for the 
hydrolysed product (figure 123). 
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XIC of +MRM (2 pairs): 507.2/257.2 amu from Sample 1 (S7) of 1001.wiff (Turbo Spray) Max. 2786.7 cps.
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
Time, min
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2787
In
te
ns
ity
, c
ps
1.08
1.27
 
Figure 123  LC-MS/MS chromatogram of 9-O-acetylhydnocarpin and its hydrolysed 
product 
 
12.7.4.2.3 Extraction  
A specific extraction method was needed to extract 9-O-acetylhydnocarpin and the 
hydrolysed product from small volumes of blood (10 μl).  Liquid-liquid extraction is often 
used to extract compounds from whole blood samples.  Different organic solvents and 
buffers were tested.  The best recovery for both compounds was obtained with ethyl 
acetate and water (pH 7).  A liquid-liquid filter paper extraction method was developed.  
The whole blood samples (10 µl) were spotted onto filter paper and left on the bench for 20 
minutes to dry.  The dried spots were cut out and transferred to clean test tubes.  Water 
(200 μl) was added and the samples were briefly vortexed.  The samples were ultra-
sonicated for 5 minutes and left on the bench for another 5 minutes.  Ethyl acetate was 
added (1 ml) and the samples were vortexed for 30 seconds.  The organic layers (750 μl) 
were transferred to clean test tubes after centrifugation (3000 rpm for 1 minute).  The 
samples were dried (30 minutes) in a rotary evaporation system at 30 °C.  The dried 
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samples were reconstituted with mobile phase (100 μl) and 5 μl injected onto the column 
for analysis. 
     
12.7.4.2.4 Preparation of calibration standards 
Whole blood was collected and cooled on ice before spiking with reference standards to 
prevent hydrolysis by the esterase enzymes.  A stock solution with a concentration of 1 
mg/ml for both 9-O-acetylhydnocarpin and the hydrolysed product was prepared in DMSO.  
A pool of blank whole blood was spiked with the stock solution to obtain a standard with a 
concentration of 10 μg/ml for both compounds.    This standard was serially diluted with 
blank whole blood to attain standards with the following concentrations:  5, 2.5, 1.25, 0.625 
and 0.313 μg/ml.  The calibration standards were aliquoted in polypropylene tubes and 
stored at approximately -20°C. 
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12.7.5   Method development of an improved assay method  
12.7.5.1   Mass Spectrometer optimisation 
An Applied Biosystems 3200 Q-trap mass spectrometer was used to analyse the study 
samples.    
 
12.7.5.1.1 9-O-Acetylhydnocarpin 
The same mass spectrometer conditions were used as described in 12.7.4.2.1.1. 
  
12.7.5.1.2 Hydrolysed product 
The same mass spectrometer conditions were used as described in 12.7.4.2.1.2.  
 
12.7.5.1.3 Internal standard 
The same methodology was used to optimise the mass spectrometer for the internal 
standard.  The mass spectrum of the internal standard is presented in figure 124 and the 
product ion mass spectrum in figure 125.  The most abundant product ion (153) was 
selected and the MS set in the multiple reaction monitoring mode (MRM). 
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Figure 124  Mass spectrum of the internal standard showing the [M+H]+ ion (m/z 287) 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 225
 
 +MS2 (287.22) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of ISTD_286.6_InitProduct_Pos.wiff (Turbo Spray) Max. 2.1e6 cps.
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Figure 125  Product ion mass spectrum of the protonated molecular ion and the product 
ions 
 
Detection was performed on an Applied Biosystems 3200 Q-trap mass spectrometer (ESI 
in the positive ion mode, MRM) and the settings on the apparatus are summarised in 
tables 42 and 43.   
 
Table 42  ESI settings 
Nebulizer gas (arbitrary value) 50 
Turbo spray (arbitrary value) 50 
Curtain gas (arbitrary value) 10 
Heated nebulizer (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
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Table 43  MS/MS settings 
 
9-O-
acetylhydno
carpin 
Hydrolysed 
product 
Internal 
standard 
Average mass 506.4656 464.4284 286.2408 
Exact mass 506.1213 464.1107 286.0477 
Protonated molecular ion (m/z) 507.2 465.2 287.2 
Product ion (m/z): 257.2 257.2 153.2 
Dwell time (ms) 150 150 150 
Declustering potential (V) 71 71 76 
Entrance potential (V) 11 10.5 8.5 
Collision cell entrance potential (V) 22 26 16 
Collision energy (eV) 55 51 45 
Collision cell exit potential (V) 4 4 4 
Collision activated dissociation gas medium medium medium 
Scan type MRM MRM MRM 
Polarity positive positive positive 
Pause time 5 ms 5 ms 5 ms 
 
 
12.7.5.2   Chromatography development 
A primary stock solution of 9-O-acetylhydnocarpin, the hydrolysed product and the internal 
standard was prepared in ac tonitrile at a concentration of 2 mg/ml.  A secondary stock 
solution was prepared by spiking the primary stock solution in acetonitrile : 0.1% formic 
acid (1:1, v/v) to obtain a concentration of 1 µg/ml of all compounds.  Mobile phase was 
prepared consisting of acetonitrile and a 0.1% formic acid solution (70:30, v/v).  A 
Phenomenex® Gemini™ C18 (5 cm x 2 mm, 5 μm) column was set up and equilibrated for 
20 minutes by pumping the mobile phase at a constant flow rate of 0.3 ml/min through the 
column.  The injection volume was 5 μl.  This mobile phase resulted in very good 
chromatography.  The retention time was 1.05 minutes for 9-O-acetylhydnocarpin, 0.75 
minutes for the hydrolysed product and 0.60 minutes for the internal standard (figure 126). 
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XIC of +MRM (3 pairs): 507.2/257.2 amu from Sample 1 (S4) of 1005.wiff (Turbo Spray) Max. 1.3e4 cps.
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Figure 126  LC-MS/MS chromatogram of 9-O-acetylhydnocarpin, the hydrolysed product 
and the internal standard  
 
12.7.5.3   Extraction 
A more robust liquid-liquid extraction method was developed.  Sodium carbonate buffer 
(50 μl, 0.1 M, pH 10.2) was pipetted into 1.5 ml polypropylene eppendorf tubes and blood 
samples (10 μl) were added to the buffer (on ice).  Ethyl acetate (250 µl) was added and 
the samples vortexed for 20 seconds and centrifuged at 1300 G for 5 minute.  The internal 
standard was spiked into the organic solvent to obtain a concentration of 1 μg/ml.  The 
organic phase was transferred to clean glass inserts and evaporated by making use of a 
cold trap under vacuum conditions at 30 °C.  The dried samples were reconstituted with 
mobile phase (100 μl), vortexed for 10 seconds, and 5 μl was injected onto the HPLC 
column. 
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12.7.5.4   Preparation of calibration standards 
Whole blood was collected and cooled on ice before spiking with reference standards to 
prevent hydrolysis by the esterase enzymes.  A stock solution with a concentration of 1 
mg/ml for both 9-O-acetylhydnocarpin and the hydrolysed product was prepared in DMSO.  
A pool of blank whole blood was spiked with the stock solution to obtain a standard with a 
concentration of 10 μg/ml for both compounds.    This standard was serially diluted with 
blank whole blood to attain standards with the following concentrations:  5, 2.5, 1.25, 
0.625, 0.313, 0.156 and 0.078 μg/ml.  The calibration standards were aliquoted into 
polypropylene tubes and stored at approximately -20°C. 
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12.7.6   Bioavailability study of 9-O-acetylhydnocarpin and its hydrolysed product in 
mice using a self-microemulsifying drug delivery system 
 
12.7.6.1   Experimental design 
9-O-Acetylhydnocarpin was formulated as described Wu and co-workers [Wu et al., 2006].  
The compositions of the formulation substances are presented in table 44. 
 
Table 44  SMEDDS formulation 
Formulation agents Composition (%) Mass (mg)
9-O-acetylhydnocarpin 8.5 50 
Ethanol 9.2 53.6 
Tween® 80 54.9 321.3 
Ethyl linoleate 27.4 161 
 
9-O-Acetylhydnocarpin was purified with HPLC as described in Chapter 4 (HPLC purity 
above 99%).  Ethanol was purchased from Merck® (purity > 99.9%, HPLC grade), Tween® 
80 was purchased from Aldrich® (lab grade) and ethyl linoleate was purchased from 
Sigma® (99% pure). 
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12.8   Metabolite study of 9-O-acetylhydnocarpin in mice 
 
12.8.1   Sample preparation 
12.8.1.1   Blood samples 
The parent compound is quickly absorbed from the gastrointestinal tract and blood levels 
could be detected 30 minutes after dosage (Chapter 8).  Metabolites should also be 
present in the blood soon after the parent compound is present; therefore blood samples 
(50 μl) were collected at 0.5 h, 1h and 2 hours after administration by cutting the tip of the 
tail. 
 
The extraction method that was previously used, for extraction of 9-O-acetylhydnocarpin 
and the hydrolysed product, was designed to selectively extract these two compounds 
from mice blood.  Metabolites are often more polar than their parent compounds and may 
not extract into the organic phase as was used previously.  For that reason it was decided 
to use a simple protein precipitation method to extract the compounds of interest from the 
mice blood. 
 
The combined blood sample (100 μl) was pipetted into a 1.5 ml polypropylene eppendorf 
tube and acetonitrile (300 μl) was added.  The sample was vortexed for 1 minute and 
centrifuged at 1300 G for 5 minutes.  The supernatant was transferred to a clean 
eppendorf tube and 100 μl of a 0.1% formic acid solution was added.  The sample was 
briefly vortexed and stored at – 70 °C until analysed.  A control sample (blood sample just 
before drug was administered) was also prepared using the same extraction method as 
described above. 
 
12.8.1.2   Urine samples 
Urine samples were collected over a period of 6 hours.  The combined sample was diluted 
(50x) with a mixture of acetonitrile and 0.1% formic acid (1:1, v/v).  The sample was briefly 
vortexed and stored at – 70 °C until analysed.  A control sample (urine sample just before 
drug was administered) was also prepared using the same methodology as described 
above. 
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12.8.1.3   Faeces samples 
Faeces samples were collected over a period of 12 hours.  The combined sample was 
placed in a small glass beaker and 20 ml acetonitrile was added.  The mixture was stirred 
on a magnetic stirrer for 10 minutes.  The extract was filtered using paper filters 
(Whatmann® no. 3) and dried under a gentle stream of nitrogen gas.  The sample was 
stored at – 70 °C until analysed.  Before analysis, the extract was dissolved in 10 ml of 
acetonitrile and diluted 50 times with a mixture of acetonitrile and 0.1% formic acid (1:1, 
v/v).  A control sample (faeces sample just before drug was administered) was also 
prepared using the same methodology as described above. 
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12.8.2   LC-MS analysis 
The mass spectrometer was set in the LC-MS mode.  Q1 was set to scan between 400 
and 900.  This range would cover the molecular ions of all the potential phase I and II 
metabolites.  
 
The mass spectrometer was coupled in tandem with an Agilent 1200 series HPLC system.  
A Phenomenex® C18 (15 cm x 4.6 mm, 5 μm) column was used to separate the 
compounds of interest.  The column was kept at 20 °C in a column oven.  A gradient 
system (table 45) at a flow rate of 0.3 ml/min was used to separate the metabolites.  The 
injection volume was 10 μl.  The analysis of the study samples was performed in the 
positive ion mode and the settings on the mass spectrometer are summarised in table 46. 
 
Table 45  HPLC gradient of LC-MS experiment 
Time 
(min) 
% acetonitrile % water 
0 5 95 
15 95 5 
16 5 95 
25 5 95 
 
Table 46  Mass spectrometer settings 
Ion source gas 1 (arbitrary value) 50 
Ion source gas 2 (arbitrary value) 50 
Curtain gas (arbitrary value) 20 
Source temperature (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
Scan time (sec) 2 
Declustering potential (V) 71 
Entrance potential (V) 10 
Scan type Q1 MS 
Polarity positive 
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12.8.3   Precursor ion scan analysis 
The mass spectrometer was set in the precursor ion mode and Q3 was set to stabilise the 
most abundant product ion of 9-O-acetylhydnocarpin, which was 257.  Q1 was set to scan 
between 400 and 900.  This range would cover all the potential phase 1 and 2 metabolites.  
The same HPLC gradient system that was used for LC-MS analysis was also used for 
precursor ion scan analysis (12.8.2).  The injection volume was 10 μl.  The analysis of the 
study samples was performed in the positive ion mode and the settings on the mass 
spectrometer are summarised in table 47. 
 
Table 47  Mass spectrometer settings 
Ion source gas 1 (arbitrary value) 50 
Ion source gas 2 (arbitrary value) 50 
Curtain gas (arbitrary value) 20 
Collision gas (arbitrary value) 5 
Source temperature (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
Scan time (sec) 2 
Declustering potential (V) 71 
Entrance potential (V) 10 
Collision cell entrance potential (V) 22 
Collision energy (eV) 50 
Collision cell exit potential (V) 3 
Scan type precursor 
Polarity positive 
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12.8.4   Neutral loss scan analysis 
The mass spectrometer was set in the neutral loss mode to search for potential 
glucuronidated metabolites.  The mass shift between Q3 and Q1 was set at 176.  The 
same HPLC gradient system that was used for LC-MS analysis was also used for neutral 
loss analysis (12.8.2).  The injection volume was 10 μl.  The analysis of the study samples 
was performed in the positive ion mode and the settings on the mass spectrometer are 
summarised in table 48. 
 
Table 48  Mass spectrometer settings 
Ion source gas 1 (arbitrary value) 50 
Ion source gas 2 (arbitrary value) 50 
Curtain gas (arbitrary value) 20 
Source temperature (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
Scan time (sec) 2 
Declustering potential (V) 71 
Entrance potential (V) 10 
Collision cell entrance potential (V) 22 
Collision energy (eV) 50 
Collision cell exit potential (V) 3 
Collision activated dissociation gas medium 
Scan type Neutral loss 
Polarity positive 
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12.8.5   LC-MS/MS analysis 
The mass spectrometer was set in the LC-MS/MS mode.  Q1 was set to stabilise the 
molecular ions of the potential metabolites described above.  Q3 was set to scan between 
50 and the mass of the molecular ion minus about 10 mass units.  This range would cover 
the product ions of the potential phase I and II metabolites.  
 
The same HPLC gradient system that was used for LC-MS analysis was also used for LC-
MS/MS analysis (12.8.2).  The injection volume was 10 μl.  The analysis of the study 
samples was performed in the positive ion mode and the settings on the mass 
spectrometer are summarised in table 49. 
 
Table 49  Mass spectrometer settings 
Ion source gas 1 (arbitrary value) 50 
Ion source gas 2 (arbitrary value) 50 
Curtain gas (arbitrary value) 20 
Collision gas (arbitrary value) 5 
Source temperature (°C) 400 
Ionspray voltage (V) 4500 
Resolution unit 
Scan time (sec) 2 
Declustering potential (V) 71 
Entrance potential (V) 10 
Collision cell entrance potential (V) 25 
Collision energy (eV) 50 
Collision cell exit potential (V) 3 
Scan type MS/MS 
Polarity positive 
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12.9   Antimalarial assessment of 9-O-acetylhydnocarpin in mice 
 
12.9.1   Mice  
Mice (male, 12 to 16 weeks old, C57BL6)  were obtained from the University of Cape 
Town’s Animal Unit and kept at the animal laboratory of the liver research group (Groote 
Schuur Hospital, Old main building, level K).  A group of 3 mice were used for each 
experiment. 
 
12.9.2   Animal model  
P. berghei Anka (PbA, Swiss Tropical Institute, Basle) malaria parasites, which is a highly 
chloroquine sensitive strain, were used to infect the study animals.  The parasites, kept in 
liquid nitrogen, were thawed and passaged intra-peritoneally to donor mice [Rudin et al., 
1997; Gumede et al., 2003].  Parasite infected erythrocytes were collected after 5 days 
into heparinized tubes by tail bleeding.  The parasitaemia was determined using Giemsa 
stained thin blood smears.  Parasitised erythrocytes (1 x 106 per 0.2 ml of saline) were 
injected intra-peritoneally into the test animals [Gumede, 2003]. 
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APPENDIX 1 
 
HPLC, UV, MS and NMR spectra 
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Compound 2 
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Figure 127  UV spectrum of compound 2  
 
 +Q1: 0.034 min from Sample 1 (TuneSampleID) of MT20061102164338.wiff (Turbo Spray) Max. 1.6e6 cps.
50 100 150 200 250 300 350 400 450 500 550 600
m/z, amu
1.0e5
2.0e5
3.0e5
4.0e5
5.0e5
6.0e5
7.0e5
8.0e5
9.0e5
1.0e6
1.1e6
1.2e6
1.3e6
1.4e6
1.5e6
1.6e6
In
te
ns
ity
, c
ps
64.5
287.6
65.5
135.4
159.479.6 119.585.4 325.6 425.7169.3
105.759.6 409.8 449.7 522.8149.6 579.873.3 177.5181.5 379.7 418.6295.8111.6 458.7 499.5369.4265.7213.5 333.7231.7 551.888.6 567.9512.8187.6 387.7315.5
 
Figure 128  Mass spectrum of compound 2 
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Figure 129  High resolution mass spectrum of compound 2 
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Figure 130  1H NMR spectrum of compound 2 
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1H-NMR (600 MHz) ppm 6.89 (d, J=8.30  Hz, 1H) 
 
Figure 131  1H peaks of compound 2 
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Figure 132  13C NMR spectrum of compound 2 
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Figure 133  13C peaks of compound 2 
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Figure 134  COSY spectrum of compound 2 
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Figure 135  Proton correlations of compound 2 
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Figure 136  HSQC spectrum of compound 2 
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Figure 137  HMQC spectrum of compound 2 
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Figure 138  3 bond correlation of compound 2 
" 
" 
l , .. , .. , .. 
j " ,-Il_" 
". 
'U, 
,u, 
",. 
,u, 
",,. 
,I.>, 
,,_ .. 
.:to , 
," 
-
". '" 
". 
,. 
..... , 
-
• 
,. 
.. , I 
-
". '" ". 
,. 
. , 
'" '" 
,. 
". 
" 
'" 
.. 
.. 
.. 
, . 
" 
.. 
.. 
~l " 
J ::.... 
1: 
.. , 
•• 
.. 
I .. 
j" ,-'u, ", .. 
l ::: ,,_0, 
",,. 
,u, 
". 
"" 
l 
.. , 
~ 
, .. , 
'''' '" , '''' 
, .. 
"'-' 
, ; 
, . ,. 
" • 
.. .. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 277
Compound 4 
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Figure 139  UV spectrum of compound 4 
 
 
 
 +Q1: 0.556 min from Sample 1 (TuneSampleID) of MT20061101105348.wiff (Turbo Spray) Max. 1.6e6 cps.
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Figure 140  Mass spectrum of compound 4  
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Figure 141  High resolution mass spectrum of compound 4 
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Figure 142  1H NMR spectrum of compound 4 
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1H-NMR (600 MHz) ppm 7.04 (d, J=1.88  Hz, 1H)  
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1H-NMR (600 MHz) ppm 6.88 (d, J=1.84  Hz, 1H)  
 
 
 
ppm (t1)
6.80006.80506.81006.81506.82006.8250
0
100
200
300
400
500
600
6.818
6.815
6.805
0.
78
0.
57
M2
6.811
ppm (t1)
6.52006.52506.53006.5350
0
100
200
300
400
500
6.527
6.524
1.
23
M1
6.526
 
 1H-NMR (600 MHz) ppm 6.81 (d, J=8.04  Hz, 1H) 1H-NMR (600 MHz) ppm 6.53 (d, J=2.01  Hz, 1H) 
 
 
 
 
ppm (t1)
6.20006.20506.2100
0
100
200
300
400
500
6.206
6.203
1.
23
M1
6.204
ppm (t1)
5.01505.02005.02505.03005.0350
0
100
200
300
400
500
5.032
5.019
0.
58
0.
62
M1
5.026
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Figure 143  1H peaks of compound 4 
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Figure 144  13C NMR spectrum of compound 4 
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Figure 145  13C peaks of compound 4 
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Figure 146  COSY spectrum of compound 4 
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Figure 147  Proton correlations of compound 4 
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Figure 148  HSQC spectrum of compound 4 
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Figure 149  HSQC spectrum of compound 4 (zoom in) 
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Figure 150  HMQC spectrum of compound 4 
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Figure 151  HMQC spectrum of compound 4 (zoom in) 
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Compound 5 
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Figure 152  UV spectrum of compound 5 
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Figure 153  Mass spectrum of compound 5 
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Figure 154  High resolution mass spectrum of compound 5 
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Figure 155  1H NMR spectrum of compound 5 
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1H-NMR (600 MHz) ppm 7.74 (d, J=2.22  Hz, 1H) 
 
 
 
ppm (t1)
7.63007.63507.64007.64507.65007.65507.6600
-100
0
100
200
300
400
500
600
700
7.659
7.652
7.649
7.638
7.634
0.
54
0.
58
M1
7.643
ppm (t1)
7.11007.11507.12007.12507.13007.13507.1400
0
500
1000
1500
7.132
7.118
1.
13
M1
7.125
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1H-NMR (600 MHz) ppm 7.06 (d, J=1.91  Hz, 1H) 
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1H-NMR (600 MHz) ppm 6.20 (d, J=2.02  Hz, 1H)   1H-NMR (600 MHz) ppm 5.06 (d, J=7.99  Hz, 1H) 
 
 
3 
11 6 
8 16 
17 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 295
ppm (t1)
4.6004.6104.6204.6304.640
0
100
200
300
400
500
4.634
4.630
4.625
4.621
4.616
4.612
4.608
1.
12
M1
4.621
ppm (t1)
4.0904.1004.1104.1204.130
0
100
200
300
400
500
4.121
4.105
4.101
4.126
1.
22
M1
4.113
 
1H-NMR (600 MHz) ppm           1H-NMR (600 MHz) ppm 4.11 (dd, J=2.53, 12.50  Hz, 1H) 
4.62 (ddd, J=2.60, 5.13, 7.85  Hz, 1H) 
 
 
 
 
ppm (t1)
3.9503.9603.9703.9803.990
0
100
200
300
400
500
3.984
3.975
3.963
3.954
1.
30
M2
3.969
ppm (t1)
3.303.403.503.603.703.80
0
1000
2000
3000
4000
5000
6000
3.751
3.654
3.779
0.
40
0.
29
13
.9
5
3.
87
 
1H-NMR (600 MHz) ppm 
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Figure 156   1H peaks of compound 5 
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Figure 157  13C NMR spectrum of compound 5 
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Figure 158  13C peaks of compound 5 
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Figure 159  COSY spectrum of compound 5 
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Figure 160  Proton correlations of compound 5 (zoom in) 
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Figure 161  HSQC spectrum of compound 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 301
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 162  HSQC spectrum of compound 5 (zoom in) 
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Figure 163  HMQC spectrum of compound 5 
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Figure 164  HMQC spectrum of compound 5 (zoom in) 
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APPENDIX 2 
 
Body weight and % parasitaemia data of mice 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 307
Polar formulation  
Table 50  Body weight data of mice (g) that were treated with a polar 100 mg/kg 9-O-
acetylhydnocarpin formulation using the 4 day suppressive treatment strategy (control 
groups included) 
Treatment Day 1 Day 3 Day 5 Day 7 Day 9 
Chloroquine control, mouse 1 29.6 29.4 29.7 29.9 29.3 
Chloroquine control, mouse 2 28.5 28.5 29.3 29.1 28.8 
Chloroquine control, mouse 3 28.6 28.2 28.8 28.8 28.1 
Placebo control, mouse 1 29.8 29.9 30.4 29.3 24.9 
Placebo control, mouse 2 30.1 30.6 29.9 26.0 25.0 
Placebo control, mouse 3 27.6 27.7 28.1 24.9 23.5 
Test compound, mouse 1 30.0 30.3 30.7 25.4 23.5 
Test compound, mouse 2 27.5 26.9 27.8 25.4 23.2 
Test compound, mouse 3 26.8 25.3 26.7 24.5 22.4 
 
 
Table 51  Parasitaemia (%) data of mice that were treated with a polar 100 mg/kg 9-O-
acetylhydnocarpin formulation using the 4 day suppressive treatment strategy (control 
groups included) 
Treatment Da  3 Day 5 Day 7 Day 9 
Chloroquine control, mouse 1 0.5 0.0 0.0 0.7 
Chloroquine control, mouse 2 0.5 0.0 0.0 0.7 
Chloroquine control, mouse 3 0.5 0.0 0.0 0.0 
Placebo control, mouse 1 0.5 1.0 3.2* 18.9 
Placebo control, mouse 2 0.5 1.1 20.3 34.0 
Placebo control, mouse 3 0.4 1.0 18.4 35.4 
Test compound, mouse 1 0.5 1.0 16.0 25.4 
Test compound, mouse 2 0.5 0.9 9.9 22.4 
Test compound, mouse 3 0.5 0.8 10.2 22.3 
* Statistical outlier, was not included during %Chemo suppression calculation 
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SMEDDS formulation  
 
Table 52  Body weight data of mice (g) that were treated with a 100 mg/kg 9-O-
acetylhydnocarpin SMEDDS formulation using the 4 day suppressive treatment strategy 
(control groups included) 
Treatment Day 1 Day 3 Day 5 Day 7 Day 8 
Chloroquine control, mouse 1 30.6 31.0 29.3 30.3 31.2 
Chloroquine control, mouse 2 30.8 28.7 28.8 30.4 30.5 
Chloroquine control, mouse 3 30.2 30.3 31.0 31.3 31.4 
Placebo control, mouse 1 30.2 30.8 30.1 29.5 25.7 
Placebo control, mouse 2 31.8 32.0 30.5 27.6 25.9 
Placebo control, mouse 3 30.8 30.8 30.5 31.7 29.3 
Test compound, mouse 1 30.7 31.0 27.7 26.3 24.6 
Test compound, mouse 2 30.5 30.2 28.8 26.9 25.7 
Test compound, mouse 3 30.0 29.5 29.2 26.8 25.5 
 
 
 
Table 53  Parasitaemia (%) data of mice that were treated with a 100 mg/kg 9-O-
acetylhydnocarpin SMEDDS formulation using the 4 day suppressive treatment strategy 
(control groups included) 
Treatment Day 3 Day 5 Day 7 Day 8 
Chloroquine control, mouse 1 0 1.0 0.6 1.17 
Chloroquine control, mouse 2 0 0.7 0.1 0 
Chloroquine control, mouse 3 0 1.2 0.5 0.1 
Placebo control, mouse 1 0 8.3 24.9 30.6 
Placebo control, mouse 2 0 8.3 35.3 40.6 
Placebo control, mouse 3 0 2.2 5.2* 10.4 
Test compound, mouse 1 0 6.1 16.7 25.0 
Test compound, mouse 2 0 4.0 21.6 28.4 
Test compound, mouse 3 0 2.2 17.6 26.0 
* Statistical outlier, was not included during %Chemo suppression calculation 
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Pheroid formulation  
 
 
Table 54  Body weight data of mice (g) that were treated with a 100 mg/kg 9-O-
acetylhydnocarpin pheroid formulation using the 4 day suppressive treatment strategy 
(control groups included) 
Treatment Day 1 Day 3 Day 5 Day 7 Day 8 
Chloroquine control, mouse 1 30.6 31.0 29.3 30.3 31.2 
Chloroquine control, mouse 2 30.8 28.7 28.8 30.4 30.5 
Chloroquine control, mouse 3 30.2 30.3 31.0 31.3 31.4 
Placebo control, mouse 1 29.8 28.8 27.8 25.7 24.0 
Placebo control, mouse 2 29.7 26.4 23.7 22.6 22.2 
Placebo control, mouse 3 29.4 28.8 28.3 26.1 24.4 
Test compound, mouse 1 30.8 30.6 29.9 27.5 26.1 
Test compound, mouse 2 30.2 27.5 27.3 27.0 25.1 
Test compound, mouse 3 30.3 27.4 29.0 26.0 25.2 
 
 
 
Table 55  Parasitaemia (%) data of mice that were treated with a 100 mg/kg 9-O-
acetylhydnocarpin pheroid formulation using the 4 day suppressive treatment strategy 
(control groups included) 
Treatment Day 3 Day 5 Day 7 Day 8 
Chloroquine control, mouse 1 0 1.0 0.6 1.17 
Chloroquine control, mouse 2 0 0.7 0.1 0 
Chloroquine control, mouse 3 0 1.2 0.5 0.1 
Placebo control, mouse 1 0 3.3 29.1 36.0 
Placebo control, mouse 2 0 2.6 8.0* 9.8 
Placebo control, mouse 3 0 5.4 33.6 39.6 
Test compound, mouse 1 0 4.7 19.9 28.0 
Test compound, mouse 2 0 6.6 14.5 15.0 
Test compound, mouse 3 0 5.3 20.6 28.0 
* Statistical outlier, was not included during %Chemo suppression calculation 
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Bioavailability data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 311
Initial bioavailability study of 9-O-acetylhydnocarpin in mice 
 
Calibration curve results & Representative chromatograms 
 
3 0 0 1 0 6 . r d b  ( c a r p i n ) :  " Q u a d r a t i c "  R e g r e s s i o n  ( " 1  /  x "  w e i g h t i n g ) :  y  =  - 0 . 0 2 7 5  x ^ 2  +  8 3 . 4  x  +  - 6 6 . 4  ( r  =  0 . 9 9 9 5 )
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0 1 0 0 0
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Figure 165  Calibration curve of 9-O-acetylhydnocarpin 
Table 56  Back-calculated concentrations of 9-O-acetylhydnocarpin  
Sample Peak Area 
Nominal conc. 
(ng/ml) 
Calculated conc. 
(ng/ml) 
Accuracy (%) 
STD 1 54900 1000 968 96.8 
STD 2 35700 500 516 103 
STD 3 19000 250 249 99.7 
STD 4 10200 125 129 103 
STD 5 4490 62.5 55.6 88.9 
STD 6 2520 31.3 31.3 99.9 
STD 7 1140 15.6 14.5 92.8 
STD 8 501 7.8 6.82 87.4 
STD 9 275 3.9 4.09 105 
STD 10 131 1.95 2.37 122 
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Sample Name: "STD 4"    Sample ID: ""    File: "1004.wiff"
Peak Name: "carpin"    Mass(es): "507.1/257.1 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      125.    ng/mL  
Calculated Conc:    129.    ng/mL  
Acq. Date:       01/30/2006  
Acq. Time:       02:07:10 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    5     
Noise Threshold:    6.92   cps
Area Threshold:   34.60   cps
,Num. Smooths:      10     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  RT Window:         40.0    sec
Expected RT:        3.20   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     3.19   min
Area:          10200.   counts
Height:         1.19e+003  cps
Start Time:         3.01   min
End Time:           3.44   min
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8
Time, min
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
340
360
380
400
420
440
460
480
500
520
540
560
580
600
620
640
660
680
700
720
740
760
780
800
820
840
860
880
900
920
940
960
980
1000
1020
1040
1060
1080
1100
1120
1140
1160
1180
1200
Intensity, cps
3.19
3.39
  
Sample Name: "STD 10"    Sample ID: ""    File: "1010.wiff"
Peak Name: "carpin"    Mass(es): "507.1/257.1 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      1.95    ng/mL  
Calculated Conc:    2.37    ng/mL  
Acq. Date:       01/30/2006  
Acq. Time:       02:41:22 PM  
 
Modified:           Yes   
RT Window:         40.0    sec
Expected RT:        3.20   min
Use Relative RT:    No    
 
Int. Type:        Manual  
Retention Time:     3.14   min
Area:            131.   counts
Height:         2.26e+001  cps
Start Time:         3.09   min
End Time:           3.30   min
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8
Time, min
0
1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
25
Intensity, cps
  
Sample Name: "Sample 4"    Sample ID: ""    File: "1014.wiff"
Peak Name: "carpin"    Mass(es): "507.1/257.1 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    29.8    ng/mL  
Acq. Date:       01/30/2006  
Acq. Time:       03:04:19 PM  
 
Modified:           Yes   
RT Window:         40.0    sec
Expected RT:        3.20   min
Use Relative RT:    No    
 
Int. Type:        Manual  
Retention Time:     3.15   min
Area:           2400.   counts
Height:         2.91e+002  cps
Start Time:         2.97   min
End Time:           3.45   min
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8
Time, min
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
Intensity, cps
3.15
3.18
3.33
1.341.30
3.391.28 1.37 1.97 3.512.00
2.67 3.990.45 2.56 3.713.562.051.41 2.76 2.80 2.961.630.88 3.882.390.32 0.81 1.060.23 2.330.67 1.20 1.73 1.81 2.070.21 1.44  
 
Figure 166  Representative chromatograms:  STD 4, STD 10 and sample 4 
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Metabolite investigation 
 
Total ion chromatogram & Precursor ion mass spectra 
 
TIC of +Prec (257.00): from Sample 1 (b1 400) of 1030.wiff (Turbo Spray) Max. 5.2e4 cps.
0.5 1.0 1.5 2.0 2.5 3.0 3.5
Time, min
0.0
5000.0
1.0e4
1.5e4
2.0e4
2.5e4
3.0e4
3.5e4
4.0e4
4.5e4
5.0e4
5.2e4 2.35
2.29
2.44 3.48
0.76
3.32
2.811.611.41 2.561.05 3.631.35
0.28 2.001.940.57 3.03 3.19 3.81
1.80
 
Figure 167  Total ion chromatogram of the 257 precursor ion (combined study sample) 
 
 +Prec (257.00): 0.750 to 0.859 min from Sample 1 (b1 400) of 1030.wiff (Turbo Spray), subtra... Max. 1429.3 cps.
400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
m/z, amu
300
400
500
600
700
800
900
1000
1100
1200
1300
1400
499.5
540.0
405.5
517.0
 
Figure 168  Precursor ion mass spectrum of the peak at 0.8 minutes 
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 +Prec (257.00): 2.282 to 2.383 min from Sample 1 (b1 400) of 1030.wiff (Turbo Spray) Max. 4002.0 cps.
400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
m/z, amu
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
3200
3400
3600
3800
4000 465.0
 
Figure 169  Precursor ion mass spectrum of the peak at 2.4 minutes 
 
 
 
 +Prec (257.00): 3.436 to 3.579 min from Sample 1 (b1 400) of 1030.wiff (Turbo Spray), subtract... Max. 889.3 cps.
400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600
m/z, amu
150
200
250
300
350
400
450
500
550
600
650
700
750
800
850
889 431.4
449.4
507.3
 
 
Figure 170  Precursor ion mass spectrum of the peak at 3.5 minutes 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 315
Bioavailability study of 9-O-acetylhydnocarpin and its 
hydrolysed product in mice using different formulations and 
administration routes 
Calibration curve results & Representative chromatograms 
 
30032007.rdb (Compound 5): "Quadratic" Regression ("1 / x" weighting): y = -1.6e+003 x^2 + 2.22e+004 x + -2.45e+003 (r = 0.9986)
0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
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5000.0
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Figure 171  Calibration curve of 9-O-acetylhydnocarpin 
Table 57  Back-calculated concentrations of 9-O-acetylhydnocarpin 
Sample Peak Area 
Nominal conc. 
(μg/ml) 
Calculated conc. 
(μg /ml) 
Accuracy (%) 
STD 1 68600 5 5.02 100 
STD 2 44900 2.5 2.63 105 
STD 3 21800 1.25 1.20 95.8 
STD 4 10100 0.625 0.589 94.3 
STD 5 4580 0.313 0.324 104 
STD 1 67100 5 4.78 95.7 
STD 2 45000 2.5 2.64 106 
STD 3 21800 1.25 1.20 95.7 
STD 4 10200 0.625 0.594 95.0 
STD 5 4860 0.313 0.338 108 
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30032007.rdb (Compound 4): "Quadratic" Regression ("1 / x" weighting): y = -1.05e+003 x^2 + 1.14e+004 x + -1.9e+003 (r = 0.9955)
0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0 3.2 3.4 3.6 3.8 4.0 4.2 4.4 4.6 4.8 5.0
Concentration, ug/mL
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
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Figure 172  Calibration curve of the hydrolysed product 
 
Table 58  Back-calculated concentrations of the hydrolysed product 
Sample Peak Area 
Nominal conc. 
(μg/ml) 
Calculated conc. 
(μg /ml) 
Accuracy (%) 
STD 1 29200 5 No Intercept N/A 
STD 2 21300 2.5 2.71 109 
STD 3 10100 1.25 1.18 94.4 
STD 4 4100 0.625 0.554 88.7 
STD 5 1980 0.313 0.351 112 
STD 1 27700 5 4.27 85.3 
STD 2 21700 2.5 2.78 111 
STD 3 10100 1.25 1.18 94.8 
STD 4 4170 0.625 0.561 89.8 
STD 5 1840 0.313 0.339 108 
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Sample Name: "s6"    Sample ID: ""    File: "1003.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:     0.300    ug/mL  
Calculated Conc:   0.433    ug/mL  
Acq. Date:       3/19/2007  
Acq. Time:       5:55:36 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    1.46   cps
Area Threshold:    7.28   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.940   min
Use Relative RT:    No    
 
Int. Type:        Valley  
Retention Time:    0.979   min
Area:           6310.   counts
Height:           1180.  cps
Start Time:        0.860   min
End Time:           1.19   min
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
Time, min
0
50
100
150
200
250
300
350
400
450
500
550
600
650
700
750
800
850
900
950
1000
1050
1100
1150
In
te
n
sity
, c
ps
0.98
0.27 0.50 1.361.230.770.10
    
Sample Name: "s6"    Sample ID: ""    File: "1003.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:     0.300    ug/mL  
Calculated Conc:   0.331    ug/mL  
Acq. Date:       3/19/2007  
Acq. Time:       5:55:36 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    0.97   cps
Area Threshold:    4.83   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.660   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.654   min
Area:           2180.   counts
Height:            458.  cps
Start Time:        0.558   min
End Time:          0.814   min
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
Time, min
0
10
20
30
40
50
60
70
80
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100
110
120
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180
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200
210
220
230
240
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Figure 173  Representative chromatograms at the LLOQ 
 
 
Sample Name: "s1"    Sample ID: ""    File: "1013.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      10.0    ug/mL  
Calculated Conc:    9.84    ug/mL  
Acq. Date:       3/19/2007  
Acq. Time:       6:18:38 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    1.46   cps
Area Threshold:    7.28   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.940   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.906   min
Area:          97400.   counts
Height:          18600.  cps
Start Time:        0.744   min
End Time:           1.16   min
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
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500.0
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Sample Name: "s2"    Sample ID: ""    File: "1011.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      5.00    ug/mL  
Calculated Conc:    5.57    ug/mL  
Acq. Date:       3/19/2007  
Acq. Time:       6:14:02 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    0.97   cps
Area Threshold:    4.83   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.660   min
Use Relative RT:    No    
 
Int. Type:       Exponential Skim  
Retention Time:    0.634   min
Area:          32800.   counts
Height:           7260.  cps
Start Time:        0.473   min
End Time:          0.760   min
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Figure 174  Representative chromatograms at 5 μg/ml 
 
 
 
Sample Name: "DO_2H_M3"    Sample ID: ""    File: "1022.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.917    ug/mL  
Acq. Date:       3/30/2007  
Acq. Time:       6:48:27 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.817   min
Area:          16500.   counts
Height:           3270.  cps
Start Time:        0.636   min
End Time:           1.01   min
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Sample Name: "TS_1H_M3"    Sample ID: ""    File: "1075.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    1.18    ug/mL  
Acq. Date:       3/30/2007  
Acq. Time:       8:54:11 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:        Valley  
Retention Time:    0.675   min
Area:          10100.   counts
Height:           2050.  cps
Start Time:        0.568   min
End Time:          0.858   min
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Figure 175  Representative chromatograms of a study sample 
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Method development and validation of an improved assay method 
 
Validation data 
 
03052007rdb.rdb (Compound 5): "Quadratic" Regression ("1 / x" weighting): y = 0.00504 x^2 + 0.723 x + 0.0281 (r = 0.9940)
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Figure 176  Calibration curve of 9-O-acetylhydnocarpin 
 
Table 59  Back-calculated concentrations of 9-O-acetylhydnocarpin 
 
Sample 
Analyte 
peak 
area 
ISTD 
peak 
area 
Peak 
Area 
Ratio 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg /ml)
Accuracy 
(%) 
STD 1 196000 25600 7.66 10 9.87 98.7 
STD 2 98800 23700 4.17 5 5.51 110 
STD 3 48200 33500 1.44 2.5 1.92 76.9 
STD 4 22900 21600 1.06 1.25 1.42 113 
STD 5 11700 23600 0.496 0.625 0.643 103 
STD 6 5980 21700 0.276 0.313 0.341 109 
STD 7 3390 26800 0.126 0.156 0.136 87.3 
STD 8 2180 25500 0.0855 0.0781 0.0793 102 
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03052007rdb.rdb (Compound 4): "Quadratic" Regression ("1 / x" weighting): y = 0.00137 x^2 + 0.332 x + 0.00165 (r = 0.9944)
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Figure 177  Calibration curve of the hydrolysed product 
 
Table 60  Back-calculated concentrations of the hydrolysed product 
Sample 
Analyte 
peak 
area 
ISTD 
peak 
area 
Peak 
Area 
Ratio 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg /ml)
Accuracy 
(%) 
STD 1 87100 25600 3.40 10 9.86 98.6 
STD 2 44400 23700 1.87 5 5.52 110 
STD 3 21900 33500 0.654 2.5 1.95 77.9 
STD 4 10100 21600 0.468 1.25 1.39 111 
STD 5 5060 23600 0.214 0.625 0.64 102 
STD 6 2470 21700 0.114 0.313 0.337 108 
STD 7 1300 26800 0.0485 0.156 0.141 90.4 
STD 8 709 25500 0.0278 0.0781 0.0788 101 
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Table 61  Long term matrix stability of 9-O-acetylhydnocarpin 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration 
(μg /ml) 
Calculated 
% of 
nominal 
10 10.9 109.0 
10 11.1 111.0 
10 10.5 105.0 
Mean 10.8 108.3 
STDEV 0.31 3.06 
CV% 2.8  
% Nom 108  
 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration
(μg/ml) 
Calculated 
% of 
nominal 
0.625 0.658 105.3 
0.625 0.678 108.5 
0.625 0.646 103.4 
Mean 0.661 105.7 
STDEV 0.02 2.59 
CV% 2.4  
% Nom 105.7  
Table 62  Long term matrix stability of the hydrolysed product 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration 
(μg /ml) 
Calculated 
% of 
nominal 
10 10.7 107.0 
10 10.7 107.0 
10 9.88 98.8 
Mean 10.4 104.3 
STDEV 0.47 4.73 
CV% 4.5  
% Nom 104.3  
 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration
(μg/ml) 
Calculated 
% of 
nominal 
0.625 0.577 92.3 
0.625 0.664 106.2 
0.625 0.636 101.8 
Mean 0.626 100.1 
STDEV 0.04 7.11 
CV% 7.1  
% Nom 100.1  
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Table 63  On bench and Freeze-thaw stability of 9-O-acetylhydnocarpin 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration 
(μg /ml) 
Calculated 
% of 
nominal 
10 10.5 105 
10 10.1 101 
10 9.85 98.5 
Mean 10.15 101.5 
STDEV 0.33 3.28 
CV% 3.2  
% Nom 101.5  
 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration
(μg/ml) 
Calculated 
% of 
nominal 
0.625 0.568 90.9 
0.625 0.659 105 
0.625 0.574 91.8 
Mean 0.600 96.1 
STDEV 0.05 8.14 
CV% 8.5  
% Nom 96.1  
 
Table 64  On bench and Freeze-thaw stability of the hydrolysed product 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration 
(μg /ml) 
Calculated 
% of 
nominal 
10 10.5 105 
10 10.1 101 
10 9.85 98.5 
Mean 10.15 101.5 
STDEV 0.33 3.28 
CV% 3.2  
% Nom 101.5  
 
Nominal 
Concentration 
(μg/ml) 
Measured 
Concentration
(μg/ml) 
Calculated 
% of 
nominal 
0.625 0.504 80.6 
0.625 0.584 93.4 
0.625 0.555 88.8 
Mean 0.548 87.6 
STDEV 0.04 6.48 
CV% 7.4  
% Nom 87.6  
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XIC of +MRM (3 pairs): 507.2/257.2 amu from Sample 1 (Blank) of 1008.wiff (Turbo Spray) Max. 193.3 cps.
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Figure 178  Chromatogram of a blank whole blood extract  
 
 
 
   
Sample Name: "NS8"    Sample ID: ""    File: "1049.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    0.00    ug/mL  
Acq. Date:       5/3/2007  
Acq. Time:       11:34:04 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    1.46   cps
Area Threshold:    7.28   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.780   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.791   min
Area:           2180.   counts
Height:            400.  cps
Start Time:        0.659   min
End Time:          0.977   min
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Sample Name: "NS8"    Sample ID: ""    File: "1049.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    0.00    ug/mL  
Acq. Date:       5/3/2007  
Acq. Time:       11:34:04 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    0.97   cps
Area Threshold:    4.83   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.640   min
Use Relative RT:    No    
 
Int. Type:        Valley  
Retention Time:    0.651   min
Area:            709.   counts
Height:            130.  cps
Start Time:        0.535   min
End Time:          0.806   min
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Figure 179  LLOQ chromatograms of 9-O-acetylhydnocarpin and the hydrolysed product 
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Bioavailability study of 9-O-acetylhydnocarpin and its 
hydrolysed product in mice using a self-microemulsifying drug 
delivery system 
 
Calibration curve results & Representative chromatograms 
 
11052007.rdb (Compound 5): "Quadratic" Regression ("1 / y" weighting): y = -120 x^ 2 + 2.11e+004 x + 798 (r = 0.9977)
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Figure 180  Calibration curve of 9-O-acetylhydnocarpin 
 
Table 65  Back-calculated concentrations of 9-O-acetylhydnocarpin 
Sample 
Analyte 
peak 
area 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg /ml) 
Accuracy 
(%) 
STD 1 194000 10 9.71 97.1 
STD 2 96100 5 4.64 92.9 
STD 3 58700 2.5 2.79 112 
STD 4 28300 1.25 1.31 105 
STD 5 14900 0.625 0.672 108 
STD 6 7830 0.313 0.334 107 
STD 7 4190 0.156 0.161 103 
STD 8 1930 0.0781 0.0535 68.6 
STD 1 210000 10 10.5 105 
STD 2 100000 5 4.86 97.1 
STD 3 51000 2.5 2.41 96.5 
STD 4 25100 1.25 1.16 92.8 
STD 5 15600 0.625 0.704 113 
STD 6 9680 0.313 0.422 135 
STD 7 4170 0.156 0.160 103 
STD 8 2030 0.0781 0.0585 74.9 
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11052007.rdb (Compound 4): "Quadratic" Regression ("1 / y" weighting): y = -45.9 x^ 2 + 9.55e+003 x + 9.21 (r = 0.9977)
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Figure 181  Calibration curve of the hydrolysed product 
 
 
Table 66  Back-calculated concentrations of the hydrolysed product 
Sample 
Analyte 
peak 
area 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg /ml) 
Accuracy 
(%) 
STD 1 88000 10 9.66 96.6 
STD 2 42500 5 4.54 90.9 
STD 3 27100 2.5 2.88 115 
STD 4 12500 1.25 1.32 105 
STD 5 6350 0.625 0.666 107 
STD 6 3150 0.313 0.329 105 
STD 7 1510 0.156 0.158 101 
STD 8 619 0.0781 0.0639 81.9 
STD 1 96000 10 10.6 106 
STD 2 45800 5 4.91 98.2 
STD 3 24200 2.5 2.56 103 
STD 4 10800 1.25 1.13 90.7 
STD 5 6100 0.625 0.640 102 
STD 6 4630 0.313 0.485 155 
STD 7 1520 0.156 0.158 101 
STD 8 793 0.0781 0.0822 105 
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Sample Name: "S8"    Sample ID: ""    File: "1008.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:    0.0780    ug/mL  
Calculated Conc:  0.0535    ug/mL  
Acq. Date:       5/11/2007  
Acq. Time:       9:40:58 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.811   min
Area:           1930.   counts
Height:            369.  cps
Start Time:        0.705   min
End Time:          0.922   min
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Sample Name: "S8"    Sample ID: ""    File: "1008.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:    0.0780    ug/mL  
Calculated Conc:  0.0639    ug/mL  
Acq. Date:       5/11/2007  
Acq. Time:       9:40:58 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.666   min
Area:            619.   counts
Height:            121.  cps
Start Time:        0.566   min
End Time:          0.783   min
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Figure 182  Representative chromatograms at the LLOQ 
 
 
Sample Name: "S1"    Sample ID: ""    File: "1001.wi ff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      10.0    ug/mL  
Calculated Conc:    9.71    ug/mL  
Acq. Date:       5/11/2007  
Acq. Time:       9:24:25 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.790   min
Area:         194000.   counts
Height:          34100.  cps
Start Time:        0.667   min
End Time:           1.26   min
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Sample Name: "S1"    Sample ID: ""    File: "1001.wi ff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      10.0    ug/mL  
Calculated Conc:    9.66    ug/mL  
Acq. Date:       5/11/2007  
Acq. Time:       9:24:25 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.654   min
Area:          88000.   counts
Height:          16200.  cps
Start Time:        0.527   min
End Time:          0.946   min
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Figure 183  Representative chromatograms at 10 μg/ml 
 
 
 
Sample Name: "sample 12"    Sample ID: ""    Fi le: "1049.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.433    ug/mL  
Acq. Date:       5/11/2007  
Acq. Time:       11:18:14 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.813   min
Area:           9900.   counts
Height:           1840.  cps
Start Time:        0.682   min
End Time:           1.06   min
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Sample Name: "sample 28"    Sample ID: ""    Fi le: "1065.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.194    ug/mL  
Acq. Date:       5/11/2007  
Acq. Time:       12:00:18 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.675   min
Area:           1860.   counts
Height:            364.  cps
Start Time:        0.581   min
End Time:          0.822   min
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Figure 184  Representative chromatograms of a study sample 
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Bioavailability study of 9-O-acetylhydnocarpin and its 
hydrolysed product in mice using Pheroid technology as a 
drug delivery system after oral administration 
 
Representative chromatograms & Calibration curve results 
 
 
 
 
Sample Name: "S8"    Sample ID: ""    File: "1008.wi ff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:    0.0780    ug/mL  
Calculated Conc:  0.0783    ug/mL  
Acq. Date:       6/13/2007  
Acq. Time:       2:37:34 PM  
 
Modified:           Yes   
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:        Manual  
Retention Time:    0.802   min
Area:           1980.   counts
Height:            416.  cps
Start Time:        0.708   min
End Time:          0.930   min
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Sample Name: "S8"    Sample ID: ""    File: "1008.wi ff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:    0.0780    ug/mL  
Calculated Conc:  0.0774    ug/mL  
Acq. Date:       6/13/2007  
Acq. Time:       2:37:34 PM  
 
Modified:           Yes   
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:        Manual  
Retention Time:    0.649   min
Area:            727.   counts
Height:            152.  cps
Start Time:        0.584   min
End Time:          0.760   min
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
Time, min
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
In
te
n
sity
, c
ps
0.65
0.68
0.81
 
 
Figure 185  Representative chromatograms at the LLOQ 
 
 
Sample Name: "OS3"    Sample ID: ""    File: "1011.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      2.50    ug/mL  
Calculated Conc:    2.51    ug/mL  
Acq. Date:       6/13/2007  
Acq. Time:       2:44:40 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.791   min
Area:          68200.   counts
Height:          13000.  cps
Start Time:        0.682   min
End Time:           1.09   min
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Sample Name: "OS3"    Sample ID: ""    File: "1011.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      2.50    ug/mL  
Calculated Conc:    2.50    ug/mL  
Acq. Date:       6/13/2007  
Acq. Time:       2:44:40 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.652   min
Area:          29200.   counts
Height:           5650.  cps
Start Time:        0.501   min
End Time:          0.930   min
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Figure 186  Representative chromatograms at 2.5 μg/ml 
 
hydrolysed 
product 
hydrolysed 
product 
9-O-
acetylhydnocarpin 
9-O-
acetylhydnocarpin 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 327
Sample Name: "Pheroid 18"    Sample ID: ""    File: "1039.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.533    ug/mL  
Acq. Date:       6/13/2007  
Acq. Time:       3:51:03 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.791   min
Area:          14900.   counts
Height:           2910.  cps
Start Time:        0.677   min
End Time:           1.01   min
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Sample Name: "Pheroid 4"    Sample ID: ""    File: "1025.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:  0.0194    ug/mL  
Acq. Date:       6/13/2007  
Acq. Time:       3:17:49 PM  
 
Modified:           Yes   
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Figure 187  Representative chromatograms of a study sample 
 
 
13062007.rdb (Compound 5): "Quadratic" Regression ("1 / x" weighting): y = -582 x^ 2 + 2.88e+004 x + -274 (r = 0.9998)
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Figure 188  Calibration curve of 9-O-acetylhydnocarpin 
 
Table 67  Back-calculated concentrations of 9-O-acetylhydnocarpin 
Standard Peak area 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg/ml) 
Accuracy 
(%) 
1 1980 0.0780 0.0783 100.4 
2 8430 0.313 0.304 97.2 
3 18200 0.625 0.650 103.9 
4 34200 1.25 1.23 98.2 
5 68200 2.50 2.51 100.3 
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13062007.rdb (Compound 4): "Quadratic" Regression ("1 / x" weighting): y = -66.2 x^ 2 + 1.19e+004 x + -195 (r = 1.0000)
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Figure 189  Calibration curve of the hydrolysed product 
 
 
Table 68  Back-calculated concentrations of the hydrolysed product 
Standard Peak area 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg/ml) 
Accuracy 
(%) 
1 727 0.0780 0.0774 99.2 
2 3550 0.313 0.315 100.6 
3 7290 0.625 0.631 100.9 
4 14500 1.25 1.24 99.2 
5 29200 2.50 2.50 100.1 
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Bioavailability study of 9-O-acetylhydnocarpin and its 
hydrolysed product in mice after intravenous administration 
 
Representative chromatograms & Calibration curve results 
 
 
 
Sample Name: "std b 0.02"    Sample ID: ""    File: "1005.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:    0.0195    ug/mL  
Calculated Conc:  0.0220    ug/mL  
Acq. Date:       7/21/2007  
Acq. Time:       11:15:26 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.787   min
Area:           1150.   counts
Height:            239.  cps
Start Time:        0.703   min
End Time:          0.904   min
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Sample Name: "std b 0.02"    Sample ID: ""    File: "1002.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:    0.0195    ug/mL  
Calculated Conc:  0.0212    ug/mL  
Acq. Date:       7/21/2007  
Acq. Time:       11:07:56 AM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.633   min
Area:            493.   counts
Height:            125.  cps
Start Time:        0.548   min
End Time:          0.739   min
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Figure 190  Representative chromatograms at the LLOQ 
 
 
Sample Name: "std 4"    Sample ID: ""    File: "1032.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      1.25    ug/mL  
Calculated Conc:    1.28    ug/mL  
Acq. Date:       7/21/2007  
Acq. Time:       12:21:39 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:        Valley  
Retention Time:    0.800   min
Area:          99800.   counts
Height:          20800.  cps
Start Time:        0.692   min
End Time:           1.01   min
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Sample Name: "std 4"    Sample ID: ""    File: "1036.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      1.25    ug/mL  
Calculated Conc:    1.26    ug/mL  
Acq. Date:       7/21/2007  
Acq. Time:       12:31:27 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.653   min
Area:          43100.   counts
Height:           8950.  cps
Start Time:        0.548   min
End Time:          0.847   min
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Figure 191  Representative chromatograms at 1.25 μg/ml 
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Sample Name: "P M3 2 min"    Sample ID: ""    File: "1014.wiff"
Peak Name: "Compound 5"    Mass(es): "507.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.653    ug/mL  
Acq. Date:       7/21/2007  
Acq. Time:       1:49:38 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    2     
Noise Threshold:    4.93   cps
Area Threshold:   24.64   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.827   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.755   min
Area:          50800.   counts
Height:           7160.  cps
Start Time:        0.563   min
End Time:          0.997   min
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Sample Name: "C M3 2 min"    Sample ID: ""    File: "1032.wiff"
Peak Name: "Compound 4"    Mass(es): "465.2/257.2 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:   0.381    ug/mL  
Acq. Date:       7/21/2007  
Acq. Time:       2:33:38 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    2.12   cps
Area Threshold:   10.60   cps
,Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:       0.671   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:    0.672   min
Area:          12800.   counts
Height:           3680.  cps
Start Time:        0.579   min
End Time:          0.780   min
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Figure 192  Representative chromatograms of a study sample 
 
 
 
21072007 IV pheroid.rdb (Compound 5): "Linear" Regression ("1 / x" weighting): y = 7.87e+004 x + -579 (r = 0.9979)
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Figure 193  Calibration curve of 9-O-acetylhydnocarpin 
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Table 69  Back-calculated concentrations of 9-O-acetylhydnocarpin 
Standard Peak area 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg/ml) 
Accuracy 
(%) 
1 1120 0.0195 0.0216 111.0 
1 1230 0.0195 0.0230 118.0 
1 1170 0.0195 0.0222 114.0 
1 1150 0.0195 0.0220 113.0 
2 2170 0.0390 0.0350 89.6 
2 2370 0.0390 0.0375 96.0 
2 2220 0.0390 0.0355 91.1 
2 2280 0.0390 0.0363 93.0 
3 5340 0.0780 0.0752 96.5 
3 5470 0.0780 0.0769 98.5 
3 5670 0.0780 0.0794 102.0 
3 5350 0.0780 0.0753 96.6 
4 10200 0.156 0.137 87.8 
4 10900 0.156 0.146 93.7 
4 11400 0.156 0.152 97.4 
4 9980 0.156 0.134 86.1 
5 25500 0.313 0.331 106.0 
5 28600 0.313 0.370 118.0 
5 24500 0.313 0.319 102.0 
5 21500 0.313 0.281 89.8 
6 45000 0.625 0.579 92.7 
6 47500 0.625 0.611 97.7 
6 49100 0.625 0.631 101.0 
6 52500 0.625 0.674 108.0 
7 99800 1.25 1.28 102.0 
7 98600 1.25 1.26 101.0 
7 94600 1.25 1.21 96.8 
7 99400 1.25 1.27 102.0 
 
 
 
Table 70  Summary of calibration curve statistics of 9-O-acetylhydnocarpin 
Standard 
Nom 
conc. 
(μg/ml) 
Number 
Of Values 
Used 
Mean Standard Deviation % CV Accuracy 
1 0.0195 4 0.0222 0.000590 2.7 113.9 
2 0.0391 4 0.0361 0.001078 3.0 92.4 
3 0.0781 4 0.0767 0.001960 2.6 98.4 
4 0.156 4 0.142 0.008217 5.8 91.2 
5 0.313 4 0.325 0.036781 11.3 103.9 
6 0.625 4 0.624 0.039711 6.4 99.8 
7 1.25 4 1.25 0.030272 2.4 100.3 
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21072007 IV pheroid.rdb (Compound 4): "Linear" Regression ("1 / x" weighting): y = 3.44e+004 x + -237 (r = 0.9967)
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Figure 194  Calibration curve of the hydrolysed product 
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Table 71  Back-calculated concentrations of the hydrolysed product 
Standard Peak area 
Nom 
conc. 
(μg/ml) 
Calc. 
conc. 
(μg/ml) 
Accuracy 
(%) 
1 493 0.0195 0.0212 109.0 
1 488 0.0195 0.0211 108.0 
1 569 0.0195 0.0235 120.0 
1 506 0.0195 0.0216 111.0 
2 1010 0.0390 0.0364 93.3 
2 982 0.0390 0.0355 91.0 
2 997 0.0390 0.0359 92.1 
2 1070 0.0390 0.0380 97.4 
3 2320 0.0780 0.0745 95.5 
3 2440 0.0780 0.0778 99.8 
3 2510 0.0780 0.0799 102.0 
3 2350 0.0780 0.0754 96.6 
4 4550 0.156 0.139 89.3 
4 4850 0.156 0.148 95.0 
4 4810 0.156 0.147 94.2 
4 3970 0.156 0.122 78.5 
5 11500 0.313 0.342 109.0 
5 13000 0.313 0.385 123.0 
5 10500 0.313 0.314 100.0 
5 9360 0.313 0.279 89.2 
6 20100 0.625 0.592 94.7 
6 21400 0.625 0.629 101.0 
6 21900 0.625 0.646 103.0 
6 23500 0.625 0.691 111.0 
7 44400 1.25 1.30 104.0 
7 41600 1.25 1.22 97.5 
7 39800 1.25 1.17 93.3 
7 43100 1.25 1.26 101.0 
 
 
 
 
Table 72  Summary of calibration curve statistics of the hydrolysed product 
Standard 
Nom 
conc. 
(μg/ml) 
Number 
Of Values 
Used 
Mean Standard Deviation % CV Accuracy 
1 0.0195 4 0.0219 0.00109 5.0 112.1 
2 0.0391 4 0.0364 0.00109 3.0 93.4 
3 0.0781 4 0.0769 0.00245 3.2 98.6 
4 0.156 4 0.139 0.01182 8.5 89.3 
5 0.313 4 0.330 0.04467 13.5 105.4 
6 0.625 4 0.640 0.04122 6.4 102.3 
7 1.25 4 1.24 0.05699 4.6 98.9 
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Metabolite spectral data 
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LC-MS analysis:  Blood sample 
Chromatograms and mass spectra of peak groups 1 - 5 
 
TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 0.568 to 0.668 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (0.100 to 0.501 min) Max. 1.1e6 cps.
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Figure 195  Chromatogram and mass spectrum of peak 1 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 7.1 7.2 7.3
Time, min
0.0
2.0e6
4.0e6
6.0e6
8.0e6
1.0e7
1.2e7
1.4e7
1.6e7
1.8e7
2.0e7
2.2e7
2.4e7
2.6e7
2.8e7
3.0e7
3.1e7
In
te
ns
ity
, c
ps
6.39
6.54
6.23
6.05
 +Q1: 5.749 to 5.882 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.214 to 5.615 min) Max. 3.7e5 cps.
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Figure 196  Chromatogram and mass spectrum of peak 2a 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 5.982 to 6.083 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.247 to 5.916 min) Max. 5.0e5 cps.
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Figure 197  Chromatogram and mass spectrum of peak 2b 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 6.183 to 6.283 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.281 to 6.116 min) Max. 6.3e5 cps.
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Figure 198  Chromatogram and mass spectrum of peak 2c 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 6.350 to 6.450 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.448 to 6.283 min) Max. 1.0e6 cps.
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Figure 199  Chromatogram and mass spectrum of peak 2d 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 6.517 to 6.584 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.548 to 6.450 min) Max. 8.1e5 cps.
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Figure 200  Chromatogram and mass spectrum of peak 2e 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 6.617 to 6.718 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.581 to 6.584 min) Max. 7.8e5 cps.
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Figure 201  Chromatogram and mass spectrum of peak 2f 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7.0 7.1 7.2 7.3
Time, min
0.0
2.0e6
4.0e6
6.0e6
8.0e6
1.0e7
1.2e7
1.4e7
1.6e7
1.8e7
2.0e7
2.2e7
2.4e7
2.6e7
2.8e7
3.0e7
3.1e7
In
te
ns
ity
, c
ps
6.39
6.54
6.23
6.05
 +Q1: 6.751 to 6.818 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.615 to 6.718 min) Max. 2.9e5 cps.
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Figure 202  Chromatogram and mass spectrum of peak 2g 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 6.851 to 6.918 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (5.615 to 6.818 min) Max. 4.3e5 cps.
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Figure 203  Chromatogram and mass spectrum of peak 2h 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
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 +Q1: 9.759 to 9.893 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (9.926 to 9.993 min) Max. 2.3e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
1.5e5
1.6e5
1.7e5
1.8e5
1.9e5
2.0e5
2.1e5
2.2e5
2.3e5
In
te
ns
ity
, c
ps
469.2
512.5
429.3
886.8614.3599.0513.2476.2 533.9481.7 715.3658.9575.1410.9 870.5466.2 569.1 684.7439.2 797.2779.5647.1 814.8762.6749.6605.0 895.1833.8
 
Figure 204  Chromatogram and mass spectrum of peak 3a 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 10.0 10.1 10.2 10.3 10.4
Time, min
0.0
2.0e6
4.0e6
6.0e6
8.0e6
1.0e7
1.2e7
1.4e7
1.6e7
1.8e7
2.0e7
2.2e7
2.4e7
2.6e7
2.8e7
In
te
ns
ity
, c
ps
9.96
 +Q1: 9.926 to 9.993 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (9.793 to 9.893 min) Max. 1.6e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
1.5e5
1.6e5
In
te
ns
ity
, c
ps
441.3
843.1
413.5
827.2461.3
425.0
460.4 512.2412.7 504.4
532.5 826.6539.4
401.0
639.4426.9 628.8481.2 752.8535.2 716.9 811.3562.5 722.7657.0501.2 592.9 845.4697.2 865.2 881.4774.3474.8448.0416.8 506.1 674.9 835.6757.1 799.0546.6 618.7 625.1492.8 725.4577.8 585.1 858.2706.2642.5 742.4 877.4
 
Figure 205  Chromatogram and mass spectrum of peak 3b 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
11.40 11.45 11.50 11.55 11.60 11.65 11.70 11.75 11.80 11.85 11.90 11.95 12.00 12.05 12.10 12.15 12.20 12.25 12.30 12.35 12.40
Time, min
0.0
2.0e6
4.0e6
6.0e6
8.0e6
1.0e7
1.2e7
1.4e7
1.6e7
1.8e7
2.0e7
2.2e7
2.4e7
2.6e7
2.8e7
3.0e7
3.2e7
3.4e7
3.6e7
3.8e7
In
te
ns
ity
, c
ps
11.85
 +Q1: 11.965 to 12.032 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (11.798 to 11.898 min) Max. 3.8e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
3.6e5
3.8e5
In
te
ns
ity
, c
ps
451.4
429.1
513.2
606.5
542.6447.4 487.1
500.6 550.8429.8 580.4515.7 652.7422.5 471.3 494.4 684.6641.8448.3 589.6 749.8 802.1563.6523.4 723.5595.6418.4 668.5526.1 712.6 766.4 875.8840.7810.7673.9629.7 796.6 858.3649.5
 
Figure 206  Chromatogram and mass spectrum of peak 4a 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
11.60 11.65 11.70 11.75 11.80 11.85 11.90 11.95 12.00 12.05 12.10 12.15
Time, min
0.0
2.0e6
4.0e6
6.0e6
8.0e6
1.0e7
1.2e7
1.4e7
1.6e7
1.8e7
2.0e7
2.2e7
2.4e7
2.6e7
2.8e7
3.0e7
3.2e7
3.4e7
3.6e7
3.8e7
In
te
ns
ity
, c
ps
11.85
 +Q1: 11.798 to 11.898 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (11.932 to 12.032 min) Max. 3.4e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
In
te
ns
ity
, c
ps
589.0
632.9
617.3
577.0
618.1
697.2
495.3 573.0 594.9 648.7
468.8459.3406.7 661.1652.0591.4 885.2530.6 578.8563.0 717.4687.5635.2 774.4 780.5442.2 746.9 803.7400.2 447.3 848.8525.3489.0 832.9 872.2677.5655.5601.2544.9 899.3
 
Figure 207  Chromatogram and mass spectrum of peak 4b 
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TIC of +Q1: from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 2.2e8 cps.
12.2 12.4 12.6 12.8 13.0 13.2 13.4 13.6 13.8 14.0 14.2 14.4 14.6 14.8 15.0 15.2 15.4 15.6 15.8
Time, min
0.00
5.00e6
1.00e7
1.50e7
2.00e7
2.50e7
3.00e7
3.50e7
4.00e7
4.50e7
5.00e7
5.50e7
6.00e7
6.50e7
7.00e7
7.50e7
8.00e7
8.50e7
9.00e7
9.50e7
1.00e8
1.05e8
1.10e8
1.15e8
1.20e8
1.25e8
In
te
ns
ity
, c
ps
12.54
12.99
14.10
14.45
13.31
 +Q1: 13.937 to 14.304 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (13.469 to 13.803 min) Max. 2.5e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
1.5e5
1.6e5
1.7e5
1.8e5
1.9e5
2.0e5
2.1e5
2.2e5
2.3e5
2.4e5
2.5e5
In
te
ns
ity
, c
ps
596.4
413.3
577.3
599.3
588.6
661.1
566.4524.6
884.4639.4594.3
546.4 729.2615.3533.2 787.3646.7422.8 676.6 683.1590.8551.4478.3 828.1771.6458.9428.6 876.9496.8 815.7557.4 701.4605.3 717.4 864.4407.4 630.1582.6
 
Figure 208  Chromatogram and mass spectrum of peak 5 
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LC-MS analysis:  Urine sample 
Chromatograms and mass spectra of peak groups 1 and 2 
 
 
TIC of +Q1: from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 8.8e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.5e8
8.8e8
In
te
ns
ity
, c
ps
0.62
6.40
6.24
6.77
6.04
5.82
 +Q1: 0.568 to 0.702 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (1.504 to 3.643 min) Max. 1.5e6 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1.0e5
2.0e5
3.0e5
4.0e5
5.0e5
6.0e5
7.0e5
8.0e5
9.0e5
1.0e6
1.1e6
1.2e6
1.3e6
1.4e6
1.5e6
In
te
ns
ity
, c
ps
569.5
541.4
591.5525.4
481.4
613.4
547.5 585.4
635.5629.4437.5
657.5503.4
497.5
679.6
701.5459.2 673.2543.5
565.3453.4
717.3
608.7 652.6 723.6
521.4499.4
696.6 745.5674.6625.6526.9477.3415.5
451.4 761.5
535.2 767.5703.1 740.6659.2588.4423.1 632.3581.4 789.5467.4433.5 517.4 692.3 784.6510.9 668.8 807.7599.3554.7 757.4 851.3721.7623.4405.2 801.4484.1 595.5512.7468.7 648.2421.4 573.6487.3 877.5792.1714.9 727.5 838.4
 
Figure 209  Chromatogram and mass spectrum of group 1 
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TIC of +Q1: from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 8.8e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.5e8
8.8e8
In
te
ns
ity
, c
ps
0.62
6.40
6.24
6.77
6.04
5.82
 +Q1: 5.648 to 7.252 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (1.872 to 3.743 min) Max. 8.5e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.5e5
7.0e5
7.5e5
8.0e5
8.5e5
In
te
ns
ity
, c
ps
569.5
525.4
481.4 613.5
657.6
437.4
701.5
565.2521.3 745.5
609.5
652.7
608.7477.4 697.5
789.5
741.5
833.6547.5495.2 503.5
407.1 591.5 635.7459.4 785.5451.2 583.4522.3 539.5 629.5
654.5 671.5450.5 829.6 877.7679.6631.4587.5 623.4 711.6491.1415.6 579.4 717.5667.4535.0499.4433.4 454.5 878.3472.6 703.4 761.5 872.8561.1403.4 637.4 767.6604.6517.4 805.5736.6677.6 713.3572.5511.3432.6 849.3488.5 685.5529.5 893.6443.5 846.1766.2
 
 
Figure 210  Chromatogram and mass spectrum of group 2  
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LC-MS analysis:  Faeces sample 
Chromatograms and mass spectra of peak groups 1 - 4 
 
 
TIC of +Q1: from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 8.9e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.5e8
8.9e8
In
te
ns
ity
, c
ps
0.60
7.57
6.88
17.76
6.38
6.22
11.88 16.94
6.04 15.47
5.82
 +Q1: 0.535 to 0.702 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (1.571 to 3.777 min) Max. 7.1e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.5e5
7.0e5
In
te
ns
ity
, c
ps
763.2
657.3
613.4569.4
525.0481.4
652.7 721.1
741.5697.5
743.6701.5 718.9630.9 655.3
696.6
609.5
784.6 829.6437.4415.6 675.6612.6
547.4
809.7 873.6
463.1 789.6591.4 806.7
764.6503.5 565.2 635.5521.4 679.5
587.4 895.6850.8419.5 833.6723.5507.4 767.8
543.6477.1
551.4
690.7 897.7595.5 733.0445.2 754.6 811.6710.7 828.2
665.2 798.6776.4646.5621.4 820.6730.0 854.7514.5499.5 544.4438.4 585.6 669.4576.9 758.5 824.6423.2 478.8 643.4 736.6 864.8448.1 683.1492.5 625.4579.8 618.9 899.7558.5 801.6686.9453.5 512.0 773.1727.2426.4 849.4581.3452.7 494.5 705.6 870.1 880.8458.1412.1
 
Figure 211  Chromatogram and mass spectrum of group 1 
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TIC of +Q1: from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 8.9e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.5e8
8.9e8
In
te
ns
ity
, c
ps
0.60
7.57
6.88
17.76
6.38
6.22
11.88 16.94
6.04 15.47
5.82
 +Q1: 5.949 to 7.954 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (2.440 to 4.345 min) Max. 4.1e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
3.6e5
3.8e5
4.0e5
4.1e5
In
te
ns
ity
, c
ps
569.4
525.4 697.5
741.5653.4
608.9
481.5
785.6
612.9565.5
657.5
829.6699.5 743.5
437.5
765.6 784.7721.6677.6
873.6633.4521.5
674.6 745.5 831.6718.6589.5 630.4 809.6762.6
833.4789.6
853.6570.3 875.6629.6547.5 806.5448.6 587.1
503.5470.2459.4419.5
897.7754.6
688.6 877.4710.2 850.8576.9 732.5514.5 625.2607.6404.4 479.4 543.0 776.6560.1 648.2 798.6669.5 751.6692.6435.5 511.5 821.1650.3445.4 555.4 895.2548.5472.2 795.4401.4 845.6768.6 864.7433.4 812.7455.5 726.6485.4 883.6750.6661.5413.0 838.7794.2
 
Figure 212  Chromatogram and mass spectrum of group 2 
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TIC of +Q1: from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 8.9e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.5e8
8.9e8
In
te
ns
ity
, c
ps
0.60
7.57
6.88
17.76
6.38
6.22
11.88 16.94
6.04 15.47
5.82
 +Q1: 11.698 to 12.032 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (9.191 to 11.129 min) Max. 2.1e6 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1.0e5
2.0e5
3.0e5
4.0e5
5.0e5
6.0e5
7.0e5
8.0e5
9.0e5
1.0e6
1.1e6
1.2e6
1.3e6
1.4e6
1.5e6
1.6e6
1.7e6
1.8e6
1.9e6
2.0e6
2.1e6
In
te
ns
ity
, c
ps
507.1
447.3
545.2
414.9
427.2 529.3
574.5483.5410.6 619.1449.3 541.5432.1 596.1 798.2477.4 662.7 843.3626.9515.4 790.9 865.7821.5741.0716.6669.1 883.1751.3707.6
 
Figure 213  Chromatogram and mass spectrum of group 3 
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TIC of +Q1: from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 8.9e8 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
5.0e7
1.0e8
1.5e8
2.0e8
2.5e8
3.0e8
3.5e8
4.0e8
4.5e8
5.0e8
5.5e8
6.0e8
6.5e8
7.0e8
7.5e8
8.0e8
8.5e8
8.9e8
In
te
ns
ity
, c
ps
0.60
7.57
6.88
17.76
6.38
6.22
11.88 16.94
6.04 15.47
5.82
 +Q1: 17.613 to 17.881 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (12.968 to 16.677 min) Max. 3.6e6 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
2.0e5
4.0e5
6.0e5
8.0e5
1.0e6
1.2e6
1.4e6
1.6e6
1.8e6
2.0e6
2.2e6
2.4e6
2.6e6
2.8e6
3.0e6
3.2e6
3.4e6
3.6e6
In
te
ns
ity
, c
ps
593.5
594.4
413.5
533.5522.7 550.4 784.7 792.7703.7494.7 758.6663.5 717.6615.5427.5 471.5 675.7 834.8605.4579.5 630.8407.4 455.3 856.1 867.9
 
Figure 214  Chromatogram and mass spectrum of group 4 
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Precursor ion scan analysis:  Blood sample 
Chromatogram and mass spectrum of peak 1 
 
 
TIC of +Prec (257.20): from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 5.3e4 cps.
8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0 12.5 13.0 13.5 14.0 14.5 15.0 15.5 16.0 16.5 17.0 17.5
Time, min
0.0
2000.0
4000.0
6000.0
8000.0
1.0e4
1.2e4
1.4e4
1.6e4
1.8e4
2.0e4
2.2e4
2.4e4
2.6e4
2.8e4
3.0e4
3.2e4
3.4e4
3.6e4
3.8e4
4.0e4
4.2e4
4.4e4
4.6e4
4.8e4
5.0e4
5.2e4
In
te
ns
ity
, c
ps
14.06
13.2312.48
17.76
15.9310.49 14.39
13.94 16.14
14.9110.06 12.30
9.639.25 16.6211.43 13.40 15.54
8.95
8.52
 +Prec (257.20): 14.004 to 14.137 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (10.561 to 13.502 min) Max. 1500.3 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
500
550
600
650
700
750
800
850
900
950
1000
1050
1100
1150
1200
1250
1300
1350
1400
1450
1500
In
te
ns
ity
, c
ps
589.1567.2
 
Figure 215  Chromatogram and precursor ion mass spectrum of peak 1 
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Precursor ion scan analysis:  Urine sample 
Chromatograms and mass spectra of peaks 1 and 2 
 
 
TIC of +Prec (257.20): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 1.4e5 cps.
4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0
Time, min
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6.0e4
7.0e4
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 +Prec (257.20): 9.191 to 9.325 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (4.579 to 6.918 min) Max. 4000.8 cps.
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Figure 216  Chromatogram and precursor ion mass spectrum of peak 1 
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TIC of +Prec (257.20): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 1.4e5 cps.
4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0
Time, min
0.0
1.0e4
2.0e4
3.0e4
4.0e4
5.0e4
6.0e4
7.0e4
8.0e4
9.0e4
1.0e5
1.1e5
1.2e5
1.3e5
1.4e5
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8.11 8.937.59
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7.26 10.72
10.42
6.25
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5.82
5.05 11.80
11.535.31
 +Prec (257.20): 9.559 to 9.659 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (4.612 to 6.785 min) Max. 6251.3 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 217  Chromatogram and precursor ion mass spectrum of peak 2 
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Precursor ion scan analysis:  Faeces sample 
Chromatograms and mass spectra of peaks 1 - 3 
 
TIC of +Prec (257.20): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 5.4e6 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e5
4.0e5
6.0e5
8.0e5
1.0e6
1.2e6
1.4e6
1.6e6
1.8e6
2.0e6
2.2e6
2.4e6
2.6e6
2.8e6
3.0e6
3.2e6
3.4e6
3.6e6
3.8e6
4.0e6
4.2e6
4.4e6
4.6e6
4.8e6
5.0e6
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11.85
10.09 10.70
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 +Prec (257.20): 9.993 to 10.194 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (8.121 to 9.358 min) Max. 2.7e4 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1000.0
2000.0
3000.0
4000.0
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7000.0
8000.0
9000.0
1.0e4
1.1e4
1.2e4
1.3e4
1.4e4
1.5e4
1.6e4
1.7e4
1.8e4
1.9e4
2.0e4
2.1e4
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Figure 218  Chromatogram and precursor ion mass spectrum of peak 1 
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TIC of +Prec (257.20): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 5.4e6 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e5
4.0e5
6.0e5
8.0e5
1.0e6
1.2e6
1.4e6
1.6e6
1.8e6
2.0e6
2.2e6
2.4e6
2.6e6
2.8e6
3.0e6
3.2e6
3.4e6
3.6e6
3.8e6
4.0e6
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 +Prec (257.20): 10.561 to 10.795 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (8.055 to 9.559 min) Max. 1.4e4 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
500.0
1000.0
1500.0
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3000.0
3500.0
4000.0
4500.0
5000.0
5500.0
6000.0
6500.0
7000.0
7500.0
8000.0
8500.0
9000.0
9500.0
1.0e4
1.1e4
1.1e4
1.2e4
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Figure 219  Chromatogram and precursor ion mass spectrum of peak 2 
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TIC of +Prec (257.20): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 5.4e6 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
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 +Prec (257.20): 11.631 to 12.065 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (8.188 to 9.525 min) Max. 1.6e5 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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4.0e4
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Figure 220  Chromatogram and precursor ion mass spectrum of peak 3 
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Neutral loss scan analysis:  Blood sample 
Chromatogram and mass spectrum of peaks 1 
 
TIC of +NL (176.00): from Sample 1 (blood sample) of 1004.wiff (Turbo Spray) Max. 1.1e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.00
5000.00
1.00e4
1.50e4
2.00e4
2.50e4
3.00e4
3.50e4
4.00e4
4.50e4
5.00e4
5.50e4
6.00e4
6.50e4
7.00e4
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8.00e4
8.50e4
9.00e4
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20.62
 +NL (176.00): 9.726 to 9.993 min from Sample 1 (blood sample) of 1004.wiff (Turbo Spray), subtracted (3.476 to 7.821 min) Max. 3056.2 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 221  Chromatogram and neutral loss mass spectrum of peak 1 
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Neutral loss scan analysis:  Urine sample 
Chromatograms and mass spectra of peak groups 1 - 5 
 
TIC of +NL (176.00): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.2e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
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1.4e5
1.6e5
1.8e5
2.0e5
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2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
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 +NL (176.00): 0.568 to 0.702 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (1.638 to 3.309 min) Max. 6501.3 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 222  Chromatogram and neutral loss mass spectrum of peak 1 
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TIC of +NL (176.00): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.2e5 cps.
4.0 4.2 4.4 4.6 4.8 5.0 5.2 5.4 5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 8.2 8.4 8.6
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
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 +NL (176.00): 6.049 to 6.150 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (4.011 to 5.214 min) Max. 1.0e4 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 223  Chromatogram and neutral loss mass spectrum of peak 2 
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TIC of +NL (176.00): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.2e5 cps.
4.2 4.4 4.6 4.8 5.0 5.2 5.4 5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 8.2 8.4
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
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2.4e5
2.6e5
2.7e5
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 +NL (176.00): 6.250 to 6.317 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (4.345 to 5.114 min) Max. 1.4e4 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1000.0
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Figure 224  Chromatogram and neutral loss mass spectrum of peak 3 
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TIC of +NL (176.00): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.2e5 cps.
4.0 4.2 4.4 4.6 4.8 5.0 5.2 5.4 5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0 7.2 7.4 7.6 7.8 8.0 8.2 8.4
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
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 +NL (176.00): 6.384 to 6.484 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (4.545 to 5.314 min) Max. 4375.9 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 225  Chromatogram and neutral loss mass spectrum of peak 4 
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TIC of +NL (176.00): from Sample 1 (urine sample) of 1008.wiff (Turbo Spray) Max. 5.2e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
3.6e5
3.8e5
4.0e5
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5.67
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 +NL (176.00): 9.158 to 9.358 min from Sample 1 (urine sample) of 1008.wiff (Turbo Spray), subtracted (10.060 to 11.932 min) Max. 6072.6 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 226  Chromatogram and neutral loss mass spectrum of peak 5 
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Neutral loss scan analysis:  Faeces sample 
Chromatograms and mass spectra of peak groups 1 – 3 
 
TIC of +NL (176.00): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 4.0e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
3.6e5
3.8e5
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7.28
6.78
10.50
15.65
 +NL (176.00): 0.535 to 0.702 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (1.103 to 3.041 min) Max. 1250.3 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
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Figure 227  Chromatogram and neutral loss mass spectrum of peak 1 
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TIC of +NL (176.00): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 4.0e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
3.6e5
3.8e5
4.0e5
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6.78
10.50
15.65
 +NL (176.00): 6.952 to 7.921 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (4.111 to 5.749 min) Max. 1250.3 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
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Figure 228  Chromatogram and neutral loss mass spectrum of peak 1 
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TIC of +NL (176.00): from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray) Max. 4.0e5 cps.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time, min
0.0
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
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 +NL (176.00): 17.647 to 17.847 min from Sample 1 (faeces sample) of 1012.wiff (Turbo Spray), subtracted (14.070 to 16.544 min) Max. 1.7e4 cps.
400 420 440 460 480 500 520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
m/z, amu
1000.0
2000.0
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Figure 229  Chromatogram and neutral loss mass spectrum of peak 3 
